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Terpenes and terpenoids make up one of the largest and most structurally diverse 
families of natural products with known compounds numbering in the tens of 
thousands. A significant proportion of terpenoids are secondary metabolites, which 
display a wide range of biological activities, and consequently many have found uses 
as therapeutic drugs, most notably paclitaxel, the anti-cancer agent; and artemisinin, 
a key drug in anti-malarial therapies. Due to the challenges in synthesising these 
highly complex compounds in satisfactory yields the majority of the supply of these 
drugs is still extracted from natural sources or produced semi-synthetically from 
naturally extracted compounds. 
Terpene synthases convert the linear isoprenyl diphosphates, precursors of all 
terpenoids, into complex hydrocarbon skeletons, which are often naturally further 
derivatised by P450 cytochromes. Recently there have been advances in exploiting 
terpene synthases for the production of terpenoid precursors, but despite these 
advances selectively derivatising the hydrocarbon skeleton remains the major barrier 
to the conversion of these skeletons to therapeutically viable compounds. 
This thesis focuses on exploring methods of generating simple terpenoids from terpene 
synthases. The project is divided into two parts both designed to investigate methods 
of generating simple terpenoids. The first part focuses on germacradien-4-ol synthase 
(GdolS), a recently discovered bacterial sesquiterpene synthase, which incorporates 
water in the cyclisation cascade to generate a single terpene alcohol. This enzyme was 
characterised and the mechanism probed using substrate analogues and single-point 
mutations to elucidate how GdolS is able to incorporate water into its product while 
still protecting the highly reactive carbocation intermediates. Our data indicated that 
germacradien-4-ol synthase catalyses the loss of the diphosphate group and ring 
closure in a stepwise manner, followed by a 1,3-hydride shift to generate a long-lived 
allylic-carbocation intermediate. We propose this carbocation is then quenched by 
water ingress into the active site due to loop movement.  
The second part of the project involved the synthesis of a range of farnesyl diphosphate 
analogues designed to offer means of trapping carbocation intermediates in the 
catalysis by a range of sesquiterpene synthases. These analogues were primarily 
epoxy-FDPs, designed to produce simple terpenoids with hydroxy- and epoxy-
functionalities. While a number of the prepared analogues were turned over by the 
tested sesquiterpene synthases two, 10,11-epoxy-FDP and 10-hydroxy-11-ene-FDP, 
were able to intercept the farnesyl cation upon loss of the diphosphate group, to 
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Terpenes and terpenoids comprise one of the largest and most structurally 
diverse families of natural products, with known compounds numbering in the 
tens of thousands.1,2 More than half of the known terpenoids are 
biosynthesised by plants and some, such as the phytol side-chain of 
chlorophyll3 and the phytosterols4 of the plant wall, are the products of 
primary metabolism, which are vital to the plant for growth and development. 
A greater number of terpenoids are formed by secondary metabolism and have 
a wide array of biological functions such as communication pheromones both 
within insect species5 and from plants to insects,6 and for phytoalexins for 
plant defence and pigments. 
The wide variety of bioactivities found within terpenes and terpenoids means 
that they have found uses in therapeutics for the treatments of a range of 
conditions, most notably paclitaxel (Taxol™, 1),7 the anti-cancer agent and 
artemisinin (2), one of the most important drugs in antimalarial combination 
therapies,8 Figure 1.1. 
 
Figure 1.1 Paclitaxel (1), artemisinin (2), pentalenolactone (3) and albaflavenone (4) with the 
hydrocarbon terpene skeletons higlighted in red. 
Terpenoids are also widely found in fungi9 and over the last decade, through 
the use of genome mining, a large number of putative terpene synthase genes 
have been identified in bacteria, particularly in Streptomyces,10,11 hinting at a 
wealth of unidentified terpenoids still to be discovered. Many of these putative 
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terpene synthase genes are within gene clusters that also contain regions 
encoding P450 cytochromes and other enzymes, which in a number of cases 
have been shown to be those responsible for the transformation of the 
hydrocarbon terpene product to oxidised terpenoids, such as with the 
Streptomyces antibiotics pentalenolactone12 (3) and albaflavenone (4).13 
1.2 Biosynthesis 
All terpenes and terpenoid derivatives are ultimately derived from two isomeric 
five-carbon precursors, isopentyl diphosphate (IDP, 5) and dimethylallyl 
diphosphate (DMADP, 6).14 These are the biologically activated counterparts of 
isoprene (7), which was postulated to make up all terpenes through regular; 
head to tail, or irregular, head to head, condensations in the ‘empirical 
isoprene rule’.  Further research led Ruzicka to postulate the ‘biogenetic 
isoprene rule’,14 which invoked the formation of simple precursors which were 
then cyclised.14 Consequently, terpenes are classified according to the number 
of five-carbon ‘isoprene’ (5) units they contain, Table 1.1; each class of 
terpenes are made from their own universal precursor formed from the 
sequential condensation of IDP (5) with the starting molecule DMADP (6). 
Table 1.1 Classification of terpenes 
Prefix- Cx Precursor Examples 
Hemi- C5 dimethylallyl diphosphate Isoprene 
Mono- C10 geranyl diphosphate Limonene 
Sesqui- C15 farnesyl diphosphate Amorphadiene 
Di- C20 geranylgeranyl diphosphate Taxadiene 
Tri- C30 (2x) farnesyl diphosphate Steroids, cholesterol 





Figure 1.2 Structure of isoprene (A) and regular (B) and irregular (C) arrangements of isoprene 
units. Examples of mono- sesqui- and diterpene skeletons with the isoprene units highlighted in 
red, from Ruzicka’s landmark paper.14 
1.2.1 Mevalonate pathway 
In eukaryotes such as animals and fungi, the cytosol of plants, and also in 
some bacteria, IDP and DMADP are biosynthesized through the mevalonate 
pathway (MVA). Three molecules of acetyl coenzyme A (acetyl-CoA, 8) undergo 
sequential Claisen and aldol condensations to yield the key thioester, 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA, 9). HMG-CoA then 
undergoes NADPH-dependent reduction with two equivalents of NADPH to 
form mevalonic acid (10), the resulting primary alcohol is then 
diphosphorylated by two molecules of adenosine triphosphate (ATP) to 5-
diphosphomevalonic acid (11); the subsequent phosphorylation of the 3-
hydroxyl drives the decarboxylation and elimination of the tertiary phosphate 
group to produce IDP (5). IDP-isomerase (IDP-I) is responsible for the 
interconversion of IDP (5) and DMADP (6) to an equilibrium ratio of 
approximately 3:1 (DMADP:IDP), through the stereospecific removal of the 2-
pro-R-proton and the addition of a proton to the re-face of the double-bond of 




Scheme 1.1 Mevalonate pathway (top) and interconversion of IDP and DMADP (bottom). 
1.2.2 Non-mevalonate pathway 
In bacteria and the chloroplasts of algae and plants, IDP and DMADP are 
biosynthesised by the non-mevalonate pathway, also called the deoxyxylulose 
phosphate (DOX) or methylerythritol phosphate (MEP) pathway after on-path 
intermediates.17,18 In this pathway, pyruvate (12) and glyceraldehyde-3-
phosphate (13) are condensed via the thiamine diphosphate (TDP) dependent 
decarboxylation of pyruvate forming 1-deoxy-D-xylulose-5-phosphate 
(deoxyxylulose phosphate, DOX, 14). This then undergoes a rearrangement, 
followed by the NADPH-dependent reduction of the resulting aldehyde to yield 
2-C-methyl-D-erythritol-4-phosphate (methylerythritol phosphate, MEP, 15). 
Methylerythritol phosphate is converted into a cyclic diphosphate, 2-C-methyl-
D-erythritol-2,4-cyclodiphosphate (16), in a series of steps involving the 
transfer of cytidyl phosphate onto the terminal phosphate, phosphorylation of 
the 2-hydroxyl and the elimination of cytidyl monophosphate (CMP) upon 
cyclisation.19 The final two steps are catalysed by two iron-sulfur proteins, of 
which the catalytic mechanisms are still in dispute.20 The first step is a 
reductive ring opening of the cyclic diphosphate and elimination of water to 
yield 1-hydroxy-2-methyl-2-(E)-butenyl diphosphate (17). The following 
transformation of 1-hydroxy-2-methyl-2-(E)-butenyl diphosphate to both IDP 
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(5) and DMADP (6) is believed to involve two stepwise single-electron transfers 
from an iron-sulfur cluster and heterolytic cleavage of the 1-hydroxy group to 
yield an allylic carbanion which can be deprotonated to yield either IDP or 
DMADP.21 
 
Scheme 1.2 Non-mevalonate pathway to IDP and DMADP 
1.2.3 Isoprenyl diphosphate elongation 
The linear terpenes, geranyl-, farnesyl- and geranylgeranyl diphosphate (GDP, 
C10, 18; FDP, C15, 19 and GGDP, C20, 20 respectively) are formed from the two 
isoprenoid diphosphate precursors by the subsequent head-to-tail additions of 
an IDP molecule (5) to a starting molecule of DMADP (6). These chain 
elongations proceed by attack of the terminal double bond of IDP at C1 with an 
inversion of configuration. Stereoselective removal of the 2-pro-R-hydrogen of 
the added IDP quenches the intermediate carbocation and completes formation 
of the elongated isoprenyl chain.20 In the case of geranyl diphosphate synthase 
(GDPS) the newly formed GDP is released from the active site, while for 
farnesyl diphosphate synthase (FDPS) and geranylgeranyl diphosphate 
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synthase (GGDPS) subsequent elongations with IDP occur in the same manner 
to form farnesyl- (19, C15) and geranylgeranyl- (20, C20) diphosphates 
respectively, Scheme 1.3. 
 
Scheme 1.3 Isoprenyl diphosphate elongation reactions to form GDP (18), FDP (19) and GGDP 
(20) 
These linear isoprenyl diphosphates undergo carbocationic cyclisations and 
rearrangements catalysed by terpene synthases to generate a structurally 
diverse range of cyclic hydrocarbon skeletons, which are then available to 
undergo P450-dependent oxidations and further transformations to generate 
complex bioactive terpenoid products. This study focuses on the cyclisations of 
FDP by sesquiterpene synthases. 
1.3 Sesquiterpene synthases 
Sesquiterpene synthases are a class of terpene synthase that catalyse the 
conversion of the 15-carbon isoprenyl diphosphate, FDP, into more than 300 
different sesquiterpenes with a diverse range of structures including linear, 
mono-, bi- and tricyclic examples, with high degrees of stereospecificity. 
1.3.1 Structure 
While there is typically very low sequence similarity between terpene 
synthases, they have a highly conserved tertiary structure that was first seen 
in avian farnesyl diphosphate synthase.22 This conserved structure is termed 
the class I terpene synthase fold and is comprised of 10 -helices joined by 
short inter-connecting loop regions, with the active site formed by a conical 
cleft between three main central helices. The loop regions are typically very 
short, 3 – 5 residues, distal to the active site, while at the end of the helices 
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proximal to the active site they are longer, 8 – 10 residues in length and more 
flexible during the catalytic cycle.23 
 
Figure 1.3 Cartoon represtenations of bacterial (pentalenene synthase from Streptomyces 
UC5319, PDB 1PS1) fungal (aristolochene from Aspergillus terreus, PDB 2OA6) and plant (5-epi-
aristolochene synthase from Nicotania tabacum, PDB 5EAT) sesquiterpene synthases, showing 
the class I fold in blue and, in the plant synthase, the N-terminal domain in turquoise. 
Terpene synthases in bacteria and fungi are single domain proteins with this 
class I fold which is typically 300 amino acids long approximately, while those 
from plants also have a second N-terminal domain, which is also -helical in 
structure.24 In some plant terpene synthases this second domain appears to be 
catalytically silent, while it has been shown that in others the N-terminal 
domain is important, covering a range of roles; domain-changing experiments 
suggest it may play an important role in ensuring the correct folding of the C-
terminal domain,25,26 and recent work within the Allemann group suggests that 
the N-terminal segment is important in desolvating and protecting the active 
site. Shortening of the N-terminal loop segment in -cadinene synthase from 
Gossypium arboreum (DCS) by 10, 20 and 30 amino acid residues leads to 
increasing proportions of a product resulting from premature quenching of a 
carbocation intermediate.27 
1.3.2 Metal-binding regions 
All terpene synthases share two consensus metal binding regions responsible 
for the binding of a tri-nuclear magnesium cluster close to the active site 
entrance. Typically these regions comprise an aspartate-rich region, DDxxD/E 
found on helix D and the NSE/DTE motif (L,V)(V,L,A)(N,D)D(L,I,V)x(S,T)xxxE 
on helix H.24 The DTE-motif is commonly found in plant terpene synthases 
while the NSE-variant is more common in fungi and bacteria. Altered metal-
binding regions have been identified in some cases such as -cadinene 
synthase from Gossypium arboreum (DCS) in which the second metal-binding 
motif is a second DDxxD motif,28 more commonly seen in isoprenyl 
diphosphate synthases; and in (R)-germacrene D synthase from Solidago 
canadensis the aspartate rich region takes the form of NDxxD.29 Nonetheless 
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the two metal-binding regions are responsible for the binding of three 
magnesium ions, which in turn coordinate to the diphosphate group of 
farnesyl diphosphate and settle the isoprenoid chain in the active site. 
 
Figure 1.4 Cartoon representation of the crystal structure of AT-AS (PDB 2OA6 chain D) in 
coordination with [Mg2+]3-PPi. Magnesium ions are shown as green balls, the PPi is shown as a 
stick structure where red denotes oxygen and orange denotes phosphorus. Water in the 
magnesium coordination sphere is also shown as small red balls. Metal-binding residues are 
labelled. 
The use of X-ray crystal structures is a powerful tool for structural analysis 
and those of a number of terpene synthases have shown that the aspartate-
rich region is responsible for binding two magnesium ions while the NSE/DTE-
motif binds to the third magnesium.22,30 Magnesium ions (or another divalent 
metal ion) have been shown to been critical for catalysis by terpene synthases, 
not only are they vital to bind the diphosphate group and orientate the 
substrate correctly but they also serve to initiate the catalytic cycle by 
triggering ionisation of the diphosphate group for initial carbocation formation. 
1.3.3 Substrate binding cycle 
While the X-ray crystal structures of a number of sesquiterpene synthases 
have been solved,23,28,30–38 studies with aristolochene synthase from Aspergillus 
terreus (AT-AS) first revealed the closed conformation while complexed with 
diphosphate and three magnesium ions.30 Further X-ray crystallographic 
studies with this enzyme and fluorinated-FDPs presented a series of 12 
independent structures displaying an array of binding interactions; while 
predominantly examples of the substrate binding in the open conformation in 
the absence of magnesium ions three examples were obtained with increasing 
numbers of magnesium ions bound and in varying conformations. Using these 
structures Shishova et al. proposed a model for substrate and metal binding, 
and the associated conformational changes necessary for the catalytic cycle to 
progress.37 Initial binding of the substrate is governed by molecular recognition 
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of the diphosphate by hydrogen bond donors in the active site; the binding of 
Mg2+B follows or possibly occurs concurrently, coordinating to the largely pre-
organised binding site and causing a reorientation of the diphosphate group. 
Binding of Mg2+C to the first aspartate in the DDxxD motif and to the 
diphosphate group causes greater conformational changes triggering active site 
closure, and binding of the third magnesium, Mg2+A, completes the magnesium 
cluster causing a shift in Mg2+C such that both Mg2+A and Mg2+C are 
coordinated to the first aspartate in the DDxxD motif and completing the 
conformational changes required for full active site closure and formation of 
the Michaelis-complex. Opening of the active site and product release upon 
completion of the catalytic cycle is proposed to occur in the reverse sequence. 
Molecular dynamics simulations performed on AT-AS by Van der Kamp et al.39 
strongly support the proposed binding cycle and also reveal further details; 
The apo-enzyme can adopt a range of conformations from open to near-closed, 
but the binding of FDP (19) and Mg2+B shifts the equilibrium to ‘distinctly open 










Figure 1.6 Model of the conformational effect of the binding of FDP and Mg2+B on AT-AS 
A recent study by Baer et al. has identified significant structural shifts in a 
bacterial terpene synthase, selina-4(15),7(11)-diene synthase from 
Streptomyces pristinaespiralis (SP-SdS), hinting at an induced-fit mechanism 
in active-site closure directed by a novel effector triad of a sensor, linker and 
effector.36 X-ray crystal structures of SP-SdS in the apo-form as well as in 
coordination with (Mg2+)3-PPi and in coordination with (Mg2+)3-DHFDP (2,3-
dihydro-FDP, a nonreactive substrate analogue) were used to identify distinct 
states of the G1/2-helix break motif between the open and closed 
conformations. The data also show a significant shift of arginine-178 towards 
the diphosphate ligand upon substrate binding, while concomitantly 
reorienting aspartate-181 to form a hydrogen bond with arginine-178. This 
strictly conserved arginine is part of a hydrogen bonding network30,31,34 in the 
active site and to be vital for the catalytic activity in PR-AS.40 In the study with 
SP-SdS, the reorientation of arinine-178 and aspartate-181 precede the 
conformational change of the G1/2-helix break motif which ‘moves the 
catalytic key carbonyl oxygen of glycine-182 inwards into the active site’.36 The 
carbonyl oxygen of the residue at the break position in the G helix (glycine-182 
in SP-SdS) has been implicated in the stabilisation of the developing 
carbocation at C1 in the ionisation of FDP by hedycaryol synthase from 




Figure 1.7 Cartoon representations of an X-ray cocrystal structure of SP-SdS in complex with 
DHFDP, A; Helix G1/2 shown in green, Mg2+ in cyan, DHFDP in yellow, oxygen atoms in red, 
Blue ribbons highlight structural elements formed on DHFDP binding. Superimposition of helix 
G1/2 in open (grey) and closed (green) conformations, B; dashed lines highlight interactions 
while the red arrows indicate the induced-fit movements. Superimpositions of the effector triad 
(sensor, linker, effector as indicated), C; SP-SdS:DHFDP (green), epi-isozizaene synthase (grey, 
3KB9), aristolochene synthase (pale blue, 4KUX), bornyl diphosphate synthase (pink, 1N20), 
limonene synthase (orange, 2ONG), 5-epi-aristolochene synthase (blue, 5EAT) and taxadiene 
synthase (yellow, 3P5R). Figures taken from reference36. 
1.3.4 Cyclisation through nerolidyl diphosphate (NDP)  
For sesquiterpene synthases the first chemical step in the catalytic cycle is the 
ionisation of FDP (19) to the farnesyl allylic cation-diphosphate anion pair 
followed by nucleophilic attack by a double-bond. Attack by the C10,C11-
double bond to form either the 10- or 11-membered rings retaining the (E,E)-
double bond stereochemistry of the FDP is possible through the transoid-allylic 
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farnesyl cation (transoid-21). However, for those sesquiterpene synthases 
which undergo a 1,6-cyclisation or form macrocycles with (Z,E)-double bond 
stereochemistry, nucleophilic attack by the C6,C7- or C10,C11-double bonds 
are geometrically forbidden.41,42 In this case, collapse of the farnesyl allylic 
cation-diphosphate anion pair has been proposed to form the tertiary 
diphosphate, nerolidyl diphosphate (NDP, 22), in the transoid conformation. 
Rotation around the 2,3-single bond yields the cisoid conformation which is 
now suitably positioned for 1,6- or 1,10-ring closure either directly with 
concerted loss of the diphosphate or indirectly through initial formation of the 
cisoid-allylic cation-diphosphate anion pair followed by nucleophilic attack of a 
double-bond to form the bisabolyl (23) or the cis-germacryl cation (24) which 
can then participate in further transformations. 
 
Scheme 1.4 Cyclisation of FDP (19) to cations containing Z-bouble bonds via NDP (22) 
A recent study by Zhang and Tiefenbacher has suggested that a direct 
isomerisation of the transoid-geranyl cation (transoid-25) to the cisoid-isomer 
(cisoid-25) is feasible.43 The authors investigated the possibility of mimicking 
the aromatic, hydrophobic active site of terpene synthases using a self-
assembling supramolecular structure that forms a large hydrophobic cavity. A 
resorcinarene unit (26) has previously been shown to form a hexamer in apolar 
solvents, which is known to complex to cationic guests and has been shown to 
be a mild Brønsted acid, Figure 1.8. This capsule was used to investigate the 
cyclisation of the monoterpene alcohols geraniol (27), nerol (28) and linalool 
(29) and was found to successfully catalyse the turnover of all three with the 
primary products demonstrating interception of carbocationic intermediates by 




Figure 1.8 Structure of resorcinarene (25) and monoterpene alcohols 
In order to reduce leaving group interception of intermediates the substrates 
were switched to the corresponding acetates. When the same reaction 
conditions were used with geranyl acetate (30) it resulted in the selective 
production of -terpinene (31), while linalyl acetate (32) produced both -
terpinene (31) and terpinolene (33). If cyclisation of geranyl acetate (30) forms 
the cisoid-allylic cation (cisoid-25) via linalyl acetate (32) intermediate, the 
product distribution from both these substrates could be expected to be 
identical; suggesting that there is no conversion of geranyl acetate to linalyl 
acetate and therefore the energy barrier to isomerisation between the transoid- 
and cisoid-cations is easily overcome at ambient conditions, Scheme 1.5. 
 
Scheme 1.5 Products formed by resorcinarene capsule and monoterpene acetates 
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1.4 Mechanistic investigations 
Catalysis by sesquiterpene synthases is initiated by the loss of diphosphate to 
form the initial farnesyl cation. Sesquiterpene synthases are then able to direct 
the reaction through cyclisations, hydride- and methyl-shifts, protonations 
and deprotonations to the final product, shuttling the carbocation through 
intermediates with an impressive degree of precision and selectivity. While 
there are examples of ‘promiscuous’ sesquiterpene synthases (which produce 
multiple products) such as -humulene synthase found in both plants44,45 and 
microbes,46 many sesquiterpenes show exceptionally high-fidelity; producing a 
single product exclusively or near exclusively. These high-fidelity synthases are 
able to differentiate between alternate reaction pathways which would 
normally be of similar energies, achieved through the templating effect of the 
active site with the metal-binding motives holding the diphosphate group in 
place and the, predominantly hydrophobic and aromatic, residues lining the 
active site cavity aligning the isoprenoid-tail into a productive orientation, and 
stabilising carbocationic intermediates and transition states.   
Many of the methods used experimentally to study the mechanisms of terpene 
synthases focus on probing the carbocationic intermediates; the use of aza-
analogues, to mimic carbocation intermediates with ammonium species; 
fluorinated substrate-analogues, to destabilise intermediate carbocations and 
intercept the reaction pathway; and single-point mutations of aromatic 
residues. These methods can also be used to investigate specific steps in the 
reaction cascade, substrate analogues stereospecifically labelled with 
deuterium can be used to elucidate regio- and/or stereochemistry of specific 
steps; and the used of site-directed mutagenesis can be used to target specific 
residues for single-point mutation to probe their function and effect on 
catalytic activity or product distribution. 
1.4.1 Aza-analogues 
Aza-analogues are nitrogen-containing analogues of proposed carbocation 
intermediates that are either quaternised or protonated in solution to form a 
stable charged carbocation mimic. Numerous example of these type of 
products have been shown to effectively mimic intermediates, acting as 
inhibitors in kinetic studies with sesquiterpene synthases,47–49 diterpene 
synthases50–54 and squalene synthase.55–57 Some examples have also proved 
effective as crystallisation aids in mono-58 and sesquiterpene synthases38,59 for 




Figure 1.9 Examples of aza-analogues and the proposed carbocations they are designed to 
investigate 
1.4.2 Substrate analogues 
Isotopologues 
Much of the stereo- and regiochemical detail of the mechanisms of several 
terpene synthases has been elucidated through the use of isotopically labelled 
substrates such as deuterated, tritiated and carbon-14 labelled FDPs.60–66 
Fluorinated analogues 
Replacement of hydrogen with fluorine at strategic positions in FDP has been 
shown to be a valuable tool in the mechanistic investigation of sesquiterpene 
synthases. Due to the similarity in size to hydrogen, replacement with fluorine 
would not be expected to have a significant effect on the size and shape of the 
FDP analogue while exhibiting a strong electronic influence at the site of 
replacement due to the high electronegativity. This electronegativity has a 
destabilising effect on carbocations at the - and -positions via a through 
bond inductive effect, while a carbocation in an -position is stabilised by -
donation of a lone-pair. By strategic positioning of fluorine in FDP-analogues 
the existence of carbocationic intermediates can be probed through the 
derailment of the cyclisation cascade; this strategy has been used successfully 
in the mechanistic elucidation of PR-AS67–69 as described earlier, Section 1.5.5, 
and fluorinated-FDP’s have also proven successful in the solving of crystal 
structures.28,37 
 
Figure 1.10 Effect of fluorine substitution -, - and - to a carbocation 
1.4.3 Site-directed mutagenesis 
Site-directed mutagenesis (SDM) can be used to specifically alter targeted 
amino acids in the protein, enabling the importance and function of specific 
amino acids during catalysis to be assessed through analysis of kinetic 
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parameters and product distribution. This technique has been used to 
investigate the metal-binding motifs,70–72 active-site aromatic residues73,74 and 
putative active-site acid/bases,75 in a number of sesquiterpene synthases; 
such as PR-AS, Section 1.5.5. 
Plasticity residues 
Using the promiscuous -humulene synthase, a sesquiterpene synthase from 
Abies grandis, grand fir, which produces 52 different sesquiterpenes from 
incubation with FDP, Yoshikuni et al. used saturation mutagenesis of the 19 
residues forming the hydrophobic core of the active site to investigate the 
contribution made by each to different reaction mechanisms; initial 1,6- 1,10- 
or 1,11-cyclisations, .76 
 
Scheme 1.6 Examples of sesquiterpenes produced by -humulene synthase via 1,6-, 1,10- and 
1,11-cyclisation mechanisms. 
The altered product distributions were profiled and normalised to the wildtype 
enzyme; while many of these residues were ‘plastic’, causing changes in 
product profile, four key ‘plasticity residues’ were identified; W315, M447, 
S484 and Y565. These plasticity residues significantly affected catalysis, 
increasing the relative selectivity of the resulting mutants by 100- to 1000-fold 
(proportions of one product relative to another). Based on the product profiles 
from saturation mutagenesis, mutations were systematically recombined to 
produce a desired enzyme function while not severely compromising the 
efficiencies of those enzymes, typically a maximal 10-fold decrease in catalytic 
efficiency (kcat/KM). Using this method the authors were able to create -
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bisabolene (BBA), sibirene (SIB), longifolene (LFN) synthases and a -humulene 
synthase with enhanced selectivity (HUM), by combining up to 5-mutations, . 
Through this study Yoshikuni et al. have demonstrated the innate evolvability 
of terpene synthases, and an insight into the evolutionary history through a 
small number of mutations to ‘plasticity residues, and provided evidence that a 
rational design approach to generating novel terpene synthases may be 
possible in the future. 
H-1 loop 
A study by Lopez-Gallego et al. investigated the importance of the H-1 loop in 
the cyclisation mechanism of a series of sesquiterpene synthases from 
Coprinus cinereus.77 Using structural models of Cop4, a non-selective synthase 
producing 7 products; and Cop6, a highly-selective synthase producing -
cuprenene (86), ; the authors postulated interactions between the H-1 loop 
and other residues lining the active site entrance. Site-directed mutagenesis on 
residues comprising the H-1 loop identified residues which dramatically 
affected the product selectivity in Cop4, and severely reduced catalytic 
efficiency. Interestingly, similar mutations to the highly selective Cop6 had a 
lesser effect on both catalytic efficiency and product distribution. Mutations to 
the H-1 loop in Cop6 caused only a small decrease in product specificity, 98% 
-cuprenene (86) production to 96% in the most adversely affected mutants. A 
loop switch from Cop4 to Cop6 had only a minor effect on Cop6 (Cop6L4 
mutant), with a slight reduction in specificity matching that observed in the 
single point mutations. The reverse switch, insertion of the Cop6 loop in Cop4, 
drastically improved the selectivity of the resulting mutant (Cop4L6), 
producing 71% of germacrene D (36) as the major product in addition to two 
other products; through causing the premature deprotonation during the 




Table 1.2 Product distributions (%) and steady-state kinetic parameters of g-humulene synthase and mutants. ND, not detected. (E)--farnesene (48), sibirene, (81), 
-humulene (83), longifolene (84), -longipinene (82), -ylangene (85), -bisabolene (49). 
Enzyme Mutations 





(s-1mM-1) 48 81 83 84 82 85 49 
WT - 3.0 23.1 45.1 13.4 4.7 3.8 6.9 0.024 4.7 51 
BBA A336V, M447H, I562T 6.4 0.4 3.8 4.7 1.1 0.1 83.6 0.022 2.9 78 
SIB F312Q, M339A, M447F 6.4 78.1 11.4 2.6 0.1 1.0 0.4 0.00046 3.0 0.15 
LFN A317N, A336S, S484C, I562V 1.7 1.4 12.6 63.0 12.6 3.2 5.5 0.070 3.8 181 





Scheme 1.7 Products produced from cyclisation of FDP by Cop6 and Cop4 and their 
proportions. Sesquiterpenes in brackets are those produced by Cop4 mutants. 
Table 1.3 Product distributions (%) from Cop6 and Cop4 and their H-1 loop mutants, from the 
headspace of E. coli cultures. U, unidentified sesquiterpenes. 
Enzyme 
Product distribution 
86 87 92 89 90 88 36 47 91 93 94 95 U 
Cop6 WT 98 2 - - - - - - - - - - - 
Cop6-C236A 96 3 - - - - - - - - - - 1 
Cop6-E237L 96 3 - - - - - - - - - - 1 
Cop6-N240L 98 2 - - - - - - - - - - - 
Cop4 WT - - 2 14 10 27 9 32 7 - - - - 
Cop4-K233I - - 10 27 5 18 12 17 3 2 2 - 3 
Cop4-H235P - - - 8 - 11 49 4 - - 15 5 - 
Cop4-T236L - - - 12 14 32 - 42 - - - - - 
Cop4-N238L - - - 21 9 32 4 34 - - - - - 
Cop4-N239L - - - 4 - 10 50 3 - - 15 5 13 
Cop6L4 96 3 - - - - - - - - - - 1 




Notably, in Cop4 the product fidelity was also found to be sensitive to the pH, 
with increased production of germacrene D at pH 5 and pH 10; this pH 
dependence is eliminated in the H235 and N239 mutants, pointing to ionic 
interactions between these residues and the active site as key in stabilising the 
H-1a helix in the closed conformation, . This study highlights the role of the H-
1a loop in product distribution in low-fidelity terpene synthases, modulated 
through interactions with the metal-binding motives and the Mg2+3-PPi complex 
during the catalytic cycle. It also demonstrates the complex nature of these 
enzymes and the subtle differences between them, with the H-1 loop playing 
an, apparently, less active role in high fidelity terpene synthases. 
 
Figure 1.11 Product profiles (%) of Cop4 and mutants at pH 5 (blue), pH 8 (red) and pH 10 
(green). 
1.5 Terpene synthases used in this study 
This study uses a number of previously studied sesquiterpene synthases 




































1.5.1 Germacrene A synthase 
(+)-Germacrene A synthase from Solidago canadensis (GAS) is a 549 amino 
acid plant sesquiterpene synthase which generates (+)-(10R)-germacrene A (R-
34). Germacrene A (34) arises from 1,10-ring closure of FDP (19) to form the 
germacryl cation followed by deprotonation at C12 to yield the final product. 
The absolute stereochemistry of germacrene A (34) produced by GAS was 
determined by chiral GC-MS; exploiting the thermal Cope rearrangement of 
germacrene A (34) to -elemene (35), with retention of configuration, Scheme 
1.8.78 
 
Scheme 1.8 Formation of (R)-germacrene A (R-34) from FDP (19), and the thermal Cope 
rearrangement to -elemene 
In addition to producing germacrene A (34) (> 96%), GAS also produces ~2% of 
germacrene D (36) and -humulene (37), along with traces of (E)--
caryophyllene (38), Scheme 1.9. The formation of -humulene (37) and (E)--
caryophyllene (38), products formed through a 1,11-cyclisation mechanism 
prompted Gonzalez et al. to investigate the origin of this 1,11-cyclase activity.79 
 
Scheme 1.9 Products of GAS with FDP (19) via 1,10- and 1,11-cyclisations 
Sequence alignment of multiple plant 1,10- and 1,11-sesquiterpene cyclases 
identified glycine-402 as a possible determinant in 1,10-cyclisation. 
Substitution of glycine-402 with residues of increasing volume lead to an 
increase in the proportions of 1,11-products, up to a maximum of 68% in the 
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G402C mutant, with many mutants displaying near wild-type catalytic activity, 
Table 1.4.80 
Table 1.4 Product distribution (%) of 1,10- and 1,11-products and steady-state kinetic 












GAS 98.25 1.75 0.043 ± 0.02 3.4 ± 0.3 12.6 ± 4.8 
GAS-G402A 56.7 43.3 0.053 ± 0.01 8.9 ± 1.3 5.9 ± 1.1 
GAS-G402S 55.8 44.2 0.021 ± n0.01 3.3 ± 0.9 6.4 ± 1.8 
GAS-G402D 50.5 49.5 0.001 ± 0.01 0.5 ± 0.07 2.0 ± 0.2 
GAS-G402C 31.6 68.4 0.030 ± 0.01 5.3 ± 1.8 5.7 ± 0.02 
GAS-G402T 41.7 58.3 0.054 ± 0.01 4.7 ± 0.5 11.5 ± 0.02 
GAS-G402V 42.1 57.9 0.025 ± 001 1.0 ± 0.2 25.0 ± 5.0 
GAS-G402F, L, I Inactive 
 
Incubation of GAS with 10-fluorofarnesyl diphosphate (10F-FDP, 39) yielded 
exclusively 10F--humulene (40) as the product, albeit 15-fold less efficiently 
than the production of germacrene A (34) with FDP (19). This was proposed to 
be due to the cyclisation bypassing formation of the destabilised 10F-
germacryl cation (41), by the formation of a bridged carbocation species (42). 
Ring expansion to the stabilised 10F-humulyl-carbocation (43) followed by 
deprotonation yields the 10F--humulene (40), Scheme 1.10. 
 
Scheme 1.10 Proposed mechanism for the cyclisation of 10F-FDP (39) by GAS 
Use of the hexadeuterated [12,12,12,13,13,13-2H6]-FDP (d6-FDP, 44) provided 
further evidence for the intermediacy of a bridged carbocation. Incubation of 
GAS and mutants with d6-FDP (44) showed a considerable change in product 
distribution, with respect to unlabelled FDP (19), Table 1.5. The simultaneous 
perturbation of the germacrene A (34): -humulene (37) and the germacrene A 
(34): germacrene D (36) product ratios can be attributed to all three products 
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arising from a common intermediate, subject to a primary deuterium KIE 
affecting the final deprotonation step, Scheme 1.11. 
 
Table 1.5 Product distributions (%) and ratios from incubations of GAS and mutants with d6-
FDP (44) compared to d0-FDP (19). Germacrene A (34), germacrene D (36) and -humulene (37) 
Enzyme Substrate 34 36 37 34:36 34:37 KIE 
GAS d0-FDP 96.58 1.67 1.75 57.83 55.18 4.98 
 d6-FDP 85 7.3 7.7 11.70 10.98  
GAS-G402A d0-FDP 54.1 2.6 41.6 20.80 1.30 4.08 
 d6-FDP 22.4 4.5 71.5 4.97 0.31  
GAS-G402S d0-FDP 50.7 5.1 42.5 9.94 1.19 5.09 
 d6-FDP 16.8 8.8 72.5 1.90 0.23  
GAS-G402C d0-FDP 13.7 15.9 61.6 0.86 0.22 4.25 




Scheme 1.11 Possible mechanisms for the turnover of d6-FDP (44) via a bridged carbocation 
species 
1.5.2 Germacrene D synthase 
While Solidago canadensis produces both (R)- and (S)-germacrene D (36). This 
study uses only the (S)-germacrene D synthase, which has previously been 




Scheme 1.12 Cyclisation of FDP by (S)-GDS. 
The mechanism of (S)-GDS was proposed to proceed through 1,10-ring closure 
followed by a 1,3-hydride shift from C6 (C1 of the FDP substrate) followed by 
deprotonation at C15 to yield (S)-germacrene D (S-36), Scheme 1.12. The 
stereochemistry of the 1,3-hydride shift was studied by incubation with 
deuterated-FDPs, (1S)-[1-2H]-FDP (45) and (1R)-[1-2H]-FDP (46) and analysis of 
the products by GC-MS.81 Incubation with (1S)-[1-2H]-FDP (45) and (1R)-[1-
2H]-FDP (46) led to products with m/z = 205, indicating the presence of one 
deuterium in place of a proton. The product from incubation with (1S)-[1-2H]-
FDP (45) has the most abundant fragment ion at m/z = 162 while that from 
incubation with (1R)-[1-2H]-FDP (46) is at m/z = 161; both these fragments 
arise from loss of the isopropyl group from M+ indicating that the pro-R-H-1 of 
FDP migrates to the isopropyl group, Scheme 1.13.64 
 
Scheme 1.13 Fragmentation of germacrene D from incubation with (1R)-[1-2H1]-FDPs 
Both (R)- and (S)-GDS share high sequence identity with each other (85% 
identity, 89% similarity) however, in the (R)-GDS the aspartate rich region is 
modified to 303NDxxD, due to a single base mutation in the DNA sequence.29 
The ‘corrected’ mutant N303D was found to be active, and the alteration had 
little effect on the catalytic efficiency with a slightly improved KM and no 
change in kcat. The inverse mutant of (S)-GDS, D303N, was however 10-fold 
less active than the wildtype, due solely to a reduction in kcat, Table 1.6. 
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Table 1.6 Steady-state kinetic parameters of (R)- and (S)-GDS and mutants 
Enzyme kcat KM 
(R)-GDS WT 0.02 3.0 ± 0.3 
(R)-GDS-D303N 0.02 2.2 ± 0.2 
(S)-GDS WT 0.03 2.9 ± 0.3 
(S)-GDS-N303D 0.002 2.9 ± 0.4 
 
1.5.3 -Cadinene synthase 
-Cadinene synthase from Gossypium arboreum (DCS) is a plant sesquiterpene 
synthase which catalyses the conversion of FDP to the bicyclic sesquiterpene 
(+)--cadinene (47).82 In place of the NSE/DTE motif common to terpene 
synthases DCS has a second aspartate rich region on helix H, 451DDVAE; the 
roles of both aspartate rich regions were probed by site directed mutagenesis. 
The 307DDTYD motif on helix D interacts with Mg2+A and Mg2+C, Section 1.3.2, 
and while the D307A, D308A and D311A mutants all produced -cadinene (47) 
only the D307A mutant was active enough to measure steady-state kinetic 
parameters. While the turnover number for this mutant is comparable to 
wildtype, replacement of the aspartate with an alanine has a dramatic effect on 
the KM, Table 1.7.28 Mutants of the second aspartate rich region similarly all 
produce -cadinene, but it is clear that the glutamate-455 has a significant 
role in coordinating with the Mg2+B, with the catalytic activity severely 
compromised in the E455A mutant. While the DCS-D451A and DCS-D452A 
display essentially unchanged steady-state kinetic parameters with respect to 
wildtype.  






DCS WT 0.010 ± 0.001 3.2 ± 0.5 
DCS-D307A 0.012 ± 0.001 43 ±1 6 
DCS-D308A n/m n/m 
DCS-D311A n/m n/m 
DCS-D451A 0.043 ± 0.001 2.4 ± 0.3 
DCS-D452A 0.014 ± 0.001 3.1 ± 1.2 
DCS-E455A n/m n/m 
 
Benedict et al. have shown that DCS is able to turnover nerolidyl diphosphate 
(NDP, 22) into -cadinene (47), albeit with lower fidelity than with FDP, also 
producing (E)--farnesene (48) and -bisabolene (49).82 Competitive studies 
with (3R)-NDP (3R-22) and (3RS)-NDP (3RS-22) demonstrate that (3R)-NDP 
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(3R-22) is the enantiomer turned over by the enzyme, but the formation of -
bisabolene (49) in the turnover of NDP (22) highlights the possibility of an 
initial 1,6-ring closure followed by hydride shift and 1,10-ring closure. 
 
Scheme 1.14 Products of the turnover of 19 and (3R)-NDP (3R-22) by DCS 
 
Scheme 1.15 Possible 1,10- (blue) and 1,6-cyclisation (red) mechanisms of DCS.  
Faraldos et al. have performed a detailed study into the mechanism of DCS 
using deuterated and fluorinated FDP-analogues to distinguish between 1,6- 
and 1,10-cyclisation pathways.65 In addition to 1,6- and 1,10-ring closures 
subsequent to isomerisation to NDP (22), a mechanism via direct 1,10-ring 
closure to form (R)-germacrene D (R-36) as a neutral enzyme-bound on-path 
intermediate, followed by 1,6-ring closure driven by protonation of the distal 
double bond has also been proposed, Scheme 1.16. This mechanism would 
avoid the necessity for the formation of NDP (22) and has been shown to 
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operate in a promiscuous, multiproduct sesquiterpene synthase from Medicago 
truncatula.83 
 
Scheme 1.16 Mechanism for conversion of 19 to -cadinene via enzyme bound (R)-germacrene 
D (R-36) intermediate 
Incubations with (2Z,6E)-2F-FDP (50), (2E,6E)-2F-FDP (51) and 10F-FDP (39) 
led to the formation of macrocyclisation products 2F-germacrene A (52), 2F-
helminthogermacrene A (53) and 10F--humulene (40) respectively, 
supporting a 1,10-ring closure mechanism. However, the intermediacy of 
enzyme bound (R)-germacrene D (R-36) was ruled out through the use of 
[15,15,15-2H3]-FDP (54), which resulted in -cadinene (47) with full 
incorporation of the deuterium atoms. When DCS was incubated with 6,7-
dihydro-FDP (55), however, no 1,10-cyclisation products were produced, 
instead the main product was (Z)--6,7-dihydrofarnesene (56). Along with the 
strong competitive inhibition of DCS by 6F-FDP (57), implicating the inhibition 
of the formation of the 6F-bisabolyl cation (58), and the exclusive production of 
bisabolene (59,60,61) products upon incubation with (2Z,6E)-FDP (62) these 




Scheme 1.17 Products formed by incubations of DCS with substrate analogues 
Overall the results did not unambiguously favour either 1,6- or 1,10-
cyclisation mechanisms instead demonstrating the possibility of multiple 
mechanistic pathways and the versatility of DCS in its ability to distinguish 
between them in a substrate dependent manner.  
Use of (1R)-[1-2H1]-FDP (46) as described with (S)-GDS (Section 1.5.2) resulted 
in the deuterated -cadinene (47) product and through the analysis of the 
mass-spectral fragmentation pattern of the product, it was demonstrated that 
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the pro-R-H-1 remains at the C1 position, identifying the stereochemistry of 
the 1,3-hydride shift as migration of the pro-S-H-1. 
1.5.4 Amorphadiene synthase 
Amorphadiene (amorpha-4,11-diene) synthase (ADS) is a plant sesquiterpene 
synthase from Artemisia annua, that catalyses the formation of amorpha-4,11-
diene (63) from FDP (19).84,85 Amorpha-4,11-diene (63) is a key intermediate in 
the biosynthesis of the naturally occurring malarial treatment artemisinin (2). 
Picaud et al. proposed a mechanism through formation of NDP (22) and 1,6-
ring closure followed by a 1,3-hydride shift, based on the observation of 
bisabolene byproducts.85 Investigations using (1R)-[1-2H]-FDP (46), (1S)-[1-2H]-
FDP (45), and [1,1-2H2]-FDP (64) with analysis of the formed amorphadiene by 
GC-MS and NMR showed that the pro-S-H-1 is transferred to C10, while the 
pro-R-H-1 remains at the C1 position (C6 in amorphadiene numbering), 
Scheme 1.18. Two subsequent 1,2-hydride shifts after formation of the 
bisabolyl cation (23) would results in deuterium incorporation at C1 and C6 
(amorphadiene numbering), while an initial 1,10-ring closure followed by a 
1,3-hydrixde shift would result in deuterium at C11. 
 
Scheme 1.18 Incorporation of deuterium into amorphadiene from deuterated-FDPs 
Only the proposed mechanism accounts for the incorporation of deuterium 
into both C6 and C10 upon incubation of ADS with [1,1-2H2]-FDP (64).66,86 
After 1,6-cyclisation and 1,3-hydride shift, the second ring closure forms the 




Recently, O’Maille and coworkers have identified an epistatic network of 
residues which controls cyclisation of FDP.87 Using ADS and (E)--Farnesene 
(EBFS), also from Artemisia annua, a large library of enzymes was created 
(>27,000). ADS and BFS share 49% amino acid identity, and structure-based 
combinatorial protein engineering was used to breed variation form ADS into 
BFS. The generated mutant enzymes were sampled and screened by GC-MS to 
identify cyclic and linear products. Subsequent sequence analysis and further 
mutation enabled the authors to identify a single substitution, Y402L, which 
was sufficient to activate cyclisation in EBFS, causing approximately 75% of 
cyclic products. Further mutations and screening lead to the identification of 
the converse cyclisation suppressing replacement, V467G. This substitution 
reverted cyclase mutants to farnesene synthases and similarly, removal of this 
substitution in farnesene-producing mutants resulted in 6-fold increase in 
cyclic products. A further network of epistatic residues was also identified, 
some in distant positions in the protein structure highlighting the role of long-
range communication across the protein. This epistatic network was also 
shown to control cyclisation in an EBFS homologue from Citrus junos. 
1.5.5 Aristolochene synthase 
Aristolochene synthases producing (+)-aristolochene (66) have been identified 
in Aspergillus terreus (AT-AS)60,88 and Penicillin roquefortii (PR-AS),89 and both  
have been extensively studied. In this study the enzyme used is PR-AS, 
producing 92 % (+)-aristolochene (66), 7.5 % (S)-germacrene A (S-34) and < 0.5 
% valencene (67). 
The relatively high proportion of (S)-germacrene A (S-34) produced by PR-AS 
led Calvert et al. to postulate germacrene A (34) as an on path intermediate, 
and upon replacement of an active site tyrosine with a phenylalanine the 
proportion of germacrene A (34) increased in the resulting mutant, Y92F.90 
Further alterations to this tyrosine residue also lead to increased proportions 
of (E)--farnesene (48) produced by the Y92V mutant, demonstrating the 
importance of tyrosine-92 in shaping FDP (19) into a suitable conformation for 
cyclisation.73 After 1,10-cyclisation and deprotonation to form the enzyme 
bound germacrene A (34), protonation of the C6-7 double bond is proposed to 
drive the second ring closure to form the eudesmane cation (68). A subsequent 
series of hydride and methyl shifts followed by deprotonation at C8 yields 
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aristolochene (66). A small proportion of deprotonation occurs at C6, yielding 
0.5% valencene (67). 
Incubation of PR-AS with (2Z,6E)-2F-FDP (2F-FDP, 50) produced a single 
product which was identified as 2-fluorogermacrene A (52), providing 
compelling evidence that germacrene A (34) is an on-pathway product of PR-
AS while simultaneously indicating that ionisation and cyclisation in PR-AS is 
a concerted process. The productive cyclisation to form 2-fluorogermacrene A 
(52) indicates that there is no development of positive charge in a -position to 
the fluorine; If ionisation and cyclisation were to occur in a stepwise manner, 
formation of the allylic farnesyl cation (21) might be destabilised by the 2-
fluoro-substituent leading to an abortive process.68 Incubations with 6-fluoro- 
(57) and 14-fluoro-FDPs (70) both produced the respective fluorinated 
germacrene A analogues (71, 72), further supporting the role of germacrene A 
(34) as an on path intermediate to aristolochene (66).69 
 
Scheme 1.19 Cyclisation of fluorinated-FDPs (50, 57, 70) by PR-AS 
A concerted mechanism for the cyclisation by PR-AS was further supported by 
the use of the [12,13]-F2-FDP (12,13-difluoro-FDP, 73) analogue, incubation 
with this analogue yielded no products and it was demonstrated to act as a 
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competitive inhibitor with a measured Ki comparable with the reported KM (Ki, 
0.8 µM ≈ KM, 2.3 µM).67 In a stepwise mechanism where the farnesyl cation 
(21) is generated prior to cyclisation, accumulation of the 12,13-
difluorofarnesyl cation (74) would be expected due to the destabilising effect of 
the two fluorine substituents on the 12,13-difluorogermacryl cation (75) at 
C11. Deprotonation of the 12,13-difluorofarnesyl cation (74) at C4 or C15 
would then lead to the 12,13-difluoro-(E,E)--farnesene (76) or 12,13-difluoro-
(E)--farnesene (77), respectively. In a situation where loss of the diphosphate 
is in concert with cyclisation the first carbocation to develop is on C11 in the 
formation of the 12,13-difluorogermacryl cation (75); in the destabilising 
presence of the two fluorine substituents this cation would not develop, 
leading to competitive inhibition. 
 
Scheme 1.20 Projected turnover of 12,13-difluoro-FDP by PR-AS 
The cyclisation of FDP (19) to aristolochene by PR-AS has been determined to 
go through a concerted 1,10-cyclisation and loss of diphosphate to form the 
germacryl cation which is deprotonated at C12 to yield the enzyme bound 
intermediate (S)-germacrene A (S-34), a small proportion of which ‘leaks’ from 
the active site. Protonation of the 6,7-double bond drives the second ring 
closure to generate the bicyclic eudesmane cation (68), subsequent 1,2-
hydride and methyl shifts are followed by abstraction of the Hsi on C8 to 




Scheme 1.21 Cyclisation of FDP (19) by PR-AS 
The 4-aza-eudesmane cation (78) has been synthesised and found to be a 
potent competitive inhibitor for PR-AS, these results suggest that this 
compound is an effective transition state mimic for the eudesmane carbocation 
(68) supporting the intermediacy of this carbocation in the reaction 
mechanism catalysed by PR-AS.47,48 
PR-AS has also been extensively studied using site-directed mutagenesis to 
probe active site residues, in particular the metal binding motives71 and 
residues identified as part of the [Mg2+]3-PPi hydrogen bonding network.40 
Replacement of the residues in the aspartate rich region (115DDxxE) showed 
aspartate-115 and -116 to play a greater role in magnesium binding than that 
played by glutamate-119; the D115E and D116E mutants displayed 12-fold 
and 60-fold reduction in catalytic activity with respect to wildtype, while 
replacement of glutamate-119 to generate the E119D mutant did not 
considerably affect steady-state kinetic parameters. Further alteration of D115 
to a glutamine produced the inactive D115N mutant, while a similar alteration 
to D116 produced the D116N mutant, which was near identical in activity to 
the D116E mutant. In addition to an effect on catalytic efficiency alterations to 
the aspartate rich region also caused a decrease in fidelity in the resulting 
mutants, with greater proportions of germacrene A (34) detected in all 
mutants, with the exception of E119D. These altered product distribution 
highlights the necessity of correct and precise substrate binding and 
positioning for correct functioning of the enzyme.71 
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Table 1.8 Steady-state kinetic parameters and product distribution (%) of PR-AS and mutants. 









66 67 34 
PR-AS 0.043 ± 0.002 0.6 ± 0.1 72 94 2 4 
AS-D115E 0.016 ± 0.0004 2.7 ± 0.2 6.0 75 6 19 
AS-D115N Inactive 
AS-D116E 0.0013 ± 0.00005 1.1 ± 0.13 1.2 62 3 35 
AS-D116N 0.002 ± 0.0001 1.5 ± 0.1 1.5 63 2 35 
AS-E119D 0.0048 ± 0.0001 0.15 ± 0.02 30 94 2 4 
AS-N244L Inactive 
AS-N244D 0.00012 ± 0.000003 3.3 ± 0.2 0.036 19 ND 81 
AS-S248A 0.0013 ± 0.00004 5.5 ± 0.4 0.24 21 ND 79 
AS-E252D 0.0022 ± 0.00009 3.4 ± 0.4 0.65 19 ND 81 
AS-E252Q 0.00022 ± 0.00001 10.1 ± 0.7 0.022 ND ND 100 
 
This study also probed the magnesium binding residues in NSE-motif 
(244NDxxSxxxE). Replacement of these residues had a greater effect on both 
catalytic efficiency and product distribution than that reported to the above 
mutants of the aspartate rich region; the replacement of asparagine-244 with 
the isosteric leucine caused a complete loss of function, while the N224D 
mutant displayed a 2000-fold decrease in catalytic efficiency with a dramatic 
change in product distribution, producing >80 % germacrene A (34). This 
dramatic shift in product distribution was also mirrored by alterations to other 
residues in the NSE-motif; the S248A and E252D mutants both produced ~80 
% germacrene A (34) coupled with a 200-fold decrease in activity, while 
mutation of the glutamate-252 to a glutamine yields a high-fidelity germacrene 
A synthase, albeit with 3500-fold lower catalytic efficiency than PR-AS.  
In addition to the metal-binding motifs, other conserved residues identified as 
part of the hydrogen bonding network to the [Mg2+]3-PPi complex in crystal 
structures of AT-AS30,37 were also investigated by SDM.40 All replacements of 
these residues, reducing the level of hydrogen-bonding capacity, caused a 
decrease in catalytic efficiency. Alterations of arginine-200 and arginine-340 to 
uncharged or negatively charged residues yielded inactive mutants, 
highlighting the importance of salt bridges between these arginine residues 
and the aspartate rich region or the diphosphate anion. The vital role of R200 
and R340 in catalysis is cooperatively aided by tyrosine-341 and lysine-251, 
and replacing these residues with amino acids of reduced hydrogen bonding 
capability produced mutants, K251Q and Y341F, with 20- and 10-fold 
reductions in catalytic activity respectively but relatively unchanged product 
profiles. This indicates that while they are important in the recognition and 
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binding of the diphosphate group, they have a lesser role for active site closure 
and contouring. 
1.5.6 (E)--farnesene synthase 
(E)--Farnesene (48) is an acyclic sesquiterpene produced by both plants and 
animals, that acts as a semiochemical in roles such as alarm and defensive 
pheromones, and feeding and pollination stimulants.91,92 (E)--Farnesene 
synthase (EBFS) from Mentha X piperita, peppermint, is a 550 residue enzyme 
made up of the catalytic domain and the noncatalytic N-terminal domain 
common to plant sesquiterpene synthases. EBFS catalyses the deprotonation 
and conjugate elimination of FDP (19) to form (E)--farnesene (48); Faraldos et 
al. investigated the mechanism of this transformation using FDP analogues. 
(2Z,2E)-2F-FDP was found to be a potent competitive inhibitor of EBFS, 
suggesting a stepwise mechanism for the formation of (E)--farnesene via the 
farnesyl cation. While the possible intermediacy of NDP was examined using 
the (2Z,6E)-FDP (62) and (3R)-NDP, ((3R)-22) both of which were converted to 
(E)--farnesene almost exclusively (>93%). From these data it was proposed 
that EBFS catalyses the conversion of FDP to (3R)-NDP via the farnesyl cation 
followed by deprotonation and elimination of the diphosphate to yield (E)--
farnesene (48) Scheme 1.22. 
 
Scheme 1.22 Cyclisation of FDP (19) by EBFS 
1.5.7 Germacradien-4-ol synthase 
Germacradien-4-ol synthase (GdolS) is a 316 amino acid bacterial 
sesquiterpene synthase discovered through genome mining for putative 
sesquiterpene synthases in Streptomyces citricolor.93 This enzyme catalyses the 
conversion of FDP (19) to germacradien-4-ol (79), a 10-membered macrocyclic 
alcohol, which is referred to by different names in the literature, 1,6-
germacradien-5-ol and germacrene D-4-ol, in addition to germcradien-4-ol. 
Throughout this report it shall be referred to as germacradien-4-ol. This 
product has previously been identified in plant species,94–97 and Yoshikuni et 
al. have previously engineered a bacterial -cadinene synthase to produce 
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primarily germacradien-4-ol (79) through the use of error-prone PCR,98 but 
this is the first bacterial terpene synthase which has been identified for its 
biosynthesis and the first synthase which produces germacradien-4-ol as the 
sole product.99  
GdolS yields germacradien-4-ol (79) as the single product from incubation with 
FDP (19), demonstrating a remarkable ability to effectively protect the 
carbocationic intermediates from water while directing the incorporation of 
water at the end of the cyclisation cascade with exceptional stereo- and regio-
control. While Nakano et al. proposed a mechanism for the formation of 
germacradien-4-ol (79), thus far, there has been no mechanistic investigation 
into how the enzyme is able to direct this transformation and control the 
incorporation of water, Scheme 1.23. 
 
Scheme 1.23 Proposed concerted (red) or a stepwise (blue) mechanisms for the conversion of 
FDP (19) to (-)-germacradien-4-ol (79) by GdolS.  
1.6 Aims of this Project 
1.6.1 Context 
While terpenoids such as paclitaxel (1) and artemisinin (2) are valuable 
therapeutic products, the vast majority of the supply of these drugs is still 
extracted from natural sources due to the challenges in the synthesis of these 
compounds with a high degree of stereocomplexity. A growing proportion of the 
supply of artemisinin (2) is produced in a semisynthetic manner from synthetic 
modification of the hydrocarbon precursor amorpha-4,11-diene (63) which is 
able to be produced in relatively high amounts, >25 g/L, via a fermentation 
process.100 More recently a group from the Max-Plank-Institute have developed 
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a continuous flow process to generate artemisinin (2) and a number of its 
derivatives also used in the treatment of malaria, from dihydroartemisinic 
acid.101  
Despite these advances in utilising terpene synthases for the preparation of 
terpenoid precursors, exploiting their ability to generate multiple stereo-
centres highly effectively, difficulties in selectively derivatising the hydrocarbon 
skeleton remains the major barrier to the conversion of the hydrocarbon 
terpenes to therapeutically viable terpenoids. If simple terpenoids such as 
terpene alcohols or epoxides could be generated using terpene synthases, the 
oxygen moiety could provide a ‘handle’ for further reactivity to be added in a 
regio- and stereospecific manner. The predictable and reliable design and 
generation of simple terpenoids could open the door for the cheap and efficient 
synthesis of complex terpenoids as well as providing means for the preparation 
of novel terpenoids as lead compounds in the development of new 
therapeutics. 
1.6.2 Aims 
The project was divided into two parts both designed to investigate methods of 
generating simple terpenoids. The first part focussed on a recently discovered 
bacterial sesquiterpene synthase, germacradien-4-ol synthase (GdolS),93 which 
incorporates water in the cyclisation cascade to generate a single terpene 
alcohol, with a high degree of stereo- and regio-specificity. This enzyme was 
characterised and the mechanism probed using substrate analogues and 
single-point mutations to elucidate how GdolS is able to incorporate water into 
its product while still protecting the highly reactive carbocation intermediates. 
The second part of the project involved the synthesis of a range of FDP-
analogues designed to offer means of trapping carbocation intermediates in the 
catalysis by a range of sesquiterpene synthases. These analogues were 
primarily epoxy-FDP’s, designed to produce simple terpenoids with hydroxy-, 
epoxy- or ether functionalities; providing further information about the 
versatility of terpene synthases as well as producing novel terpenoids which 




2 Characterisation and mechanistic investigation of 









As described previously (Section 1.5.7) germacradien-4-ol synthase is a 316 
amino acid bacterial sesquiterpene synthase from Streptomyces citricolor. The 
enzyme converts FDP (19) to germacradien-4-ol (79) as the single product, 
demonstrating an ability to effectively protect the carbocationic intermediates 
from water while directing the incorporation of water at the end of the 
cyclisation cascade with exceptional stereo- and regio-control.  Thus far, there 
has been no mechanistic investigation into how the enzyme is able to direct 
this transformation and control the incorporation of water. 
Here, we aimed to fully characterise germacradie-4-ol synthase to determine 
its structure and stability, and the germacradien-4-ol (79) product. We also 
aimed to investigate and elucidate the mechanism of germacradien-4-ol 
synthase using fluorinated- and deuterated-FDP analogues, and to use 
isotopologues of water to determine the source of the water incorporation. 
2.2 Enzyme characterisation 
2.2.1 Expression 
The expression vector containing the gene for germacradien-4-ol synthase 
(pET16b-SC1) was a generous gift from Professor Ohnishi, University of Tokyo. 
The pET16 expression vector contains a T7 promoter for controlling gene 
expression. The gene for GdolS had been cloned into the polycloning site with 
an in-frame sequence encoding an N-terminal deca-histidine tag enabling 
purification by nickel-affinity chromatography and the plasmid was used as it 
was received from Professor Ohnishi.93 E. coli BL21-(DE3) strains are an ideal 
host for expressing these genes, because the chromosome contains the gene 
for T7 RNA polymerase, whose expression is regulated by the lac operon and 
thus allows gene expression to be controlled by IPTG (isopropyl--D-1-
thiogalactopyranside). Two cells lines, BL21-(DE3) and BL21-Star™-(DE3), 
were transformed with the pET16b-SC1 expression vector and the expressions 
tested as described in methods, Section 6.1.10. Both cell lines have high 
transformation efficiencies (1 – 5 x107 and 1 x108 for BL21-(DE3) and BL21-
Star™-(DE3), respectively) and are deficient in lon and OmpT proteases; this 
deficiency reduces the degradation of heterologous proteins. In addition to 
these characteristics, BL21-Star™-(DE3) carries a mutated version of the 
rne131 gene, encoding a truncated RNAse E enzyme lacking the ability to 
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degrade mRNA. This mutation results in an increase in the stability of mRNA 
and generally increases the yield of recombinant proteins from T7 expression 
vectors. Also available was the BL21-CodonPlus(DE3)-RP strain. CodonPlus 
strains contain extra copies of the genes encoding the tRNAs which most 
commonly limit translation of recombinant proteins. The BL21-CodonPlus-RP 
strain contains copies of the genes encoding the tRNAs for arginine and 
proline, which are rare in E. coli but more frequently used in GC-rich 
organisms, such as Streptomyces. 
Samples taken from the expressions at regular intervals were analysed by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE, Section 6.1.12), Figure 
2.1. Expression in E. coli BL21-(DE3) showed increasing levels of a protein 
after IPTG addition. This band is at a molecular weight of approximately 35 to 
40,000, which corresponds to the molecular weight of GdolS with the N-
terminal His-tag (molecular weight 38,687). In the test expression in E. coli 
BL21-Star™-(DE3) there is a small increase in the protein band at 35,000 up 
to 3 hours post-IPTG addition, but not the level of over-expression seen in 
BL21-(DE3). The harvested cell pellets were resuspended in buffer and cells 
lysed by sonication (Section 6.1.11). The resulting suspension was clarified by 
centrifugation and the supernatant solution and pellet were analysed by SDS-
PAGE, Figure 2.1, showing the presence of recombinant protein in both the 
supernatant solution and as inclusion bodies in the pellet.  
 
Figure 2.1 SDS-polyacrylamide gels of the test expression of pET16b-GdolS in BL21(DE3) and 
BL21-Star(DE3). Left, analysis of samples taken at hourly periods after induction, where the 
lanes are labelled by the number of hours after induction (X is an empty lane). Right, analysis of 
the cell pellet (P) and supernatant solution (SN) taken after 21 h, after cell lysis, SN2 is twice the 
concentration of SN1 in both cases. MW, molecular weight x103, approximate expected mass of 
GdolS highlighted in red. 
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Due to the effective expression in E. coli BL21-(DE3) it was decided not to 
investigate the expression in E. coli BL21-CodonPlus(DE3)-RP. In order to 
increase the proportion of protein in the supernatant solution further 
expressions were performed in E. coli BL21-(DE3); with reduction of the 
temperature to 16 °C after addition of IPTG, and inducing with a lower 
concentration of IPTG and maintaining the temperature at 37 °C. 
When the temperature of the cell culture was reduced to 16 °C after addition of 
IPTG, expression was allowed to continue for 21 hours. While expression was 
effective and soluble protein was obtained from the supernatant solution after 
cell lysis, there was still considerable protein formed as inclusion bodies. When 
reducing the concentration of IPTG used to induce the expression, from 0.5 
mM to 0.2 mM, and allowing the expression to continue at 37 °C for 3 hours, 
the proportion of soluble protein appeared to be greater than that formed as 
inclusion bodies, Figure 2.2. Expression in this manner produced sufficient 
protein for further studies, and no further optimisation was carried out. 
 
Figure 2.2 SDS-polyacrylamide gels of the expression of pET16b-GdolS in BL21(DE3). Left, at 
37 °C for 3 h after addition of 0.2 mM IPTG. Right, at 16 °C for 21 h after addition of 0.5 mM 
IPTG. Also showning purification fractions; pellet (P), supernatant solution before and after 
filtering (SN and SNf), flowthrough (FT), washes (W), elution (E) and stripping with 500 mM 
imidazle (S).MW, molecular weight x103, approximate expected mass of GdolS highlighted in red. 
Expressed protein was isolated and purified to greater than 95 % purity by 
nickel-affinity chromatography (Figure 2.3, Section 6.1.11). The supernatant 
solution was applied to the Ni-NTA resin pre-equilibrated in the same buffer 
(50 mM Tris, 100 mM NaCl, 10 mM imidazole, pH 8.0), and then washed 
sequentially with increasing concentrations of imidazole (10 mM, 250 mM and 
500 mM). The 10 mM imidazole washes remove any proteins bound through 
non-specific interactions and proteins with low histidine content, and the 
desired protein is eluted in the 250 mM imidazole washes. While a small 
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amount of protein is also removed in the 500 mM imidazole wash, only the 250 
mM imidazole elutions were combined and carried forward. Nickel-affinity 
chromatography yields a single band between molecular weights 35 and 
40,000 by SDS-PAGE, Figure 2.3. The purified protein was dialysed to remove 
imidazole, and concentrated by ultrafiltration before it was characterised in 
terms of structure, stability and steady-state kinetic parameters. 
 
Figure 2.3 Purification of GdolS from expression of pET16b-GdolS in BL21(DE3), showing the 
pellet (P), supernatant solution before and after filtering (SN and SNf), flowthrough (FT), washes 
(W), elution (E) and stripping with 500 mM imidazole (S). 
2.2.2 Kinetics 
The steady-state kinetic parameters for the reaction catalysed by GdolS were 
measured using a radiolabelled-substrate assay commonly used with terpene 
synthases, involving incubation of a range of concentrations of [1-3H]-FDP ([1-
3H]-19) with a known concentration of enzyme for a defined length of time.102 
Measurements of the radioactivity of the hexane extractable products through 
scintillation counting are then fitted against the Michaelis-Menten equation to 
give Vmax and KM. (Section 6.1.19) 
Prior to the measurement of steady-state kinetic parameters optimal 
conditions for pH, concentration of magnesium ions and concentration of 
enzyme were determined. While optimising parameters the buffer conditions 
reported by Nakano et al. were used as a starting reference, 50 mM HEPES (2-
[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid) buffer at pH 8, 5 mM 2-
mercaptoethanol was used with 5 nM enzyme and 4 M FDP (19) for the 
optimisation of magnesium ion concentration in the range of 0.5 to 10 mM, 
and incubation of the reaction for 10 minutes at 30 °C. Within the range [Mg2+] 
=  0.5 – 10 mM there was only a small increase in rate and so 2.5 mM was 
chosen, in consistency with Nakano et al., Figure 2.4.  
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When optimising pH, 50 mM buffers (MES, pH 6 – 6.5; HEPES, pH 7 – 8.5; 
CHES, pH 9 – 10) with 2.5 mM MgCl2, 5 mM 2-mercaptoethanol were used 
with 14 nM enzyme and 4 M FDP (19), and incubation of the reaction for 10 
minutes at 30 °C. In the pH range 7.5 to 9.5 GdolS proved stable with pH 
having very little effect on the rate of catalysis, while beginning to drop off 
either side of this plateau, at pH 7 and pH 10. A pH of 8 was therefore chosen 
for the measurement of kinetic parameters, a value on the stable plateau while 
not too close to the point at which the rate reduces. 
The enzyme activity was measured in the range, [GdolS] = 10 nM – 1  using 
50 mM HEPES buffer at pH 8 with 2.5 mM MgCl2, 5 mM 2-mercaptoethanol, 4 
M FDP and incubation of the reaction for 10 minutes at 30 °C. Activity versus 
enzyme concentration was found to be linear in the range below 50 nM, at this 
concentration the rate plateaued, suggesting that the enzyme was beginning to 
aggregate, a behaviour which has previously been reported with other terpene 
synthases.71 Due to this, a concentration of enzyme of 20 nM was used for the 
measurement of kinetic parameters, a concentration in the linear range while 





Figure 2.4 Graphs showing maximal rate versus (top left) [Mg2+], (top right) pH and (bottom) 
enzyme concentration for turnover of [1-3H]-FDP with GdolS 
Using the optimised conditions of [Mg2+] = 5 mM, pH 8.0 and [E] = 30 nM, 
measurement of the steady state kinetic parameters was carried out varying 
[1-3H]-FDP ([1-3H]-19) concentration from 0.02 to 7 µM, Figure 2.5. The kcat 
and KM were found to be 0.079 ± 0.003 s-1 and 1.07 ± 0.13 µM respectively. 
Ohnishi et al. measured steady state kinetic parameters using a GC-MS based 
method and the values they reported differ to those reported here. The kcat, 
0.198 ± 0.004 s-1, is approximately three-fold higher than we find while there is 
a 10-fold decrease in KM, 0.115 ± 0.0035 M. Differences between steady state 
kinetic parameters based on the method used have been reported for other 
terpene synthases.103,104 Both sets of values reported here are comparable with 
those reported for other bacterial terpene synthases, although the majority of 












































































Figure 2.5 Representative graph for the calculation of steady-state kinetic parameters of GdolS 
2.2.3 Product Analysis 
Analysis of the pentane extractable products from the incubation of GdolS with 
FDP (Section 6.1.17) by GC-MS showed a single product peak with a molecular 
ion of m/z = 222 (major fragments m/z  = 207 ([M - CH3]+), 204 ([M – H2O]+), 
161 ([M – (H2O + C3H7)]+)). The mass spectrum did not compare well with that 
reported in the literature for this compound.93,96,98 In the mass spectra 
reported in the literature the most abundant peak is that at m/z 81, with the 
molecular ion, [M]+ (m/z 222), approximately 5% and the peaks for [M - H2O]+ 
(m/z 204) and [M – CH3]+ (m/z 207) approximately 10 and 15% respectively. In 
comparison, the spectra reported here has the most abundant peak at m/z 
161, with the molecular ion at approximately 1%. The peak for [M – H2O]+ is 
much more abundant, 60%, while the peak for [M – CH3]+ is also less intense, 

































Figure 2.6 GC-MS analysis of the pentane extracted products of an overnight incubation of 
GdolS with FDP. Top, gas chromatogram. Middle, background subtracted mass spectrum of the 
peak at 29.25 minutes. Bottom, reported mass spectrum of germacradien-4-ol.93 
NMR spectroscopic analysis of germacradiene-4-ol. 
While analytical scale incubations (total volume 250 µL) are usually sufficient 
to analyse the pentane extractable products of the enzymatic incubations by 
GC-MS, it was necessary to prepare a larger sample to unambiguously identify 
the product of GdolS and so a preparative-scale incubation (total volume 500 
mL) was used to produce milligram quantities of the terpene alcohol. As 
described in Methods (Section 6.1.21) 90 mg of FDP was incubated over 3 days 
with GdolS (0.4 mM) and the product extracted into pentane. After gentle 
removal of the pentane at room temperature under reduced pressure, a single 
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product was recovered in 80.5% yield (36.8 mg) as a colourless oil. The sample 
was characterised using both 1H and 13C NMR spectroscopy using a series of 
1D and 2D experiments and was identified as the reported germacradien-4-ol 
(79), showing the characteristic doublets for the isopropyl group at 0.78 and 
0.82 ppm, in addition to the singlets for the allylic-C14, 1.54 ppm, and the 
C15, 1.19 ppm, methyl groups. The vinylic-proton, H1, shows as a broad 
doublet with a coupling constant of 11 Hz consistent with a large dihedral 
angle of coupling, while the vinylic H5 and H6 protons are a doublet and a 
doublet of doublets respectively, coupling to each other with a coupling 
constant of 16 Hz, Figure 2.7, Table 2.1.  
 
Figure 2.7 Structures of germacradien-4-ol (79) with numbering system used in assignment 
Table 2.1 Complete assignment of germacradien-4-ol (79). Chemical shifts are reported relative 
to TMS in ppm 
 1H 13C 
1 4.95 (bd, J = 11 Hz, 1H) 129.0 
2 2.50 (dddd, J = 14, 12.5, 11, 3.5 Hz, 1H) 
1.99 – 1.88 (m, 1H) 
23.8 
3 1.68 – 1.56 (m, 2H) 39.7 
4 - 73.3 
5 5.25 (d, J = 16 Hz, 1H) 140.2 
6 5.16 (dd, J = 16, 9.0 Hz, 1H) 125.8 
7 2.07 – 1.95 (m, 1H) 52.9 
8 1.40 – 1.33 (m, 2H) 26.1 
9 2.32 – 2.16 (m, 2H) 41.4 
10 - 132.7 
11 1.46 – 1.37 (m, 1H) 33.1 
12 0.78 (d, J = 6.5 Hz, 3H) 20.8 
13 0.82 (d, J = 6.5 Hz, 3H) 19.1 
14 1.54 (s, 3H) 16.9 
15 1.19 (s, 3H) 30.8 
 
This data is consistent with the (4S, 7S)-stereoisomer as reported by Nordin et 
al.,105 who performed the most in depth assignment of this compound to-date. 
The optical rotation of the enzymatically produced sample was measured as -
163.4° ([]20D c.0.991, CHCl3), while the maximum value reported by Nordin et 
al.105 is – 184.6° ([]25D c.1.02, CHCl3), differing by approximately 20° from the 
sample generated herein.  
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GC-FID analysis of enzymatically produced germacradien-4-ol (79) 
To examine the optical purity of the sample produced by GdolS, it was 
analysed by gas chromatography using a column containing a cyclodextrin 
based chiral stationary phase (SUPELCO Aztec CHRIRALDEX™ B-DM). In the 
absence of a racemic sample to ensure separation of enantiomers, the sample 
was eluted using a variety of methods including those that have been 
successfully used for the separation of the tertiary terpene alcohols, bisabolol 
(96) and nerolidol (97) (Programs 1 & 2, respectively).106 Care was taken not to 
overload the column by injecting 5 L and using a 50:1 split of the injected 
sample, the peak shape was carefully monitored throughout for any indication 
of shoulder peaks.  
Table 2.2 GC-FID Programs 
Program 1 2 3 4 
Initial temperature 
(°C) 
70 90 155 100 
Initial time 
(minutes) 
3 2 60 2 
Temperature ramp 
(°C/minute) 
5 5 - 2 
Final temperature 
(°C) 
160 170 - 150 
Hold time 
(minutes) 
30 40 - 30 
Program length 
(minutes) 
51 58 60 57 





Figure 2.8 GC-FID Chromatograms showing (A) separation of racemic bisabolol (96) using 
method 1, (B) separation of racemic trans-nerolidol (97) using method 2,and analysis of 
germacradien-4-ol (79) using methods 2, 3 and 4 (C, D and E respectively). 
In all methods, only a single compound eluted and the peak shape was regular 
and symmetrical, particularly when a temperature gradient was used. The 









enantiomeric excess (e.e) of 88.5%, indicating that any secondary peak would 
be approximately 6 % of the major peak and should be easily distinguishable 
from the baseline. While not conclusive, this is strongly suggestive that only a 
single stereoisomer was present. 
While the majority of the time only a single product was seen by GC-MS, which 
was consistent with the NMR spectra, occasionally two other products were 
seen in the chromatogram by GC-MS analysis. One peak was identified as -
cadinene by comparison with a genuine enzymatically produced sample, while 
the second peak was tentatively assigned as -cadinene by comparison with 
the NIST mass spectral library.107 These peaks were not consistent in 
proportion with the germacradien-4-ol and it was proposed that they were 
being generated by rearrangement of the germacradien-4-ol to eliminate water. 
Indeed, further review of the literature found reports that after treatment with 
dilute formic acid germacradien-4-ol yields a mixture of hydrocarbon and 
alcohol products.94,105 In the absence of water in the gas chromatograph no 
alcohol products were observed, Figure 2.9. The addition of triethylamine to 
the pentane extracted products prior to injection in the GC-MS reduced the 
amount of - and -cadinene to nearly zero, while replacement of the GC inlet 
liner and syringe eliminated any rearrangement. In future chapters the 
presence of - and -cadinene in gas chromatograms will not be discussed, but 
will be taken into account in integrations for the calculation of product 
distributions. 

Figure 2.9 Gas chromatogram of the pentane extracted products from incubation of GdolS with 
FDP, showing traces of -cadinene (A) and -cadinene (B)
2.2.4 Structure of GdolS 
The protein, like other terpene synthases, was expected to have a high content 
of -helices. GdolS proved to be unstable in 50 mM phosphate buffer, clearly 
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precipitating in the cuvette instantly; due to the strong absorbance of Tris and 
HEPES buffers below 200 nm, measurements were taken with enzyme diluted 
to approximately 10 M in distilled water. Circular dichroism of GdolS was 
recorded between 190 and 270 nm and showed a typical -helical spectrum 
with minima at 208 and 222 nm, and a maximum at 190 nm. Measuring the 
mean residual ellipticity at 222 nm while increasing the temperature gave a 
melting temperature of 55 °C, Figure 2.10. Full spectra were also recorded at 
different temperatures to give more information about the melting temperature 
of the protein, while recording the spectrum of the sample after returning to 20 
°C indicated that the structural changes upon heating irreversibly denatured 
the protein. 
 
Figure 2.10 Top left, Circular dichroism spectra of GdolS. Spectrum of GdolS at 20 °C. Top 
right, Mean residue ellipticity at 222 nm across a temperature gradient from 5 – 90 °C. Bottom 
left, Full CD spectrum of GdolS at increasing temperatures. Bottom right, Comparison of GdolS 
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CD spectra were also measured across a range of pH values to compare with 
the findings of the pH optimisation. There was no change to the spectrum of 
GdolS at pH 8 over 60 minutes. The protein was also stable over 10 minutes at 
pH 7 to 10, while at pH 6 the spectrum was visibly less -helical upon the first 
measurement, and showed further reduction in helicity after 10 minutes, 
Figure 2.11. Notably, at pH 10 there is very little (if any) decrease in helicity 
even after 10 minutes, suggesting that while at pH 6 the reduction in rate of 
catalysis is due to a loss of structure this is not the case at pH 10 and may be 
due to some other effect on the rate of the reaction.
 
 
Figure 2.11 CD spectra of GdolS at different pH levels. Top left, Spectra at pH 8 at 10 minute 
intervals. Top right, Spectra at different pH values. Bottom, Spectra at 0 (dark) and 10 minute 
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2.3 Investigation of the mechanism of GdolS 
2.3.1 Investigation into the origin of the C4-hydroxyl in 
germacradien-4-ol (79) 
The hydroxyl group at C4 was proposed to originate directly from the bulk 
solvent, through quenching of a carbocation by an active site bound water 
molecule or through a channel into the active site. Other possible mechanisms 
for the incorporation of the hydroxyl could include involvement of an active site 
amino acid or the diphosphate anion, to form either an enzyme bound 
intermediate or a tertiary diphosphate, followed by hydrolysis to yield 
germacradien-4-ol, Scheme 2.1. These postulated mechanisms were 
investigated using incubations performed in buffers prepared using 
isotopologues of water.  
 
Scheme 2.1 Possible pathways for the GdolS catalysed incorporation of water in germacradien-
4-ol. Top, direct attack of a free or enzyme-bound water molecule; Middle, formation of a 
germacradienyl diphosphate followed by hydrolysis; Bottom, formation of an enzyme-bound 
germacradienyl ester followed by hydrolysis. The fate of the oxygen atom derived from the bulk 




Incubation in buffer prepared with D2O (2H2O) showed an increase of 1 amu in 
the molecular ion to m/z 223, and an increase of 1 amu to m/z 208 for the [M 
– CH3]+ fragment, while no change was observed in any of the fragments of 
lower molecular weight after dehydration (m/z 204, [M – H2O]+). 
 
Figure 2.12 Mass spectrum of germacradien-4-ol arising from incubation of GdolS and FDP in, 
left, H2O and right, D2O buffer. Both show only expansion of the molecular ion. 
This indicates that the proton on the hydroxyl group may originate from the 
bulk solvent; however, this could also be contributed to exchange of the proton 
with the solvent. To trace the origin of the oxygen atom, proposed to provide a 
truer indication of the origin of the hydroxyl, incubations were carried out in 
buffer containing 50% H218O. 
These incubations show incorporation of an 18O atom in to 4-hydroxyl group of 
germacradien-4-ol. Analysis of the mass spectrum shows 0.75:1 incorporation 
of 16O:18O, a 57% incorporation from H218O. indicating that the hydroxyl arises 




Figure 2.13 Mass spectrum of germacradien-4-ol arising from incubation of GdolS and FDP in, 
left, H2O and, right, 50 % H218O buffer, showing expansion of the molecular ion. 
2.3.2 Incubation of substrate analogues with GdolS 
Incubations of GdolS with FDP (19) and FDP-analogues were carried out as 
described in methods, Section 6.1.17. 12,13-F2-FDP (73) was prepared as 
described in Chapter 4, Section 4.2.1, while the other FDP-analogues were 
samples available in the lab. These analogues were primarily prepared by Drs. 
Juan Faraldos, David Miller and Sabrina Touchet, who have my thanks for 
allowing me use of their samples. 
Nerolidyl diphosphate (NDP, 22) 
Incubation of GdolS with the tertiary diphosphate nerolidyl diphosphate (NDP, 
22), produces germacradien-4-ol (79) as a single product. Measurement of the 
steady-state kinetic parameters with racemic-3H-NDP (prepared by Dr Juan 
Faraldos) gave kcat and KM of 0.076 ± 0.003 s-1 and 1.3 ± 0.03 µM respectively, 
values remarkably similar to those measured for FDP (19). Use of the 
enantiopure (3H)-(3R)-NDP (3R-22, prepared by Dr Juan Faraldos) for the 
measurement of kinetic parameters showed a 3-fold increase in kcat paired with 
a 2-fold in increase in KM (0.24 ± 0.007 s-1 and 2.6 ± 0.18 M respectively) 
leading to a modest improvement in catalytic efficiency over the substrate FDP 
(19), Table 2.3. 
Table 2.3 Comparison of steady-state kinetic measurements of turnover of [1-3H]-substrates by 
GdolS 
[1-3H]-substrate kcat (s-1) KM (µM) kcat/KM (s-1 µM-1) 
FDP 0.079 ± 0.003 1.07 ± 0.13 73.8 x 10-3 
Rac-NDP 0.076 ± 0.003 1.30 ± 0.03 58.5 x 10-3 
(3R)-NDP 0.240 ± 0.007 2.60 ± 0.18 92.3 x 10-3 
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While these results may suggest that the catalytic mechanism of GdolS 
proceeds through isomerisation of FDP (19) to NDP (3R-22) prior to 1,10-ring 
closure this proposal seems counterintuitive due to the apparent lack of 
necessity for this isomerisation. The proposed active site conformation of (3R)-
NDP (3R-22) potentially shows a favourable alignment between the 1,2-*-anti-
bonding orbital and the 10,11-- and 3C-O-* orbitals which would allow the 
concerted ring-closure and allylic elimination of the diphosphate in a single 
step, Scheme 2.2. Molecular modelling of the LUMO of (3R)-nerolidol (kindly 
performed by Dr Stefano Leoni) constrained to the active site volume shows 
that in this conformation the orbitals are aligned to productively drive ring 
closure and the allylic elimination of the diphosphate upon excitation of 
electrons from the HOMO. While product release is rate determining for the 
overall conversion of FDP by terpene synthases, the initial ionisation of FDP 
(19) is widely accepted as the rate limiting chemical step.108,109 This 
configuration of NDP (22) is optimal to directly generate the transoid-germacryl 
(98) cation in a concerted manner, hence accelerating the reaction. 
 
Scheme 2.2 Left, Active site conformation of (3R)-NDP (3R-22) and ring closure to the transoid-
germacryl cation (98). Right, Calculated LUMO of (3R)-nerolidol confined to active site volume. 
(2Z,6E)-Farnesyl diphosphate ((2Z,6E)-FDP, 62)  
Incubation of GdolS with (2Z,6E)-FDP (62) did not solely yield germacradien-4-
ol (79) as would be expected if isomerisation of the 2,3-double bond were 
necessary to allow cyclisation. Instead germacradien-4-ol (79) is produced as 
only a minor product (<3%) among a large number (>20) of other products, 




Scheme 2.3 Conversion of (E,E)-FDP (19) to NDP (22) to allow cyclisation to the cis-germacryl 
cation (24) and direct cyclisation of (Z,E)-FDP (62) 
 
 
Figure 2.14 Gas chromatogram of the pentane extracted products from the incubation of GdolS 
with (Z,E)-FDP (62). The only peak positively identified is that of germacradien-4-ol (79, 
highlighted). 
Geranyl diphosphate (GDP, 18) 
Many sesquiterpene synthases are able to turn over the ten-carbon isoprenyl 
diphosphate, geranyl diphosphate (18), into linear and cyclic 
monoterpenes44,65,66,110,111 and so geranyl diphosphate (18) was incubated with 
GdolS and the pentane extractable products analysed by GC-MS. GdolS was 
able to turn over GDP (18), albeit much less effectively than the natural 
substrate as determined by comparison of the total ion count (3 x 104, GDP; 2 
x 106, FDP). The products were identified by comparison with genuine samples 
of known monoterpenoids showing primarily linear (>88%), but also small 
proportions of cyclic (<12%), monoterpenes; the presence of cyclic products 
suggests that GdolS might be catalysing the conversion of GDP (18) to linalyl 
diphosphate (LDP, 99). However, as discussed earlier, Section 1.3.4, a recent 
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study by Zhang and Tiefenbacher has found allylic cations to be rotatable 
under ambient conditions.43 
 
Figure 2.15 Gas chromatogram of the pentane extractable products arising from incubation of 
GdolS with GDP (18). Compounds identified by comparison with authentic samples. 
 
Scheme 2.4 Formation of the products identified from incubation of GDP (18) with GdolS. 
Percentages are approximate to the closest significant figure. 
Inhibition of GdolS by 2F-FDP (50) and [15,15,15]-F3-FDP (100) 
Incubation of GdolS with 2F-FDP (50) and [15,15,15]-F3-FDP (15F3-FDP, 100) 
generated no pentane extractable products that could be detected by GC-MS 
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analysis, even after extended incubation times. The effect of these two FDP-
analogues as inhibitors was investigated by measuring steady-state kinetic 
parameters in the presence of varying amounts of the fluorinated-FDP. 
15F3-FDP (100) was found to be a good inhibitor with a Ki of 3.9 ± 0.2 M, 
comparable to the KM for FDP (19); a Lineweaver-Burke double reciprocal plot 
of the data showed inhibition to be competitive, as is typically found with 
terpene synthases due to having a single active site into which binding of the 
diphosphate group is highly favourable in the presence of Mg2+. The 2F-FDP 
(50) was found to be a potent inhibitor with a Ki of 0.3 M, however the type of 
inhibition could not be clearly determined despite numerous attempts. The 
Lineweaver-Burk plot shows the lines intercepting before the y-axis and above 
the x-axis, indicating a difference in Vmax and an effect on KM, indicative of 
mixed inhibition. Mixed inhibition is rare in systems such as terpene 
synthases where there is a single binding site. In terpene synthases substrate 
binding is primarily driven by the [Mg2+]-PPi coordination and the absence of 
any secondary regions for binding means deriving an explanation for mixed 
inhibition is difficult. 
  
  
Figure 2.16 Lineweaver-Burk (left) and plot of KM,app against [I] for the calculation of Ki (right) for 





































Figure 2.17 Lineweaver-Burk plot (left) and plot of KM,app against [I] for the calculation of Ki 
(right) for 2F-FDP (50), legend shows the concentration of inhibitor. 
The inhibition of GdolS by both the 2F-FDP (50) and the 15F3-FDP (100) is 
strong evidence for a stepwise cyclisation mechanism, whereby dissociation of 
the diphosphate occurs prior to the ring-closure. This dissociation generates 
the allylic farnesyl cation (21); it is this cation which is destabilised by the 
electron-withdrawing nature of the fluorine-substituents in the cases of the 
2F-FDP (50) and 15F3-FDP (100) and formation of this cation is prevented, and 
the cyclisation is unable to proceed. 
 
Scheme 2.5 Abortive stepwise (red) and productive concerted (blue) cyclisation mechanisms 
with 2-F-FDP (50) and 15F3-FDP (100). Intermediates where R1=F, R2=CH3 arise from 2-F-FDP 
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GdolS catalysed turnover of 12,13F2-FDP (73) 
GC-MS analysis of the pentane extractable products from incubation of 
12,13F2-FDP (73) with GdolS shows a single peak. Analysis of the mass-
spectrum is consistent with this peak being the 12,13-E--farnesene (77), 
arising from inhibition of the 1,10-ring closure. This is supported by the 
production of the same product from incubation of 12,13-F2-FDP with EBFS, 
Figure 2.18.  
 
Figure 2.18 GC-MS analysis of the pentane extracted products of the incubation of GdolS with 
12,13F2-FDP (73).  
Formation of the 12,13-difluorofarnesyl cation (74) is not destabilised and so 
dissociation of the diphosphate is able to proceed; the subsequent 1,10-ring 
closure would generate the 12,13-difluorogermacryl cation (75) and this would 
be strongly destabilised by the presence of the fluorines on C12 and C13 and 
so this ring closure does not occur; instead direct deprotonation leads to the 
farnesene derivative (77). The formation of linear instead of cyclic products 
could also be explained by a reduction in the nucleophilicity of the 10,11-
double bond due to the electron withdrawing nature of the fluorine 






















substituents, but this would still be in support of a stepwise mechanism with 
the intermediacy of the 12,13-difluorofarnesyl cation. 
 
Scheme 2.6 Productive stepwise (blue) and abortive concerted GdolS catalysed cyclisation 
mechanisms with 12,13F2-FDP (73). 
GdolS Catalysed Cyclisation of 10F-FDP (39) 
Incubation with 10F-FDP (39) was expected to yield a similar result as that 
with 12,13F2-FDP (73), producing the farnesene derivative due to 
destabilisation of the 10F-germacryl cation (41) by the fluorine in the 10-
position, Scheme 2.7. However, analysis of the pentane extractable products 
by GC-MS showed three main products. Two of these peaks were identified as 
10F-E--farnesene (101) and 10-F--humulene (40); a product of a 1,11-
cyclisation. These peaks were identified by coelution with enzymatically 
produced authentic samples using GDS(Section 1.5.2), Figure 2.19.65,79 The 




Scheme 2.7 Anticipated results from incubation of GdolS with 10F-FDP. 
 
Figure 2.19 Gas chromatogram of the pentane extractable products from inubation of 10F-FDP 
(39) with GdolS, top, and GDS, bottom.  
Measurement of the steady-state kinetic parameters with tritiated 10F-FDP ([1-
3H]-39) show that while the rate of the 1,11-cyclisation is slower than the 
natural cyclisation it is still able to turn over the 10F-FDP (39) with modest 
efficiency (kcat 0.018 ± 0.0009 s-1, KM 0.6 ± 0.09 µM), Figure 2.20. The ability of 
the enzyme to catalyse a 1,11-cyclisation with this substrate-analogue could 
be explained by a number of possible mechanisms after the dissociation of the 
diphosphate; a direct 1,11-ring closure of the 10F-farnesyl cation (102) 
yielding the 10F-humulyl cation (43) which is now stabilised due to the -effect 
of the fluorine substituent, initial slow 1,10-ring closure forming the 
destabilised 10F-geramcryl cation (41) followed by rapid ring-expansion to the 
stabilised 10F-humulyl cation (43) or ring closure via a bridged cyclopropyl 
cation (42) which then rapidly collapses to the 10F-humulyl cation (43). 




Scheme 2.8 Possible pathways for GdolS catalysed cyclisation of 10-F-FDP (39) to 10F--
humulene (40). 
 
Figure 2.20 Representative graph for the calculation of steady-state kinetic parameters of GdolS 
with 10F-FDP (39) 
Analysis of the GdolS catalysed turnover of deuterated-FDPs 
While Nakano et al. proposed a 1,3-hydride shift in the mechanism catalysed 
by germacradien-4-ol synthase,93 it is also possible that two consecutive 1,2-
hydride shifts are involved in the transfer of the carbocation from C11 to C6, 
Scheme 2.9. This mechanism of consecutive 1,2-hydride shifts has been 
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the enzyme with the FDP substrate bearing deuterium atoms at the 1-
position.64 
 
Scheme 2.9 Possible 1,3- and double 1,2-hydride shifts in the mechanism catalysed by 
germacradien-4-ol synthase. 
Germacradien-4-ol synthase was incubated with 1-2H2-FDP (2H2-19) and the 
pentane extractable products were analysed by GC-MS showing a single peak 
for germacradien-4-ol. By analysing the fragmentation in the mass spectrum of 
the product, in particular the fragment derived from the loss of the isopropyl 
tail; m/z = 161 for the non-deuterated FDP, we can infer the positions of the 
deuterium atoms. If the 1,3-hydride shift is in operation, then the product (79) 
will bear one deuterium atom on the isopropyl tail and one deuterium on the 
macrocycle, resulting in m/z = 162. In the case that a double 1,2-hydride shift 
is in operation the isopropyl tail will contain a hydrogen atom and both 




Scheme 2.10 Possible mechanisms for the GdolS catalysed conversion of 1-2H2-FDP. 
The mass spectrum of the 2H2-79 produced by incubation of GdolS with 2H2-
19 shows a molecular ion of m/z = 224, an increase of 2 amu as expected from 
the incorporation of two deuterium atoms. The [M – H2O]+ also shows an 
increase of 2 amu, m/z = 206. The fragment derived from the loss of the 
isopropyl tail shows m/z = 162, indicating the incorporation of a single 




Figure 2.21 Mass spectrum of germacradien-4-ol produced by incubation of GdolS with 19 
(Top) and 2H2-19 (Bottom). 
This step was further investigated using a mono-deuterated-FDP, 1-2H-(R)-
FDP. The pentane extractable products of the incubation of GdolS with the 
deuterated-FDP were analysed by GC-MS showing a single peak for 
germacradien-4-ol (79). The mass-spectrum and in particular the 
fragmentation pattern imparts information about which hydride has been 
transferred; by looking at the fragment peak from the loss of the isopropyl tail 
we can see which fragment bears the deuterium. For example in the 
incubation of DCS with the deuterated-FDP there is clear enrichment of the 
peak at m/z = 162, indicating that the 1-(S)-1H is transferred to the isopropyl 




Scheme 2.11 Possible reaction pathways for GdolS catalysed conversion of 1-(R)-2H-FDP. 
However, in the incubation of GdolS with 1-(R)-2H-FDP there is no clear 
enrichment in either m/z 161 or 162. This indicates that either the hydride 
shift is not stereospecific, which seems highly unlikely due to the nature of 
terpene synthases, or that there is scrambling of the stereochemical 
information by a different mechanism. 
 
Figure 2.22 Mass spectra of the product peak, from the incubations of 1-(R)-2H-FDP with GdolS 
(top) and DCS (bottom). 
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The carbocation formed by the hydride shift is stabilised across C1 to C3 by 
allylic transposition and so it could be proposed that this intermediate is 
relatively long lived and an equilibrium between this stabilised carbocation and 
the germacryl cation would scramble the stereochemical evidence of the initial 
hydride shift leading to no overall enrichment of either m/z upon 
fragmentation of the isopropyl group, unfortunately causing the loss of any 
stereochemical information about this step. The interconversion of 
germacrenoids between different conformers has previously been 
reported.112,113,114,115 If the allylic cation is sufficiently long-lived with respect to 
the rate of conformational change of the 10-membered ring this could allow 
realignment of the vacant p-orbital and cause scrambling of the 
stereochemistry of the shift.  
 
Figure 2.23 Scrambling of stereochemical information due to rapid germacryl-cations equilibria. 
R1 ≠ R2 = D or H 
2.4 Summary 
In summary, this chapter has focused on a sesquiterpene synthase, 
germacradien-4-ol synthase, from Streptomyces citricolor. The enzyme was 
produced by overexpression in E. coli as previously described, and 
characterised in terms of stability and kinetic parameters. 
Prior to the measurement of steady-state kinetic parameters the conditions for 
the assay were optimised and it was found that the activity was linear at 
concentrations below 50 nM; the concentration used for further measurements 
was 20 nM. In the range tested, 0.5 to 10 mM, the concentration of 
magnesium ions had little effect on the activity of the enzyme and 2.5 mM was 
used. The enzyme was structurally and catalytically stable to a range of pH 
values above pH 7 as determined by rate and -helicity measured by circular 
dichroism spectroscopy; extended incubation at even pH 10 had no effect on 
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the helicity of the protein. The kinetic parameters were measured using a 
radiolabelled-substrate assay commonly used in the characterisation of 
terpene synthases; while the results obtained with this method differed from 
those originally reported by Nakano et al.93 using a GC-MS analysis method, 
differences between steady state kinetic parameters based on the method used 
have been reported for other terpene synthases.103,104 
The identity of the product from incubation of GdolS with FDP was analysed by 
GC-MS and while the mass spectrum produced differed from that previously 
reported, sufficient product was obtained to unequivocally determine the 
structure as germacradien-4-ol through the use of NMR spectroscopy. Analysis 
of the product by gas chromatography with a chiral column, strongly indicated 
that the product was stereochemically pure (-)-germacradien-4-ol, which 
corresponds to the (4S, 7S)-stereoisomer, according to the report by Nordin et 
al..105 
Incubations of GdolS with FDP in buffers prepared with 2H2O and H218O 
indicated that both the proton and oxygen in the 4-hydroxyl group originate 
from the bulk solvent suggesting a simple mechanism of carbocation 
quenching by water for the incorporation of the hydroxyl group. Due to the 
highly reactive nature of the carbocation intermediates in cyclisation by 
terpene synthases these enzymes typically function by desolvating the active 
site upon formation of the Michaelis complex and so the mechanism of this 
incorporation was probed further as described in Chapter 3. 
GdolS was incubated with NDP, both racemic and the (3R)-stereoisomer, and 
the products isolated and the steady-state kinetic parameters suggested that 
the enzyme catalysed cyclisation may go via the formation of the tertiary 
diphosphate NDP. However, incubation with (2Z,6E)-FDP, which can directly 
cyclise to the cisoid-germacryl cation germacradien-4-ol amongst numerous 
other, unidentified, products. 
Fluorinated FDP analogues 2F-FDP and 15CF3-FDP were found not to be 
substrates for GdolS, and proved to be potent inhibitors, pointing to the 
intermediacy of the farnesyl cation, and indicating a stepwise mechanism in 
the GdolS catalysed cyclisation of FDP. This was further supported by the 
ability of GdolS to turnover 12,13F2-FDP to the farnesene derivative, through 
ionisation to the farnesyl cation followed by deprotonation due to inability to 
then undergo cyclisation because of the destabilisation of the germacryl cation 
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by the fluorine substituents. However, this result could also be attributed to a 
reduction in nucleophilicity of the 10,11-double bond. While a similar result 
was expected from incubation with 10F-FDP, GdolS was also able to turn this 
analogue over to the -humulene derivative, a product with an 11-membered 
ring. While a number of processes including a 1,11-ring closure, a 1,10-ring 
closure followed by rapid 1,2-alkyl shift to the more stable humulyl cation or 
the formation of an intermediate cyclopropyl carbocation could be proposed to 
explain this phenomenon, none can be favoured with the data available. 
Nonetheless, this ability of the enzyme to circumvent the unfavoured 1,10-
cyclisation to form an 11-membered product highlights the remarkable 
versatility of the terpene synthases. 
Analysis of the product from incubation of GdolS with 1-2H2-FDP 
demonstrated that the enzyme catalyses a 1,3-hydride shift subsequent to the 
ring closure. Incubation of GdolS with 1-(R-2H1)-FDP to probe the 
stereochemical course of the 1,3-hydride shift led, somewhat surprisingly, to a 
product resulting from no stereochemical bias in the 1,3-hydride shift. This 
was hard to reconcile with the stereospecific nature of terpene synthases and a 
relatively long-lived stabilised cation in rapid-equilibrium with the germacryl 
cation was proposed to explain this discovery; possibly with the enzyme 
allowing water ingress to the active site as a unintended consequence of loop 





Scheme 2.12 Summary of key results from incubation of GdolS with FDP analogues 
In conclusion we propose that the reaction catalysed by GdolS goes via a 
stepwise mechanism for the loss of the diphosphate, to give the germacryl 
cation. An equilibrium between the tertiary germacra-11-yl cation and the 
allylic germacra-6-yl cation is mediated by a rapid 1,3-hydride shift, prior to 
the quenching at the 4-position by water, which originates from the solvent.  
 
 






3 Structure–function investigation into 













This chapter will discuss the effects of a number of amino acid substitutions 
on the catalysis by GdolS. As discussed earlier, Section 1.5.5, it has been 
reported that substitutions to the metal binding domains in PR-AS have a 
detrimental effect on the rate of reaction and affect the distribution of 
products,71 with similar effects reported in investigations with other 
sesquiterpene synthases.70,72 A number of GdolS-mutants were generated to 
investigate the metal-binding motives and to attempt to identify residues 
involved in incorporating water during the catalytic cycle. 
Mutants were generated using mismatched DNA primers and the polymerase 
chain reaction to introduce mutations to the cDNA, Section 6.1.6, the mutated 
and confirmed DNA was then used to express the gene with the same 
conditions used for the wildtype protein in the first instance, Section 6.1.10. 
The use of X-ray crystal structures, particularly when substrate is bound, can 
be valuable in identifying active site residues involved in the catalytic cycle and 
used to direct the choice of residues for investigation. These data can be used 
to complement information gained from  sequence alignments with other 
sesquiterpene synthases, in particular, those which have been extensively 
studied previously. 
In the absence of a crystal structure, homology models can be generated using 
the protein sequence and crystal structures of terpene synthases that have 
previously been resolved. Due to the highly conserved tertiary structure found 
with the terpene synthases this can be a particularly effective starting point in 
the analysis of the active site in these enzymes.  
3.2 Crystal structure and homology models 
In collaboration with Professor David Christianson, University of Pennsylvania, 
we have obtained the X-ray crystal structure of GdolS in the apo-state; that is, 
without any ligands bound. In this structure the active-site loops, D165-T175 
and S222-E248, are unrefined due to the inherent mobility of these loops in 
the unliganded form, and so the structure is of limited use. In addition to the 
crystal structure we have also made use of homology models generated using 
80 
 
SWISS-MODEL and I-TASSER.116,117 Both of these methods are based 
primarily on the published crystal structure of a pentalenene synthase mutant 
(PS-N219L, pdb: 1hm7), but I-TASSER uses multiple templates to generate a 
model and also predicts structure in regions where there is no crystal 
structure to model it on. Both methods produce very similar models, in good 
agreement with other terpene synthases and indeed the refined regions of the 
GdolS-apo structure; the main differences are in the helix-termini and the loop 
regions. Due to the inherent flexibility necessary in these regions during the 
catalytic cycle, (Section 1.3.3) this mobility is unsurprising. 
 
Figure 3.1 Superimposed cartoon representations of GdolS-apo (cyan) and two homology 
models, SWISS-MODEL (purple) and I-TASSER (green). Metal binding residues are shown with 
carbons in the respective ribbon colour, oxygens in red, nitrogens in blue and hydrogens in 
white. 
Figures in the remainder of this document will primarily be based on the 
SWISS-MODEL homology model, or the apo-crystal structure where 
appropriate. 
3.3 Metal-binding regions 
GdolS has both conventional metal binding regions; an aspartate rich region, 




Figure 3.2 Metal binding regions shown in 'coordination' with [Mg2+]3-PPi in GdolS-apo, left, and 
GdolS homology model, right. Both structures are overlaid with AT-AS in complex with [Mg2+]3-
PPi (pdb: 2OA6 chain D) with the ribbon of AT-AS not shown. Metal binding residues are shown 
with carbons in the respective ribbon colour, oxygens in red, nitrogens in blue and hydrogens in 
white. Phosphorus atoms are orange, magnesium is shown as green balls and water as small red 
balls. 
Initially each of the metal binding residues within the metal binding domains 
were individually targeted with small substitutions; changing the amino acid to 
one of identical functionality but with a greater (DE, NQ) or lesser (ED) 
number of CH2 units, the only exception to this rule was with serine, which 
was changed to alanine with a loss of functionality. 
 
Figure 3.3 Amino acid residues involved in the metal binding mutations. 
3.3.1 Aspartate-rich region 
Single amino acid replacements in the aspartate rich region to glutamate 
residues all created functional germacradien-4-ol synthase mutants, although 
with a very minor effect on the product distribution. Each of these mutants 
produced minor, albeit noticeable, traces of germacrene A and D (34 and 36, 
total <2 %). While functional, measurement of the steady-state kinetic 
parameters of these mutants showed that they are much less active than the 
wildtype with GdolS-D80E being too slow to measure any steady-state kinetic 
values. GdolS-D81E and GdolS-D84E were catalytically eight to ten-fold slower 




Figure 3.4 Overlaid normalised gas chromatograms of the incubations of FDP with metal-
binding mutants 
Further replacements of the aspartate residues to asparagine had an 
increasingly detrimental effect on the activity of the enzymes, yielding the 
inactive GdolS-D80N and GdolS-D84N mutants, and the GdolS-D81N mutant, 
which, while functional by GC-MS analysis, was not active enough to allow 
measurement of steady-state kinetic parameters. 
These results are consistent with previously reported effects of amino acid 
replacements in the metal-binding domains, with mutation of the first 
aspartate in the DDxxD motif (Aspartate-80 in GdolS) causing a much greater 
effect on catalytic activity than mutation of the other residues in the aspartate 
rich region. This is consistent with the findings of Van der Kamp et al.39 which 
indicated that upon the formation of the Michaelis complex two of the requisite 
magnesium ions are coordinated to this first aspartate, Section 1.3.3. 
Replacement of aspartate-81, the second aspartate in the DDxxD motif, 
displayed relatively little effect on the catalytic efficiency, with an 8-fold 
decrease in kcat accompanied by a very minor decrease in KM. The equivalent 
substitution in trichodiene synthase (TS) displays a similarly moderate, 3.5-
fold, decrease in kcat, but accompanied by a 1.5-fold increase in KM;70 while in 
pentalenene synthase (PS) replacement of the second aspartate with a 
glutamate leads to a dramatic 50-fold decrease in kcat, and a 9-fold increase in 
KM.72 This indicates that while the aspartate-rich region is highly conserved in 
terpene synthases, the specific roles played by each of the metal-binding 
residues are not identical throughout all terpene synthases. 












































Table 3.1 Steady state kinetic parameters and product distribution (%) of GdolS-WT and metal 
binding mutants. Germacradien-4-ol (79) Germacrene A (34) and Germacrene D (36). a no 
detectable activity – activity too low for kinetic parameters to be determined. b not active 
Enzyme kcat KM 
Product Distribution 
79 34 36 
GdolS-WT 0.079 ± 0.003 1.07 ± 0.13 100 - - 
GdolS-D80E ndaa ndaa 98.6 0.5 0.9 
GdolS-D80N n/ab n/ab n/ab n/ab n/ab 
GdolS-D81E 0.010 ± 0.0006 0.82 ± 0.11 99.0 0.7 0.3 
GdolS-D81N ndaa ndaa 99.8 0.2 - 
GdolS-D84E 0.009 ± 0.0003 0.92 ± 0.09 98.7 0.9 0.4 
GdolS-D84N n/ab n/ab n/ab n/ab n/ab 
GdolS-E226D ndaa ndaa 99.8 0.2 - 
GdolS-S222A ndaa ndaa 98.6 - 1.4 
GdolS-N218Q ndaa ndaa 47.6 50.7 1.8 
GdolS-N218L ndaa ndaa 99.8 0.2 - 
GdolS-N218T n/ab n/ab n/ab n/ab n/ab 




Substitution of the asparagine-218 of the NSE-motif with glutamine generated 
a functional germacradien-4-ol/germacrene A synthase, producing almost 
identical quantities of germacradien-4-ol and germacrene A (79:34, 55%:45%). 
This substitution also had a severe, detrimental impact on the catalytic 
efficiency, and it was not possible to measure steady-state kinetic parameters. 
It was postulated that the increase in volume in the active site shifted the 
folded-FDP (19) further into the active site cleft and the conformation of the 
larger glutamine blocked access of water into the necessary position for the 
quenching to form germacradien-4-ol (79). In an attempt to further shift the 
product distribution towards germacrene A (34) asparagine-218 was further 
replaced with leucine, a residue with similar shape and volume but with no 
hydrogen-bonding capability. With the loss of hydrogen bond acceptors and 
donors and a corresponding increase in hydrophobicity it was proposed that 
this might further prevent ingress of water into the active site and further 
reduce the proportion of germacradien-4-ol (79) produced. 
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The GdolS-N218L mutant was a functional but inefficient enzyme, while 
reverting more closely to the product distribution displayed by wildtype 
enzyme, producing over 98 % germacradien-4-ol (79) with only a minor trace of 
germacrene A (34), Figure 3.5. Further replacements of this residue with 
amino acids of varying degrees of hydrogen-bond donors and acceptors 
(threonine, glutamate) only yielded inactive proteins. 
 
Figure 3.5 Overlaid normalised gas chromatograms of the functional NSE-motif mutants 
Serine-222 and glutamate-226 
Substitutions of serine-222 and glutamate-226 generated functional but 
inefficient mutants GdolS-S222A and GdolS-E226D, both producing 
germacradien-4-ol. While GdolS produced purely germacradien-4-ol (79), 
traces of germacrenes A (34) and D (36) were also produced by GdolS-S222A; 
both mutants are too inefficient to be able to measure steady-state kinetic 
parameters. 
Substitutions to the NSE-motif impacted the functioning of the generated 
mutants to a much greater degree than those to the aspartate rich region, with 
the catalytic efficiencies of all NSE-mutants impaired to the extent that they 
could not be measured. This is consistent with results from other 
sesquiterpene synthases. Replacement of the arginine-219 in pentalenene 
synthase with hydrophobic residues leucine and alanine caused a complete 
loss of activity in the resulting mutants,72 and similarly the N244L mutant of 
PR-AS was found to be inactive.71 The investigation into PR-AS also generated 
mutants of the serine and glutamate metal-binding residues with the resulting 
S248A and E252D mutants displaying a 300-fold decrease in catalytic 














































efficiency with respect to wild-type, and the E252Q mutant a more dramatic 
3500-fold decrease in catalytic efficiency.71 
Most interesting of the DDxxD and NSE-mutants is the dramatic impact on the 
product distribution by the GdolS-N218Q mutant, which produces 45 % 
germacrene A (34). This mutant may indicate that, in GdolS, the metal-binding 
motif has a greater function than the locating of the substrate and initiation of 
the catalytic cycle, also actively involved in product specificity and locating of 
water in the active site. 
Arginine-172 
In response to the result with the arginine-218 mutants, the highly conserved 
hydrogen-bonding network was investigated. Arginine-200 in PR-AS is in close 
proximity to the [Mg2+]3-PPi cluster, and replacement of this residue with lysine 
results in a 300-fold decrease in catalytic efficiency, along with a significant 
increase in the proportion of germacrene A (34) produced. This was attributed 
to arginine-200 being important for the stabilisation of the diphosphate anion 
in the active site, and indirectly contributing to the protonation of germacrene 
A.40 The corresponding residue in GdolS is arginine-172, and it was proposed 
that replacement of this residue with lysine could affect the positioning and 
stability of the diphosphate anion as seen in PR-AS, leading to an increase in 
germacrene A (34) production. Replacement of arginine-172 with lysine results 
in a functional mutant with steady-state kinetic parameters showing a 200-
fold decrease in kcat. The product distribution was not drastically altered by 
this mutation, producing minor proportions of germacrenes A and D (34 and 
36, < 6%), similar to other mutants described earlier, Table 3.2. Further 
replacement of arginine-178 with glutamate lead to primarily insoluble protein, 
and the small amount of soluble protein isolated demonstrated no cyclisation 
activity upon incubation with FDP (19). While these results clearly 
demonstrate the importance of this residue for catalysis, it has only a minor 
effect on the product distribution on GdolS. This could be due to a lesser effect 
on the positioning of the diphosphate anion or due to the relative rates of the 
competing deprotonation with the nucleophilic attack of water on the 






Table 3.2 Steady state kinetic parameters and product distribution (%) of GdolS-WT and metal 
binding mutants. Germacradien-4-ol (79) Germacrene A (34) and Germacrene D (36) a not active 
Enzyme kcat KM Product Distribution 
79 34 36 
GdolS-WT 0.079 ± 0.003 1.07 ± 0.13 100 - - 
GdolS-R172K 0.00035 ± 0.00002 0.82 ± 0.062 >96 <4 <2 
GdolS-R172E n/aa n/aa n/aa n/aa n/aa 
 
3.4 Water-binding residues 
Careful analysis of the active site using a combination of homology models and 
the X-ray crystal structure of the apo-enzyme highlighted two other residues 
on the terminal helix which were proposed to play a role in hydrogen-bonding 
to water in the active site, glutamate-307 and tyrosine-303. Serendipitously, 
Chen et al. in a crystallographic study on aristolochene synthase from 
Aspergillus terreus (AT-AS) found evidence of water molecules trapped in the 
upper active site by hydrogen bonds with three key residues: N213, N299 and 
S303.38 Sequence alignment of AT-AS with GdolS showed that these three 
residues were the equivalent of N218, Y303 and E307; Asparagine-218 having 
previously been noted as a possible key residue in the incorporation of water, 
Section 3.3.2. 
3.4.1 Tyrosine-303 
As well as being highlighted as a water-bonding residue tyrosine-303 was also 
proposed to be likely to have importance as a residue for the stabilisation of 
developing carbocations, indeed in Figure 3.6 (bottom right) the proximity of 
the tyrosine to the C10-C11 bond can be noted and it can be postulated that it 
would be suitably positioned to stabilise the germacryl cation upon ring 
closure. Both hydrogen-bonding and stabilising functions were probed by 
separate replacements to the tyrosine-303. Loss of the hydroxyl in the GdolS-
Y303F mutant probed the importance of the hydrogen-bonding nature of this 
residue, while a more drastic change to a non-aromatic, hydrophobic residue 
to generate the GdolS-Y303I mutant probed the importance of the aromaticity 
to the activity of the enzyme, a third mutation retained the hydroxyl 






Figure 3.6 Top, Sequence alignment of the terminal helix and loop of GdolS with AT-AS and PR-
AS. N299 and S303 in AT-AS and the aligning residues in GdolS and PR-AS are highlighted in 
yellow. Bottom left, AT-AS bound to FSDP (farnesyl-S-thiolodiphosphate) and [Mg2+]3-PPi, with 
the active site water highlighted in magenta and interactions with N213, N299 and S303 shown 
as black dashes (pdb: 4KUX, chain A). Bottom right, GdolS-homology model aligned with AT-AS 
and the highlighted active site water (magenta) interacting with N218, Y303 and E307. Residues 
are shown with carbons in the respective ribbon colour, oxygens in red, nitrogens in blue and 
hydrogens in white. Phosphorus atoms are orange, sulfur yellow, magnesium is shown as green 
balls and water as small red balls, with the exception of the highlighted magenta water. 
As predicted, tyrosine is an important active-site aromatic residue for the 
stabilising of developing carbocations. Substitution of this residue to isoleucine 
generated the functional GdolS-Y303I mutant, but the kinetic efficiency was 
severely hampered and it was not possible to determine steady-state kinetic 
parameters. This mutant generates primarily germacradien-4-ol (79), but also 
traces of other products including germacrene A (34) and D (36). 
 
Figure 3.7 Overlaid normalised gas chromatogram of functional tyrosine-303 mutants 
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The smaller change to generate the GdolS-Y303F mutant has a lesser effect on 
catalytic efficiency, with a four-fold decrease in kcat compared to wild type and 
a small decrease in KM. Product distribution is only mildly affected by the loss 
of the hydroxyl-group in the active site with a minor increase in level of 
germacrene A (34). 
Table 3.3 Steady state kinetic parameters and product distribution (%) of GdolS-WT and 
tyrosine-303 mutants. Germacradien-4-ol (79) Germacrene A (34) and Germacrene D (36). a no 
detectable activity – activity too low for kinetic parameters to be determined. b not active 
Enzyme kcat KM 
Product Distribution 
79 34 36 
GdolS-WT 0.079 ± 0.003 1.07 ± 0.13 100 - - 
GdolS-Y303I ndaa ndaa > 99 trace - 
GdolS-Y303F 0.014 ± 0.006 0.66 ± 0.12 > 96 > 2 < 1 
GdolS-Y303T n/ab n/ab n/ab n/ab n/ab 
 
The third mutant, GdolS-Y303T, was expressed effectively; however, upon 
purification it was found that the majority was expressed as insoluble 
inclusion bodies, which was not improved by inducing with a lower 
concentration of IPTG, or by expression at a lower temperature. A small 
amount of soluble protein was isolable, purified and found to be inactive by 
GC-MS analysis. Basic extraction of the inclusion bodies failed to improve the 
yield of soluble protein, as did attempts at purifying the enzyme in denaturing 
conditions and refolding the purified enzyme; all failing in producing any active 
protein. 
Tryptophan-306 
Another aromatic active-site residue, tryptophan-306, was also probed by site-
directed mutagenesis. This tryptophan residue, highly conserved in terpene 
synthases, corresponds to tryptophan-334 in PR-AS, a residue which has been 
proposed to stabilise the eudesmane cation (68) in aristolochene 
biosynthesis.74 Replacement of tryptophan-334 in PR-AS with residues of 
decreasing aromatic character leads to decreasing catalytic efficiency and 
increasing proportions of germacrene A (34) formed. This was proposed to be 
due to the importance of this tryptophan residue in stabilising formation of the 
eudesmane cation through quadrupolar charge- interactions. Substitution of 
the corresponding residue in GdolS, tryptophan-306, with alanine generated 
the functional GdolS-W306A mutant; While the resulting mutant was 
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functional, producing germacradien-4-ol (79) with traces of germacrenes A and 
D (34 and 36, < 1 %), no kinetic parameters could be measured due to the 
very low activity of this mutant. This implicates tryptophan-306 as a vital 
residue for the catalytic efficiency of GdolS, necessary for the stabilisation of a 
carbocation intermediate in the cycle catalysed by GdolS. 
3.4.2 Glutamate-307 
A similar approach was taken in the investigation into the role of glutamate-
307, exchanging it for residues of lesser hydrogen bonding ability while 
maintaining a similar volume in the active site. Functional mutants GdolS-
E307Q and GdolS-E307M were generated, and the pentane extractable 
products of the incubations with FDP analysed by GC-MS; GdolS-E307Q 
produced >96 % germacradien-4-ol (79) with a small increase in hydrocarbon 
terpenes, germacrenes A (34) and D (36); while GdolS-E307M, with less 
hydrogen bonding ability, further decreased the proportion of germacradien-4-
ol (79, < 95 %), with an associated increase in germacrene A (34, > 4 %).  
 
Figure 3.8 Overlaid normalised gas chromatogram of functional glutamate-307 mutants 
Measurement of the steady-state kinetic parameters of these mutants found 
GdolS-E307Q to be moderately active with a four-fold decrease in kcat coupled 
with a two-fold increase in KM leading to a thirteen-fold decrease in efficiency 
(kcat 0.015 s-1, KM 2.7 µM, kcat/KM 5,500 M-1 s-1). Further mutation to the 
GdolS-E307M mutant caused such retardation in catalytic activity that it was 
not possible to measure kinetic parameters. These results implicate this 
residue as important for catalysis, possibly involved in the binding and 
organisation of one of the magnesium ions, leading to the increase in KM upon 






















replacement with a neutral residue. While important to catalysis, the minor 
perturbation of product distribution displayed by the GdolS-E307Q and GdolS-
E307M mutants suggest this residue is not involved in the incorporation of 
water in the product. 
Table 3.4 Steady state kinetic parameters and product distribution (%) of GdolS-WT and 
glutamate-307 mutants. Germacradien-4-ol (79) Germacrene A (34) and Germacrene D (36). a 
no detectable activity – activity too low for kinetic parameters to be determined. 
Enzyme kcat KM 
Product Distribution 
79 34 36 
GdolS-WT 0.079 ± 0.003 1.07 ± 0.13 100 - - 
GdolS-E307Q 0.013 ± 0.0004 2.24 ± 0.16 > 98 < 1 < 1 
GdolS-E307M ndaa ndaa > 95 > 4 < 1 
 
3.4.3 Helix-hybrid 
It was noted that these two residues are in relatively close proximity to 
asparagine-218 of the NSE-motif and they are located on the C-terminal helix, 
and so it was proposed to create a hybrid bearing the C-terminal of another 
terpene synthase which produces a hydrocarbon terpene product. The 
synthase selected was -cadinene synthase from Gossypium arboreum (DCS), 
due to its availability within our lab and the published X-ray crystal structure, 
which could be used in the preparation of a protocol for the helix-switching. 
  
Figure 3.9 Sequence alignment of GdolS (Accession: BAL14866.1) with a bacterial -cadinene 
synthase (DCS-SC, from Streptomyces clavuligerus ATCC 27064, Accession: EFG03819.1118) and 
with DCS-GA (Accession: Q39761.1) 
Sequence alignment and comparison of the GdolS homology model with the X-
ray crystal structure of DCS showed that the C-terminal helix of DCS is longer 
than that in GdolS by approximately ten amino acids and it is also positioned 
slightly differently; beginning higher up the active-site cleft. Effectively leaving 
a significant proportion of this helix available to cover the active-site entrance 
and possibly more efficiently desolvating the active site. 
GdolS       SMSLDPAQRLAAERYADGMALWLAGYLHWESHTRRYHHG----------- 
DCS-SC      ALGLPDTVRTHADDCAASLLVWVRGHLEWGLETPRYRPGTTGTGTD---- 




Figure 3.10 apo-GdolS (cyan) overlaid with the terminal helices of DCS (orange). The exchanged 
regions are highlighted by the darker colour. 
Preparation 
Cloning 
It was decided to replace the entire C-terminal helix including the preceding 
loop, to minimise the effects on the folding of the helix. Both cDNA for GA-DCS 
and GdolS bear a BamHI restriction site at the 3’ end and this site was used 
for the removal and insertion of the fragments. A second unique restriction site 
prior to the methionine-279 of the loop in GdolS was needed; unfortunately no 
unique restriction sites were already present and no silent mutations were 
possible to generate a unique site. A unique SmaI restriction site could be 
generated by mutation of a single base-pair causing the single point mutation 
of aspartate-274 to a glycine and so this mutation was introduced using site-
directed mutagenesis. The desired section of the cDNA for GA-DCS was 
amplified using the polymerase chain reaction with the forward primer bearing 
the desired loop sequence and the SmaI restriction site, Figure 3.11. 
After confirmation of the successful mutation, the gene encoding the GdolS-
D274G mutant was digested sequentially with SmaI followed by BamHI 
(Section 6.1.6), and purified by gel electrophoresis (1 % agarose, Figure 3.12 C) 
to isolate the open plasmid. The DCS-fragment was isolated from the pET21d-
DCS expression vector by PCR amplification, and the PCR product was then 
isolated by gel electrophoresis (2 % agarose, Figure 3.12 A) and directly ligated 
into a StrataClone™ Blunt PCR cloning kit. The resulting plasmid containing 
the DCS-fragment was then sequentially digested with SmaI followed by 
BamHI and purified by gel electrophoresis (2 % agarose, Figure 3.12 B) to 




Figure 3.11 A. Mutation of GdolS to insert SmaI restriction site, with the mutated base and 
resulting amino acid change in bold italics; B. forward primer to generate DCS loop helix cDNA 
fragment with GdolS section in red and DCS complementary fragment in green; C. Diagram of 
subcloning strategy. 
The fragment and open plasmid were then ligated with T4 DNA ligase (16 °C, 
14 hours) and supercompetent XL1-blue cells then transformed with 5 µL of 
the resulting mixture. A selection of colonies were grown up and the plasmid 
isolated and tested for successful ligation by digestion with NdeI restriction 
enzyme; there is an NdeI site at the beginning of the cDNA for GdolS and 
another within the inserted DCS-fragment yielding a 900 basepair (bp) 
fragment when digested. Digested samples were analysed by gel 
electrophoresis (2 % agarose, Figure 3.12 D) and sample showing a band at 
~900 bp were sequenced to confirm generation of the GdolS-DCS hybrid 
plasmid. 
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A.  B.  C.  
D.  
Figure 3.12 Agarose gels for the preparation of the GdolS-DCS hybrid gene; A. Purification of 
the PCR product of the DCS loop-helix fragment (1); B. Purification of the DCS loop-helix 
fragment digested from cloning vector (1 & 2); C. Purification of the GdolS-SmaI vector fragment 
digested from pET16b (1 & 2); D. NdeI digests of ligated plasmids (1-4 from different colonies). In 
all images lanes labelled ‘M’ are DNA ladder with sizes shown to the left, where ‘bp’ is number of 
basepairs and ‘kb’ is number of kilobases. In all images the desired fragments are underlined in 
red. 
Expression and purification 
E. coli BL21-(DE3) cells were transformed with the constructed plasmid and 
the gene was overexpressed at 16 °C for 21 hours, producing almost 
exclusively insoluble protein, Figure 3.13 A.; while a small quantity of protein 
was isolated by affinity chromatography this protein was inactive when 
incubated with FDP. A test expression was performed to follow the production 
of protein, inducing with 0.1 mM IPTG and growing at 37 °C for 6 hours before 
reducing the temperature to 16 °C for a further 15 hours (overnight). Samples 
were taken before induction, 2.5, 4, 6 and 21 hours post-induction and 
analysed by SDS-PAGE, Figure 3.13 B., indicating the greatest proportion of 
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protein at 2.5 hours post induction. GdolS-DCS hybrid was then produced 
using these conditions; unfortunately despite the high yield of protein, this 
was solely as insoluble inclusion bodies and so efforts were directed towards 
solubilising and purifying the protein rather than improving the level of soluble 
protein produced. The standard method of basic extraction was initially tried 
and failed to yield any soluble protein and so a number of modifications were 
trialled; extending the period allowed for refolding from one hour to 15 hours; 
adding MgCl2 (Final concentration 10 mM) after adjusting the pH to 12 and 
before reducing the pH to 8; and adding detergent (0.1 % Tween-20) to the 
buffer used for resuspension of the pellet. In the cases of MgCl2 and Tween-20 
additives refolding was also left for 15 hours. 
A.  B.  
C.  D.  
Figure 3.13 SDS-polyacrylamide gels of the production and purification of the GdolS-DCS 
hybrid. A) Purification from the expression of pET16b-GdolS-DCS at 16 °C, showing the pellet 
(P), flowthrough (FT), washes (W) and elution (E). B) Test expression of pET16b-GdolS-DCS in 
BL21(DE3), analysis of samples taken at periods after induction, where the lanes are labelled by 
the number of hours after induction (X is an empty lane). C) Analysis of the pellets (P) and 
supernatant solutions (SN) after basic extraction of the insoluble inclusion bodies in buffer 
(B/E), buffer with 10 mM MgCl2 (B/E MgCl2) and buffer with 0.1% Tween 20 (B/E Tween). D) 
Purification of the soluble GdolS-DCS;; Showing the flowthroughs from basic extractions in 
buffer (FT1) and buffer with 0.1% Tween 20 (FT2), washes (W) and elution (E). MW, molecular 
weight x103, approximate expected mass of GdolS higfhlighted in red. 
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The addition of MgCl2 was proposed to aid in the refolding by directing the 
organisation of the metal binding region; this method failed to solubilise any 
protein, instead causing a precipitate to form rapidly after addition of the 
MgCl2. The other two methods were marginally more successful with the 
extended refolding time yielding a small amount of soluble protein and the 
addition of Tween-20 further increasing the soluble yield, Figure 3.13 C. These 
soluble fractions were both applied to the same Nickel-affinity column and 
purified by affinity chromatography (Section 6.1.11). Analysis of the fractions 
by SDS-PAGE showed the majority of the soluble protein failed to bind to the 
column, and was found in the flowthrough fractions, Figure 3.13 D. A small 
proportion of GdolS-DCS hybrid protein was successfully purified and 
concentrated by ultrafiltration. 
Analysis 
The pentane-extract of the incubation of purified GdolS-DCS with FDP showed 
no peaks and neither did that of the incubation with the soluble, unpurified 
hybrid. 
 
Figure 3.14 Overlaid CD spectrum of GdolS-WT and the GdolS-DCS hybrid 
In order to understand if the inactivity was due to an unproductive active-site 
conformation or primarily due to incorrect or poor folding the circular 
dichroism spectrum of the GdolS-DCS hybrid was measured and compared 
against wildtype GdolS, Figure 3.14. Due to the low concentration of the 
GdolS-DCS sample a neat sample was used for measurement of the CD 
spectrum, and the Tris present (10 mM) creates noise in the spectrum at lower 

































relative to the protein, it has more of an effect. Due to the presence of Tris-
buffer the sample is quite noisy, but clearly lacks the definite minima shown in 
the wildtype sample, in particular that at 222 nm. The magnitude of the 
typical -helical minima at 209 and 222 nm are clearly less than those of the 
wildtype. The shape and magnitude of the spectrum strongly suggest that the 
protein is not fully folded, and the lack of terpene synthase activity is due to 
this incorrect folding. 
3.5 H-1-loop 
In the X-ray crystal structure of apo-GdolS the H-1 loop, the loop succeeding 
the NSE-motif, and the E-F loop are not resolved due to the high mobility of 
these regions. Previous research on the H-1 loop in fungal sesquiterpene 
synthases from Coprinus cinereus found that mutations to this region could 
markedly influence the product profile in some cases,77 and so the H-1 loop 
in GdolS was studied using sequence alignments and homology model of 
GdolS to identify residues that may be important in the movement and locating 
of the loop during catalysis. The previous study by Lopez-Gallego et al.77 
highlighted the role of ionic interactions between the H-1a loop and the metal-
binding motives (Section 1.1) and so residues with this ability were identified 
in the H-1 loop of GdolS; glutamate-228, arginine-229, aspartate-231 and 
asparagine-234. Of these residues, glutamate-228 does not appear to be 
positioned suitably for interaction with the active site, situated on the outer 
edge of the H-1 loop facing towards the solvent. Arginine-229 and aspartate-
231 are facing into the active site, while in the homology model they are too far 
away to interact with the [Mg2+]3-PPi complex and metal binding residues, 6 – 8 
Å, it could be imagined that the mobility of the loop will bing them into closer 
proximity during the catalytic cycle. Asparagine-234 is facing towards the H-
helix and suitably positioned to interact with serine-222 and glutamate-226 of 
the NSE-motif, with distances of 4.7 Å and 2.6 Å respectively in the homology 




Figure 3.15 Alignment of the H-1 loop regions of bacterial and fungal sesquiterpene synthases; 
COP1-6, various sesquiterpene synthases from Nostoc cyanobacteria;46 EABS, epi--bisabolol 
synthase from Streptomyces citricolor;93 G11OL, germacradien-11-ol synthase from Streptomyces 
coelicolor;119 PS, pentalenene synthase from Streptomyces UC5319;120 SC-DCS, -cadinene 
synthase from Streptomyces clavuligerus;118 PRAS, Aristolochene synthase from Penicillin 
roquefortii.60 The NSE-motif is highlighted in yellow, with other conserved residues highlighted in 
other colours. 
 
Figure 3.16 GdolS homology model showing charged residues of the H-1loop and, below, 
overlaid with [Mg2+]3-PPi (AT-AS, pdb: 2OA6). Residues are shown with carbons in the respective 
ribbon colour, oxygens in red, nitrogens in blue and hydrogens in white. Phosphorus atoms are 
orange, sulfur yellow, magnesium is shown as green balls and water as small red balls. 
As the residues with the greatest potential for interactions with the metal-
binding regions and, as such it was proposed, the greatest effect on catalysis 
arginine-229 and aspartate-231 were selected for study through the 
replacement of these residues. Mutants GdolS-R229E and GdolS-D231L were 
GDOLS  NDVRSFAQESERGDVA NLVMIVRR 
COP6  NDLLSFYKEELDCETV NFIS 
COP4  NDVYSTDMEQAKGHTGNNVVTVLMK 
COP3  NDIFSYNVEQSKGDTH NMIIILM 
COP2  NDIFSFNREQSRHDSF NMVSIVM 
COP1  NDIFSFNVEQSKGDTH NMIPVVM 
EABS  NDLCSLQREEGLPAVQFNMVMTLQRTH 
G11OL  NDLFSYQREVEDEGENANCVLVLERFLNV 
PS  NDVYSLEKEEARGDMD NLVLVLVLEHTR 
PSCANE NDIASLEKEEARGEQN NMVMILRREH 
DCSSC  NDLMTVDKEAAHGDLH NLVLVTEHDR 




generated with the aim of detrimentally affecting any electrostatic coordination 
to other active site residues, both mutants were expressed and purified as 
previously described, and the purified proteins were incubated with FDP and 
the pentane extractable products analysed by GC-MS. The arginine-229 
mutant showed terpene synthase activity, producing solely germacradien-4-ol 
(79), while the aspartate-231 mutant showed to be inactive, generating no 
pentane extractable products upon incubation with FDP. This implies that this 
aspartate residue is vital for catalytic activity; suggesting it has a role in the 
catalytic cycle. Given the likely positioning of this residue, as can be seen in 
the homology model, Figure 3.16, it is unlikely to play a direct role in the 
cyclisation of FDP. However, it is suitably positioned to play a role in the 
binding of the [Mg2+]3-PPi cluster, and a role in the formation of the Michaelis 
complex would account for the complete loss of activity upon replacement of 
this residue with one of a hydrophobic nature. 
 
Figure 3.17 Normalised chromatogram of arginine-229 mutant 
3.6 Monomer/dimer 
The X-ray crystal structure of the apo-structure of GdolS was comprised of two 
GdolS monomers in very close proximity, suggesting that GdolS may form a 
dimer in solution. Close analysis of the interface between the two chains 
highlighted a possible contact point between the two monomers comprising a 
salt bridge and a disulphide bridge. The possible disulphide bridge was not 
shown in the crystal structure with the two cysteine-141 residues facing away 
from each other and a distance of >4.5 Å, rotation of the cysteine only 
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minimises the distance to <3.4 Å with a dihedral angle of <45°, making 
formation of a disulphide bond in this orientation unlikely.  
 
Figure 3.18 apo-crystal structure of GdolS (A) showing dimer interface with salt bridges and 
cysteine residues (B). Bottom, cysteine-cysteine distance is highlighted (C), minimised cysteine-
cysteine distance (D). 
The residues highlighted as a possible salt bridge were glutamates-99 and -
144 on one monomer with the arginine-134 of the second monomer effectively 
creating two salt bridges, one at either end of the contact face, with distances 
of <2.7 Å. To investigate the possibility of a solution state dimer the central 
residue of the saltbridge trio, arginine-134 was mutated to an aspartate and 
an alanine, and the resulting mutants analysed by size-exclusion 






The GdolS-R134E mutant was expressed primarily as insoluble inclusion 
bodies but a small amount of soluble protein was isolated. Basic extraction of 
the inclusion bodies yielded a further sample of soluble protein. Both samples 
of GdolS-R134E produced solely germacradien-4-ol prior to purification, 
however, less than 24 hours later after purification and dialysis the activity 
was severely reduced and no attempt at measuring steady-state kinetic 
parameters was made. Repeated attempts at preparing a sample with 
maintained activity highlighted rapid aggregation as the probable cause of the 
loss of activity. Expression and purification of GdolS-R134A was 
straightforward, yielding the functional mutant which, upon incubation with 
FDP, produced solely germacradien-4-ol (79). Measurement of the steady-state 
kinetic parameters found this mutant to be 5-fold less active than wildtype (kcat 
0.0013 s-1), although with a reduced KM (0.42 M). 
 
Figure 3.19 Normalised overlaid gas chromatogram of incubations with arginine-134 mutants. 
Analysis of GdolS-WT by size-exclusion chromatography showed a small 
amount of aggregated protein eluting in the void volume (~7 mL) and a single 
peak eluting at 14.4 mL; Comparison against proteins of known size indicated 
that this is a monomer. Despite the low concentration of the R134E samples 
they were analysed by size-exclusion chromatography and it was found that 
the majority of the protein was aggregated and ran through the column in the 
void volume. There were two other peaks, poorly resolved due to the low 
intensity of the sample, one of these peaks eluted at the same time as the 
GdolS-WT, while the second peak eluted slightly earlier, suggesting monomer 





















and dimer. In the sample of R134E solubilised by basic extraction (Figure 3.20 
left, dark green) the proportion of monomer appears to be greater than that 
seen in the soluble protein obtained directly from expression; Similarly, 
repeating the size-exclusion analysis in the presence of salt (150 mM NaCl) 
increases the proportion of the monomer over the dimer, while in the wildtype 
enzyme it causes the appearance of a second peak at earlier retention time, 
thought to be dimer. Analysis of the R134A mutant by size-exclusion 
chromatography shows two peaks similar to that shown by the GdolS-R134E 
mutant, however with a lesser proportion of aggregation. This mutant was also 
less prone to rapid aggregation than the R134E mutant. The relative instability 
of the R134E mutant compared to the GdolS-WT and the R134A mutant could 
be attributed to the close proximity of three negative charges. 
 
 
Figure 3.20 Normalised and overlaid size-exclusion chromatograms of GdolS-WT, GdolS-R134A 
(GdolS-R134A stored at 4 °C for 4 weeks, R134A 1; and freshly defrosted prior to injection, 
R134A 2) and GdolS-R134E (GdolS-R134E solubilised by basic extraction, R134E 1; and soluble 
protein directly from purification of expression, R134E 2), in the absence (Left) and presence 








































































In addition to the size-exclusion chromatography, non-denaturing gel 
electrophoresis was used to analyse the protein. Blue native polyacrylamide gel 
electrophoresis (BN-PAGE) was used, following the protocol developed by 
Schägger et al. which uses Coomassie brilliant blue dye as the charge shift 
agent.121,122 The charge shift agent is necessary so that the mobility of the 
proteins is dependent on their charge-to-mass ratio, rather than shape of 
natural charge state. Coomassie brilliant blue dye is used because it 
complexes to the protein without denaturing it, allowing the protein to run 
according to size while also maintaining levels of higher order structure such 
as the formation of complexes. The GdolS-R134A was analysed by BN-PAGE in 
addition to GdolS-WT, other proteins and NativeMark™ protein standard from 
Life Technologies, Figure 3.21. 
 
Figure 3.21 BN-PAGE analysis of GdolS-WT and GdolS-R134A against marker (M) and other 
proteins. BSA, bovine serum albumen, MW 66.4; WT, freshly defrosted GdolS-WT, MW 38.7; 
R134A, GdolS-R134A, MW 38.7; R134E, GdolS-R134E, MW 38.7; WTf, fridge stored GdolS-WT, 
MW 38.9; DHFR, dihydrofolate reductase from E. coli, MW 18.0; GAS, germacrene A synthase, 
MW 64.0; AS, PR-AS, MW 38.0. MW, molecular weight x103.  
The BN-polyacrylamide gels do not definitively show the molecular weight of 
neither the GdolS-WT nor the GdolS-R134A mutant (the sample of the GdolS-
R134E mutant is too dilute to be visible on the gel), with both samples running 
at just below the 66,000 MW band on the protein ladder. However the gel 
clearly shows bands of increasing MW in the samples of GdolS-R134A. In the 
samples of GdolS-WT, there are two bands with the second band at 
approximately a MW of 120,000, the same molecular weight as the second 
band in the samples of R134A. In the sample of WTf the second, heavier 
molecular weight band, correlates to the third band in the R134A samples; 
with a molecular weight of approximately 150,000. This suggests that the 
GdolS-WT is present in solution as an equilibrium of two forms, which tends 
towards aggregation upon long-term storage, this is consistent with the 
observed formation of a precipitate over the long term storage of the protein in 
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the fridge. The BN-polyacrylamide gel shows that the GdolS-R134A mutant is 
present in a greater number of forms, tending towards aggregation much 
quicker than the wild-type protein.  
The result of the BN-PAGE in conjunction with the size-exclusion data 
suggests that the solution state of GdolS-WT is a monomer, and that while the 
dimer in the crystal state may be directed by the saltbridges; in the solution 
state these residues aid in the solubility of the enzyme and prevent 
dimerization and aggregation. 
3.7 Summary 
In this chapter we have used site-directed mutagenesis to probe, primarily the 
active site of, GdolS. Initial point mutations were directed at the metal binding 
motives, which gave results in good agreement with previous studies on other 
terpene synthases; with mutations to the NSE motif and the first aspartate in 
the aspartate rich region dramatically affecting catalytic efficiency while 
mutations to the remaining residues in the aspartate rich region caused on 
minor decreases in efficiency. The most interesting mutation was that to the 
arginine of the NSE-motif. Mutation of this residue to a glutamine caused, 
along with a severely impaired efficiency, a dramatic shift in the product profile 
of GdolS, to yield 45 % of germacrene A (34) in addition to the natural product, 
germacradien-4-ol (79). Further mutations to this residue caused a return to 
wildtype product profile (N218L), or inactive mutants (N218E, N218T). 
Nonetheless, this mutation indicates that, in GdolS, the metal-binding motif 
may also be actively involved in product specificity and locating of water in the 
active site. 
A crystallographic study on AT-AS by Chen et al. highlighted an active site 
bound water molecule. This molecule was coordinated to the arginine of the 
NSE-motif, arginine-213; in addition to arginine-299 and serine 303. The 
corresponding residues in GdolS were tyrosine-303 and glutamate-307 which 
had serendipitously, been mutated and shown a slight moderation in product 
profile although not to the extent seen in the N218Q mutant. Both these 
residues showed more of a role in maintaining enzyme activity than in guiding 
product selection, with minor mutations (tyrosine to phenylalanine, glutamate 
to glutamine) causing small decreases in catalytic activity while greater 
mutations (tyrosine to alanine, glutamate to threonine) severely impacted 
catalytic efficiency.  
104 
 
To further investigate interactions between arginine-218 and proximal residues 
a helix-switch approach was adopted; changing the terminal loop-helix region 
of GdolS with the same, slightly longer region, from DCS; a -cadinene 
synthase available in our lab. Unfortunately this generated hybrid showed only 
sparing solubility due to incomplete folding and was completely inactive. 
Following a report on the effect of the H-1 loop on product distribution in 
fungal sesquiterpene synthases, this region was analysed and mutated in 
GdolS. Two mutants were generated to disrupt ionic interactions between the 
H-1loop and the active site, resulting in one wildtype-like enzyme (R229E) 
and an inactive mutant (D231L); suggesting that the aspartate residue is key 
in closing the active site to form the Michaelis complex. 
The X-ray crystal structure of GdolS appeared to show a dimer and closer 
analysis of the interface between the two units of GdolS appeared to show a 
salt bridge comprised of two glutamate residues and an intercalating arginine. 
Replacements of this arginine with glutamate and alanine generated two 
functional mutants, which were analysed by size-exclusion chromatography 
and native-polyacrylamide gel electrophoresis. The R134E mutant was prone 
to rapid aggregation and the size-exclusion chromatography showed 
aggregation in addition to peaks for monomer and dimer. This was also the 
case for the R134A mutant, but with less aggregation. Due to the low 
concentration of the R134E sample it was not visible on the BN-polyacrylamide 
gel, but the R134A sample showed clearly the presence of a number of 
different size forms suggesting that while in the crystal structure these 
residues direct the dimer formation, in solution they are important for 



















This chapter will describe the rationale behind and synthesis of, several FDP-
analogues and their incubation with a range of sesquiterpene synthases. The 
sesquiterpene synthases used in this study have been described in Section 
1.4. 
4.1.1 Diphosphorylation of farnesol analogues 
To generate FDP-analogues the corresponding farnesol-analogues were 
prepared and then diphosphorylated. Two methods of diphosphorylation were 
used in the preparation of the FDP-analogues described herein; a direct 
displacement of the farnesyl chloride (103) with a diphosphate salt and the 
condensation of farnesol (104) with inorganic phosphate using 
trichloroacetonitrile (105) as an activating agent.  
The displacement method used was that described by Davisson et al.123 This 
method involves the generation of the farnesyl chloride (103) from farnesol 
(104) via an intermediate mesylate; the farnesyl chloride (103) is isolated and 
used without further purification, stirring with tris-
(tetrabutylammonium)hydrogen diphosphate (106) overnight (15 h) in dry 
acetonitrile before removal of the solvent. The crude farnesyl diphosphate 
tris(tetrabutylammonium) salt is then passed through a column of DOWEX 
50W-X8 cation exchange resin (ammonium form) to generate the 
trisammonium farnesyl diphosphate salt which is purified by HPLC and pure 
fractions lyophilised to yield the product in, typically, 40 to 60 % yield from the 
farnesol (104), Scheme 4.1. While the tris(tetrabutylammonium) farnesyl 
diphosphate salts may be used without ion exchange they are harder to 
handle, being a sticky solid, whereas the trisammonium salts are isolated as a 




Scheme 4.1 Diphosphorylation of farnesol via the intermediate farnesyl chloride as developed 
by Davisson et al.123 
The condensation method followed was as described by Keller et al.,124 a 
modification of the procedure originally described by Cramer125 and modified 
by Cornforth,126 involving mixing an alcohol with trichloroacetonitrile (105) 
and inorganic phosphate. The original method as described by Cramer127 
produces a complex mixture of mono-, di- and triphosphates; Keller et al.124 
have reported the optimisation of the protocol to improve the yield of the 
diphosphate and also describe the purification of the diphosphate using flash 
column chromatography on silica. Farnesol (104) was incubated with 
inorganic phosphate and trichloroacetonitrile (105) in acetonitrile for 15 
minutes at 37 °C (three additions at five minute intervals) with mixing on a 
rotary evaporator and then the whole reaction mixture applied to a silica 
column pre-equilibriated with running buffer (iPrOH:NH4OH:H2O, 6:2.5:0.5), 
fractions were analysed by TLC (iPrOH:NH4OH:H2O, 6:3:1) and the diphosphate 
isolated and lyophilised to yield the product in 20 – 40 % yield. The inorganic 
monophosphate used can be tetrabutylammonium dihydrogen phosphate 
(107), which is available commercially, or bis(triethylammonium) hydrogen 
monophosphate (108) which can be prepared prior to use as a solution in 
acetonitrile.128 When using the bis(triethylammonium) hydrogen phosphate 
(108), it was found during this study that the triethylammonium counter ions 
are readily exchanged during the silica purification to yield the trisammonium 
farnesyl diphosphate salt as a white powder directly. Use of the 
tetrabutylammonium dihydrogen monophosphate (107) results in the 
tetrabutylammonium farnesyl diphosphate salt, which requires an additional 
ion-exchange column. Lira et al. proposed a mechanism for this reaction via 
the formation of a mixed anhydride (109) formed between the 
trichloroacetonitrile (105) and the monophosphate, Scheme 4.2.129 Following 
experiments by 13C-NMR spectroscopy no reaction was detected when 4-
methoxybenzyl chloroacetimidate (110) was mixed with tetrabutylammonium 
dihydrogenphosphate (107), nor upon the premixing of geraniol (27) with 
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trichloroacetonitrile (105). These results rule out a mechanism through 
activation of the alcohol by trichloroacetonitrile (105) to form a 
trichloroacetimidate intermediate (110, 111) that is then displaced by the 
phosphate. When geraniol (27), trichloroacetonitrile (105) and 
tetrabutylammonium dihydrogenphosphate (107) were mixed in succession, 
the disappearance of the 13C-signals of trichloroacetonitrile (105) were noted, 
in addition to the appearance of the signals corresponding to the 
phosphorylated alcohol (18). 
 
Scheme 4.2 Diphosphorylation using the trichloroacteonitrile coupling, via a mixed 
anhydride.129 
While the direct displacement method is superior for the preparing the 
diphosphate salts in higher yield and purity necessary for use in kinetic 
studies, it is a time consuming and protracted method. The 
trichloroacetonitrile coupling is a time-efficient method for the preparation of 
diphosphate salts suitable for the exploratory work described in this chapter. 
Both methods have been used for the diphosphorylation of the farnesol 
analogues described herein. 
4.2 FDP analogues 
4.2.1 12,13-Difluorofarnesyl diphosphate (73) 
The 12,13-difluoro-FDP (73) was prepared as part of the mechanistic 
investigation of GdolS as described earlier (Section 2.3.2). While the 12,13-
difluoro-FDP (73) has been synthesised previously, it was necessary to repeat 
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the preparation and a new synthesis was devised. The previous synthesis of 
12,13-difluorofarnesol (112) by Miller and Yu was completed from 
bromoketone 113 using three chain extension steps.67 A Horner-Wadsworth-
Emmons reaction was used to generate the bromoester 114 with good 
stereoselectivity (E/Z 11:1); Functional group interconversions then yielded the 
allylic alcohol protected as the tetrahydropyran ether (OTHP) 116. This was 
used to prepare the phosphonium bromide 117 which underwent a Wittig 
reaction with difluoroacetone 118 to yield the THP protected difluorogeraniol 
119. The final chain extension was completed using a Heck coupling with 
diene 122 and crotonyl iodide 123 to yield the ester 124 that, upon reduction, 
yielded the desired 12,13-difluorofarnesol (112). 
 
Scheme 4.3 Original synthesis of 12,13-difluoroarnesol (112) by Miller and Yu. Reagents and 
conditions: i. triethyl phosphonoacetate, NaH, THF, 0 °C, 68%; ii. DIBAL-H, THF, -78 °C, 98%; iii. 
3,4-DHP, DCM, p-TsOH, 98%; iv. PPh3, MeCN, ; v. LiHMDS, THF, -78 °C, then 118, 87%; vi. PPTS, 
EtOH, 55 °C, 97%; vii. TPAP,NMO, MeCN, 82%; viii. CH3PPh3Br, n-BuLi, THF, 78%; ix. 9-BBN, THF 
then 123, PdCl-dppf, NaOH, AsPh3,THF, 50 °C, 28%; x. DIBAL- H, THF, -78 °C, 68%.  
A new synthesis was devised to reduce the number of chain extension steps 
using farnesol as the starting material, which also removed any issues of 
stereoselectivity in the synthesis. The new method was based upon the using a 
similar Wittig reaction to Miller and Yu, with difluoroacetone for a single key 
extension step, but using the longer phosphonium bromide (125) bearing an 
additional isoprene unit, Scheme 4.4. Phosphonium bromide 125 was 
111 
 
prepared from farnesol (104) using a number of literature procedures,67,130,131 
and generated intermediate compounds that have been utilised in the 
preparation of a number of other targets. 
 
Scheme 4.4 Retrosynthesis of 12,13-difluoroarnesol (112) 
Farnesol (104) was first protected using 3,4-dihydropyran and catalysed by 
pyridinium para-toluene sulfonate (PPTS) to generate the tetrahydropyran 
ether (126) in 98% yield.130 The THP protecting group was chosen despite the 
likely complication of the 1H-NMR spectra due to the introduction of an 
asymmetric carbon. The distal (10,11)-double bond of farnesol can be 
regioselectively epoxidised in a two-step procedure via the bromohydrin. 
Reaction of 126 with N-bromosuccinimide (NBS) in aqueous saturated THF 
yields the bromohydrin 127 in 70% yield, the epoxide 128 is then formed by 
base catalysed ring closure. Epoxide 128 then undergoes oxidative cleavage 
with HIO4, to yield aldehyde 129 and acetone.131 Aldehyde 129 is readily 
reduced to the alcohol 130 with NaBH4, which can then be converted to 
bromide 131 via a mesylate intermediate. Heating bromide 131 under reflux in 
acetonitrile with triphenylphosphine yielded the desired phosphonium bromide 
125, which was partially purified by repeated trituration with diethyl ether to 




Scheme 4.5 Redesigned synthesis of 12,13-difluorofarnesol. Reagents and conditions: i. 3,4-
DHP, DCM, PPTS, 0 °C, 98 %; ii. NBS, THF/H2O, 70 %; iii. K2CO3, MeOH, 99 %; iv. H5IO6, NaIO4, 
THF, 0 °C, 79 %; v. NaBH4, MeOH, 0 °C, 69 %; vi. Et3N, MsCl, -45 °C then LiBr, RT, 79 %; vii. PPh3, 
MeCN, ; viii. n-BuLi, THF, -45 °C, then 118, 61 %; ix. pTsOH, EtOH, 91%. 
The ylid was formed by the dropwise addition of n-butyl lithium to a solution of 
phosphonium bromide 125 in THF at -45 °C, generating a deep, bright yellow 
colour. Dropwise addition of 118 to the ylid caused a lessening in the intensity 
of the colour, and the reaction was allowed to warm to room temperature over 
2 hours.67,132 Removal of the THP-group with p-TsOH in methanol from the 
resulting THP-ether (132), yielded the 12,13-difluorofarnesol 112. 
The symmetry of the aldehyde makes this a simple and effective method for the 
generation of farnesol analogues with identical modifications at the C12 and 
C13 positions and has also been used for the preparation of 
[12,12,12,13,13,13-2H6]-farnesol (133) using d6-acetone (134).79 This method 
was also used in an attempt to prepare the 13-hydroxy-farnesol 135 using 
acetoxyacetone 136 as the aldehyde, Scheme 4.6. While this method 
demonstrated high selectivity for the (Z)-isomer (86-90 %, Figure 4.1) the yield 
of the Wittig reaction was poor and further work by a project student, Simon 
Robinne, indicated that this problem was due to the nature of the ketone used, 
acetoxyacetone (136).133,134 Similarly poor yields (< 10 %) of product were 
isolated from reactions of 136 with methyl and phenyl phosphonium 
halides.135 With further development and a change in protecting group this 
method may provide access to the 13-hydroxy-FDP but this was not pursued 




Scheme 4.6 Generation of other FDP-analogues through alternative Wittig reactions using 
phosphonium bromide 125 
 
 
Figure 4.1 1H-NMR spectra (300 MHz, CDCl3) of 12-OAc-farnesyl THP ether (upper) and 13-
OAc-farnesol 135 (lower) with the CH2O peaks picked and integrated. 1H-NMR (300 MHz, MeOD, 





A series of epoxy-farnesols were prepared to investigate the ability of a range of 
sesquiterpene synthases to turn over FDP-analogues with the aim of opening 
the epoxide in the cyclisation cascade and trapping carbocation intermediates, 
generating novel terpenoids, Scheme 4.7. To this end, each of the double-
bonds in farnesol was individually epoxidised to prepare the 2,3-, 6,7- and 
10,11-epoxy-farnesols (137, 138 and 139, respectively). The (6,7-10,11)-
diepoxy-farnesol (140) was also prepared, Scheme 4.7. The epoxides were 
prepared as racemates due to the exploratory nature of this investigation. 
 
Scheme 4.7 Epoxy-farnesol target compounds (top) and conversion of 6,7-epoxy-FDP to a novel 
terpenoid by AS (below). 
While it is possible to regiospecifically epoxidise the terminal 10,11-double 
bond as described earlier (128, Scheme 4.5),131 through formation of the 
bromohydrin 127, direct regiospecific epoxidation of C6,C7 double bond is not 
known. Lichtor and Miller have been able to increase the levels of C6,C7 
epoxidation of farnesol through their development of a short peptide 
catalyst;136,137 Using the peptide catalyst they were able to produce up to a 4:1 
mixture of the desired 6,7-epoxy-farnesol (138) with the 10,11-epoxy-farnesol 
(139) in a 43 % yield, however this would require preparation of the necessary 
peptide and would still need further purification to procure the desired 6,7-
epoxy-farnesol (138). Because separation of the epoxy-farnesols was possible 
we instead chose to prepare a mixture of the epoxides using 3-
chloroperbenzoic acid (mCPBA) and to perform the separation on the epoxy-
farnesol mixture; Epoxidation of farnesyl acetate (141) with one equivalent of 
mCPBA for 1 hour yielded a mixture of unreacted starting material (141, 13 
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%), the monoepoxides (142 & 143, 75 %) in a ratio of 58:42, and a small 
amount of the diepoxide (144), Scheme 4.8. The identification of the two 
epoxides was made through comparison with the literature and with NMR-
spectra of 128 showing that the major epoxide was the 10,11-epoxyfarnesyl 
acetate (142).  
 
Figure 4.2 1H-NMR spectrum (300 MHz, CDCl3) of the mixed epoxyfarnesyl acetates 
These compounds were separated by column chromatography on silica gel and 
the mixture of the mono-epoxyfarnesyl acetates (142 & 143) was deprotected 
quantitatively with potassium carbonate.  The separation of the epoxyfarnesols 
(138, 139) was effected using an automated chromatography system over a 
gradient of 10 – 60 % diethyl ether in petroleum ether yielding 21% of the 6,7-
epoxyfarnesol (138), 32 % of the 10,11-epoxyfarnesol (139) and 20 % of the 
unresolved mixture. Resolution of the two epoxides by thin layer 
chromatography required multiple developments across the same gradient, 
with the 10,11-epoxyfarnesol (139) marginally less polar than the 6,7-epoxide 
(138). 
The diepoxyfarnesol (140) was prepared in the same fashion as the mono-
epoxides, oxidising farnesyl acetate (141) with 2-equivalents of mCPBA for 1 
hour at 0 °C and hydrolysis of the acetate group to yield 140 in 65 % yield over 
two steps, Scheme 4.8. 
The 2,3-epoxyfarnesol (137) could be prepared efficiently and in high yield, 
directly from farnesol (104) using the Sharpless epoxidation,138 Scheme 4.8, 
this method would also allow stereospecific synthesis of the two enantiomers 
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by using the Sharpless asymmetric epoxidation, with titanium 
tetraisopropoxide and (R,R)- or (S,S)-diethyl tartrate to impart the 
stereospecificity.139 
 
Scheme 4.8 Synthesis of epoxy-farnesols. Reagents and conditions: i. VO(acac)2, Toluene, t-
BuOOH, 0 °C, 95 %; ii. mCPBA 1 eq., DCM, 0 °C, 1 h, 75 %; iii. K2CO3, MeOH, 100 %; iv. mCPBA 2 
eq., DCM, 0 °C, 1 h; v. K2CO3, MeOH, 65 % over two steps.  
The diphosphate salts were prepared from the farnesol analogues as discussed 
at the start of this chapter (Section 4.1.1), to yield the epoxy-FDP analogues in 
30 – 68% yield. Analytical incubations were prepared with the range of 
sesquiterpene synthases available (Section 1.4). 
Table 4.1 Methods of diphosphorylation for the epoxyfarnesols 
Analogue Method Yield (%) 
2,3-epoxyfarnesol (137) Kramer 68 
6,7-epoxyfarnesol (138) Poulter 58 
10,11-epoxyfarnesol (139) Poulter 66 






Figure 4.3 Epoxy-FDP analogues prepared in this study 
2,3-Epoxy-FDP (145) 
The 2,3-epoxy-FDP (145) was found not to be a substrate for any of the 
enzymes tested; with no pentane extractable products detected in the GC-MS 
analysis of the product mixture even after extended incubation of 145 with the 
enzymes. Formation of the farnesyl cation is thought to be the first step in the 
catalytic mechanisms of GAS, GDS, DCS, ADS, EBFS and GdolS. Stabilisation 
of the 2,3-epoxyfarnesyl cation is not possible, and without stabilisation 
formation of the primary carbocation is highly disfavoured. The cyclisation of 
FDP by PR-AS has been proposed to proceed through a concerted ring-closure 
and loss of the diphosphate; the failure of PR-AS to turnover 145 might 
suggest that this step is not a symmetrical SN2 reaction. Instead the loss of the 
diphosphate group might begin to occur before the attack by the 10,11-double 
bond leading a developing positive charge on C1, Scheme 4.9.  
 
Scheme 4.9 Possible mechanisms for the failed turnover of 145 
In addition to the lack of stabilisation the introduction of the epoxide has 
changed the configuration at C2 and C3. In FDP, C1 to C4 and C15 are all co-
planar due to the sp2 nature of C2 and C3; In the 2,3-epoxy-FDP, C2 and C3 
are now sp3 in nature and tetrahedral with the added complexity of two 
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stereocentres. This change in conformation may alter substrate folding in the 
active site and does not provide productive alignment between the C10 and C1 
for cyclisation. 
Diepoxy-FDP (148) 
The diepoxy-FDP (148) was found to be a substrate for EBFS, but not for any 
of the other enzymes tested. Analysis of the gas chromatogram of the pentane 
extracted products from incubation of 148 with EBFS showed four main 
products, although the total ion count for the gas chromatogram (TIC) was 
relatively low (1 x 104), indicating that the turnover of this substrate by EBFS 
was poor compared to FDP (TIC 6 x 105). Analysis of the mass spectra of the 
products is consistent with formation of diepoxy-farnesenes (150 - 152), which 
shows that EBFS is able to accept the analogue into the active site and 
catalyse the conversion to the NDP-derivative (149) and deprotonation. The 
presence of other farnesenes might suggest that the presence of the epoxides 
has an effect on the contouring of the farnesyl chain in the active site leading 
to an alternative deprotonation to form diepoxy--farnesenes (151, 152) in 
addition to the diepoxy-(E)--farnesene (150), Scheme 4.10. Due to the racemic 
nature of the epoxidations the diepoxy-FDP (148) is a mixture of 4-
stereoisomers, two pairs of enantiomers, and while the enantiomers are in 
separable by the gas chromatography system used, it is possible to separate 
the diastereomers further complicating analysis of the products by GC-MS. 
 
Scheme 4.10 Turnover of 148 by EBFS, and the stereoisomers present in 148 
6,7-Epoxy-FDP (146) 
The 6,7-epoxy-FDP (146) was not a substrate for GAS, GDS, DCS or ADS. That 
analogue was a good substrate for GdolS, PR-AS and EBFS, as judged by total 
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ion count (1-2 x 105). Incubation of 146 with EBFS produced 5 products, and 
analysis of the mass spectra was consistent with formation of farnesenes. 
Incubation with PR-AS produced two major products and a number of minor 
products, while incubation with GdolS produced multiple trace products and 4 
products in greater proportions, Figure 4.4. While eluting with similar 
retention times, comparison of mass spectra showed none of the products 
produced by AS or GdolS were farnesenes. 
All of the products show a molecular ion with m/z = 220, corresponding to 
C15H23O products and the retention of the epoxide moiety. None of the 
products produced by GdolS display a m/z  = 238, which would be consistent 
with the incorporation of an additional hydroxyl group.  
While the mass spectra of compounds A and F, Figure 4.4, have a fragment of 
m/z = 161 indicative of loss of an isopropylidene group (-41 m/z, C3H5) the 
other peaks; B,C,D and E; have a major fragment at m/z = 159, -43 m/z. This 
loss of m/z = 43 is indicative of loss of an isopropyl fragment (C3H7), suggesting 
that while all of these peaks are 10-membered macrocycles peaks A and F may 
be germacrene A type products, with a double bond in the isopropyl tail. None 
of these products were isolated or definitively identified at this time due to the 
lack of a single overriding product. 
  































Figure 4.4 Overlaid normalised gas chromatograms of the pentane-extractable products arising 
from incubation of 6,7-epoxy-FDP with AS and GdolS. Mass spectra of the major compounds as 
labelled in the chromatogram (A-F). 
10,11-Epoxy-FDP (147) 
Incubation of the 10,11-epoxy-FDP (147) with EBFS produced a single product 
with a mass spectrum consistent with the 10,11-epoxyfarnesene. The TIC (9 x 
105) suggested that this substrate is turned over by EBFS with a similar 
efficiency as FDP (3 x 105).  
Incubation of 147 with GdolS yielded a single major product with a trace of the 







product had a molecular ion with m/z = 220, corresponding to a C15H23O 
product. 
 
Figure 4.5 Gas chromatogram (top) of the pentane extractable products arising from incubation 
of 10,11-epoxy-FDP with GdolS and EBFS, and mass-spectra (bottom) of the major compounds. 
The putative catalytic mechanism of GdolS was used to propose possible 
products. Assuming loss of the diphosphate occurs first, forming the 10,11-
epoxyfarnesyl cation 154, the epoxide can open at C10 or C11 to attack the 
cation and yield a macrocyclic ether. Opening of the epoxide at C10 would 
yield a tertiary carbocation 155, more stable than the secondary carbocation 
156, generated by opening in the 11-position. However, a rapid C11-C10 
methyl shift from 156 would yield the carbocation stabilised by conjugation 
with the oxygen, potentially leading to a long-lived intermediate (157). Further 
methyl- and hydride shifts followed by deprotonation of any of the intermediate 
carbocations could lead to a number of potential products (158 – 161), 
Scheme 4.11. 























Scheme 4.11 Possible products of the cyclisation of 10,11-epoxy-FDP 
 
 
Figure 4.6 Overlaid normalised gas chromatogram the pentane extractable products arising 
from incubation of 10,11-epoxy-FDP with all enzymes. Mass spectra of the two compounds 
arising from incubation of 10,11-epoxy-FDP with AS as labelled in the chromatogram (A and B). 
Incubations with AS, GAS and DCS also showed 147 to be a good substrate for 
these enzymes. With GAS and DCS the same compound was found to be the 




























sole product, while PR-AS also yielded this product in addition to a second 
product with a longer retention time. Analysis of the mass-spectrum of the 
second product with PR-AS showed a compound with m/z = 238, possibly 
suggesting a diol. 
Incubations with ADS found 10,11-epoxy-FDP 147 to be an extremely poor 
substrate, with a small amount of the macrocyclic ether 158 discernible from 
the baseline. This analogue was not turned-over by GDS. 
4.2.3 Second generation analogue 
The 11-membered macrocyclic ether 158 was proposed to be the most likely 
product from incubation of 10,11-epoxy-FDP (147) with all enzymes due to the 
short and simple, germacrene A-like, catalytic mechanism from which it arises; 
generating only a single tertiary carbocation intermediate. To test this proposal 
another analogue was designed which, if a substrate, would trap the farnesyl 
cation and generate the proposed macrocyclic ether directly without the 
generation of further intermediate carbocations. The designed analogue, 10-
hydroxy-11-ene-FDP (162), could be prepared by heating a 10,11-
epoxyfarnesol (139) derivative with aluminium isopropoxide in toluene in a 
sealed tube; this variation of the Meerwein-Ponndorf-Verley reduction gave the 
desired product in 65% yield.140,141 
 
Scheme 4.12 Meerwein-Pondorf-Verley reduction of the epoxide 139. 
Initially this analogue was prepared from the previously prepared 128 by 
protecting the secondary 10-hydroxy group as the acetate 166 prior to 
exposing the primary allylic alcohol 167 for the diphosphorylation step, the 
acetate group was then removed after ion exchange and HPLC to yield 162. 
The deprotection of the acetate was carried in D2O to allow the reaction to be 
monitored by NMR spectroscopy. A second look at the method highlighted the 
difference in reactivities of the two-alcohols and so an improved synthesis took 
advantage of this to shorten the synthesis and remove the necessity of 
orthogonal protecting group use. Use of farnesyl acetate (141) yielded 139 in 
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two steps; treatment of the bromohydrin 170 with K2CO3 in methanol resulted 
in both the closure of the epoxide and saponification of the acetate group. After 
Meerwein-Pondorf-Verley reduction of the epoxide the primary alcohol of 163 
was selectively activated with 1-equivalent of tosyl chloride and the 
diphosphate generated from the tosylate (164). It was also possible to 
selectively diphosphorylate the primary alcohol directly using the 
trichloroacetonitrile coupling.124 
 
Scheme 4.13 Syntheses of 162. Reagents and conditions: i. Al(OiPr)3, toluene, Δ, 65 %; ii. Ac2O, 
Py; iii. PPTS, EtOH, 65 % over two steps; iv. s-collidine, MsCl, LiCl, 0 °C; v. (Bu4N)3HP2O7, MeCN 
then DOWEX ion exchange, HPLC, 56 %; vi. NH4OD, D2O: vii. NBS, THF/H2O, 65 %; viii. K2CO3, 
MeOH, 92 %; ix. Et3N, pTsCl. 
With the exception of EBFS, incubation of 162 with the range of sesquiterpene synthases 
gave the same product as with 10,11-epoxy-FDP (147) to varying extents,  
Table 4.2, Figure 4.7. Interestingly, incubation with AS once again produces a 
second product with a longer retention time. This second product is different 




Table 4.2 Relative efficiencies of sesquiterpene synthases with 10-hydroxy-11-ene-FDP (162) 
and 10,11-epoxy-FDP (147) based on TIC. nas*, not a substrate. 
Enzyme 10-hydroxy-11-ene-FDP 10,11-epoxy-FDP 
EBFS nas* Good 






DCS Poor Average 
GAS Poor Average 
GDS Average nas* 
ADS Average V.poor 
 
 
Figure 4.7 Overlaid normalised gas chromatogram of the pentane extractable products arising 
from incubation of 162 with all enzymes 
In order to definitively identify the product generated by all enzymes upon 
incubation with 147 and 162, a preparative-scale incubation of GdolS with 
162 was used to generate sufficient compound for NMR spectroscopic analysis; 
generating 12.2 mg of compound which was identified as being the 11-
membered cyclic ether, 158, in 41.3 % yield. The resulting compound was 
analysed by GC-FID using a chiral column. While the epoxide 139, and 
therefore the resultant diol 163, was prepared in a non-stereoselective manner 
we wanted to analyse whether there was any preference in stereochemistry for 
the ring closure. Integration of the resolved peaks shows a ratio of 48:52, 
indicating that there is no stereochemical preference for this ring closure. This 
might be due to the relative proximity of the attacking hydroxyl group to the 
highly reactive farnesyl cation, 171, in either stereochemistry, the carbocation 
is rapidly quenched with very little involvement of the enzyme other than the 


























folding of the substrate in the active site. Incubation of the analogue with the 
acetate-protected secondary alcohol gave no pentane-extractable no products 
with any enzymes. 
 
 
Figure 4.8 Overlaid normalised gas chromatogram of the pentane extractable products arising 
from incubation of 10,11-epoxy-FDP (147) and 10-hydroxy-11-ene-FDP (162) with AS (top) and 
mass spectra of the labelled compounds (below). 
 
Scheme 4.14 Cyclisation of 162 by sequiterpene synthases 


























Figure 4.9 GC-FID chromatograms of macrocyclic ether 158 (Left) and diol 163 (Right)  
4.2.4 Third generation analogue 
Following on from the success of 162 to directly quench the farnesyl cation we 
decided to extend this principle and investigate the minimum substrate 
recognition motif necessary for sesquiterpene synthases for cyclisation of the 
substrate. The isopropyllidine tail was envisioned as being removed from 162 
to create a ‘truncated’ 12-carbon-hydroxy-diphosphate with a 10-carbon chain, 
172, to test if the enzymes are able to accept this as a substrate and still able 
to fold the full length of the analogue into a cyclisation ready configuration in 
the active site, Figure 4.10.  
 
Figure 4.10 Rational design of truncated FDP analogue by removal of isopropylidine tail (red) 
The synthesis of this analogue used an intermediate from the synthesis of the 
12,13-F2-FDP (73), the alcohol 130. The free terminal alcohol was protected as 
an acetate and the tetrahydropyran ether removed to expose the allylic alcohol, 
173, for diphosphorylation. The diphosphate was prepared using the Keller 
method to generate the tetra-n-butyl ammonium salt with the acetate intact, 
174. A sample of the terminal alcohol was prepared by the removal of the 
acetate by stirring in NH4OD/D2O for 12 hours as previously described, and 
the reaction progress monitored by NMR spectroscopy. The resulting tetra-n-




Scheme 4.15 Synthesis of 172. Reagents and conditions: i. Ac2O, Py; ii. PPTS, EtOH, 61% over 2 
steps; iii. Cl3CCN, (Bu4N)H2PO4, MeCN, 31%; iv. NH4OD, D2O, 96%. 
GC-MS analysis of the pentane-extractable products after overnight incubation 
of the 10-OH-DP (172) with all sesquiterpene synthases showed that it was a 
substrate for all cyclases and the same product was generated, eluting at 23.1 
minutes Figure 4.11. Compound 172 was not a substrate for EBFS. As judged 
by TIC, it was a poor substrate for ADS, GAS and GDS; while for the other 
enzymes it was a good substrate.  
 
Figure 4.11 Overlaid normalised chromatogram of the pentane extractable products arising 
from incubation of 10-OH-decadiene-DP 172 with enzymes 
The mass spectrum of the product formed by all cyclases with 172 (retention 
time 23.1 minutes) possessed a molecular ion with m/z = 180, and the 
fragmentation pattern also shows loss of progressive CH2 units, Figure 4.12 B. 
This product may be the farnesene-type product 175 formed by deprotonation, 
or the macrocyclic ether 176, formed by quenching of the allylic cation, 177. 
Alternatively, another possibility would be the ionisation of the diphosphate 
with rearrangement to the tertiary diphosphate, 178, followed by 1,6-ring 
closure and deprotonation to yield a bisabolyl-type product, 179. While the 
formation of the bisabolyl-type product may be less likely due to the lack of 


























any evidence of aristolochene synthase following a mechanism through NDP, 
at present none of these products can be ruled out with the available data. 
 
 
Figure 4.12 Mass spectra of the products arising from incubation of 172 with GDS (A) and AS 
(B), and incubation of 174 with AS(C) and EBFS (D). 
Incubation with GDS, ADS and GDS also produces a second compound which 
is the major product formed by GDS, eluting at 21.8 minutes Figure 4.11. The 
mass spectrum of this product possessed a molecular ion with m/z = 180, and 
the fragmentation pattern shows loss of progressive CH2 units, Figure 4.12 A. 
However, the fragment of m/z = 145 is the most abundant for this product, 
compared to the mass spectrum for product A, in which the fragment with m/z 






Scheme 4.16 Conversion of 172 with sesquiterpene synthases and possible products. 
The 10-OAc-DP, 174, was only a substrate for PR-AS and EBFS, while the 
products have almost identical retention times, Figure 4.13, analysis of the 
mass spectra clearly shows that different compounds are produced,Figure 4.12 
C and D. The compound produced by EBFS possesses a molecular ion with 
m/z = 222, congruent with loss of the diphosphate to form a linear or 
monocyclic product. The mass spectrum produced no consistent hits with the 
NIST spectral library, but the fragmentation pattern is congruent with a 
‘farnesene’-type product. That EBFS is able to turn over the longer 10-OAc-DP 
174, but not the 10-OH-DP 172 is of interest, possibly demonstrating that in 
EBFS the longer chain is needed to correctly orientate the molecule in the 
active site for turnover.  
  
Figure 4.13 Overlaid normalised gas chromatogram of the pentane extracted products from 
incubation of EBFS and PR-AS with 172 and 174 

























Aristolochene synthase was found to be the one of the most versatile of the 
enzymes tested, being the only cyclase able to turn over the 10-OAc-DP, 174, 
and the more specific of the two cyclases (PR-AS and GdolS) able to turn over 
the 6,7-epoxy-FDP, 146. The presence of the second products in the 
incubations with the 10,11-epoxy-FDP, 147, and the 10-hydroxy-11-ene-FDP, 
162 indicates that in addition to the simple quenching of the farnesyl cation to 
produce the cyclic ether 158, AS is able to perform another function 
generating the second products in almost equal proportion. 
To further probe the versatility of PR-AS and the flexibility of the active site, an 
FDP-analogue was designed whereby the 6,7-double bond was shifted to the 
7,14-position to create the 7-methylene-FDP, 180 Scheme 4.17. It was 
postulated that this alteration would have no effect on the initial cyclisation, to 
yield the intermediate germacrene A analogue, 181; if the second ring-closure 
was then able to proceed and protonation to occur at the 7-methylene to yield 
the eudesmane cation 68, the carbocation cascade could continue; producing 
aristolochene 66. 
 
Scheme 4.17 Structure of 7-methylene-FDP (180, top) and proposed cyclisation of 180 to 66 by 
PR-AS (bottom) 
The 7-methylene-farnesol (182) was prepared using a combination of 
established procedures.142–145 -Geraniol (183, 7-methyl-3-methyleneoct-6-en-
1-ol) was prepared via the dilithiation of 3-methylbut-3-en-1-ol (184) and 
trapping with prenyl bromide (185). While the reported yield of 84% was never 
achieved, extending the period over which 185 was added, from 15 minutes to 




Scheme 4.18 Retrosynthesis of 7-methylene-farnesol 182 (top) and synthesis of γ-geraniol 183 
(bottom) Reagents and conditions: i. TMEDA, n-BuLi, THF, 0 °C, then 184, 0 °C to RT, 6 h followed 
by 185 -78 °C to RT, 16 h. 
Due to the relative simplicity of the reaction for the extension of the chain it 
was proposed that the -geranyl chain could be extended to 182 in a similar 
manner by dilithiation of prenol (186) and the -geranyl bromide (187). This 
reaction was first tested using 186 and 185, yielding only the diisoprenyl ether 
(188, in good yield, proposed to arise from formation of the singly lithiatiated 
alkoxide species, Scheme 4.19. In order to counter this, the alcohol was 
protected as the THP-ether (189) and the reaction repeated, this time yielding 
only unreacted starting material (189).  
After numerous failed attempts it was decided to use the reliable and established, 
although longer, method of chain extension using the acetoacetate dianion 190,  
 
Scheme 4.20.144,145 The acetoacetate dianion 190, was formed by successive 
deprotonations of ethyl acetoacetate (191) with sodium hydride and n-butyl 
lithium; alkylation with 187 then forms -keto ester 192. Deprotonation of 
192 with sodium hydride formed enolate 193, which was trapped as the enol 
phosphate (194) with diethylchlorophosphate and then used without 
purification for the methylation with lithium dimethylcuprate to yield ester 
195. Reduction with DIBAL-H yields the allylic alcohol (182).143 The farnesol 




Scheme 4.19 Proposed elongation of -geraniol 183 (above) Failed elongation tests (below). 
Reagents and conditions: i. Et3N, MsCl, -45 °C then LiBr, RT, 72 %; ii. TMEDA, n-BuLi, THF, 0 °C, 
then 186, 0 °C to RT, 6 h followed by 185 -78 °C to RT, 16 h. 
While initially designed to probe the versatility and active site flexibility of AS, 
this analogue was also incubated with the other available sesquiterpene 
synthases and the pentane-extractable products analysed by GC-MS. 
 
 
Scheme 4.20 Elongation of -geranyl bromide to 7-methylene-farnesol. Reagents and conditions: 
i.NaH, THF, 0 °C, then n-BuLi, followed by -geranyl bromide, 65%; ii. NaH, THF, 0 °C, then 
diethylchlorophosphate; iv. Me2Cu, -78 °C, then addition of enolphosphate, -78 °C for 2 h, -45 °C 
for 2 h, followed by addition of MeI, -45 °C, 0.5 h, 30 % over two steps; v. DIBAL-H, toluene, -78 °C, 
85 %. 
Incubation of the 7-methylene-FDP (180) with AS shows that, as proposed, AS 
is able to turn over the analogue to generate aristolochene (66) as the major 
product (A, 26.01 minutes, 37 %), along with a number of other products; one 





Figure 4.14 Normalised chromatogram of the pentane extractable products arising from 
incubation of FDP and 7-methylene-FDP with AS 
Compound 180 is also a substrate for all the other sesquiterpene synthases 
used in this study. With the exception of EBFS, all of the enzymes generate 
product B (retention time, 26.88 minutes) in varying proportions along with 
other products. Incubation of 180 with EBFS generated 3 products, and 
analysis of the mass spectra is consistent with production of the farnesenes, 
Figure 4.15. Incubation with GAS generated almost exclusively product B (>90 
%); the mass-spectrum possesses a molecular ion with m/z = 204, while the 
fragmentation pattern is near identical to germacrene A suggesting that this 
































Figure 4.15 GC-MS analysis of the pentane extractable products arising from incubation of 180 
with EBFS. Top, gas chromatogram; middle, mass spectra of compounds labelled corresponding 
to product; Bottom, mass spectra of (Z)--farnesene and (E)--farnesene. 



























Figure 4.16 Normalised gas chromatogram of the pentane extractable products arising from 
incubation of 180 with GAS (top) and mass spectra of the product at 26.88 minutes (bottom 
right) and germacrene A 34 (bottom left) 
This would be consistent with the observation that this compound is produced 
as the second major product by AS; naturally AS produces some germacrene A 
(34 7.5 %) from incubation with FDP (19), so it could be concluded that 
incubation with 180 would also produce some 181. Due to the less productive 
positioning of the double bond in 181, protonation of the double bond to drive 
the second ring closure and formation of the eudesmane cation 68 is slower 
leading to greater proportions of 181 released from the active site, Scheme 
4.21. 






















Scheme 4.21 Cyclisation of 7-methylene-FDP by PR-AS 
In addition to compound B (181), the major product from incubation with GDS 
appears to be a cyclic product from analysis of the mass-spectrum, with a 
molecular ion with m/z = 204. The fragment at m/z = 161 is 100% intensity, 
indicating loss of the isopropyl group, this might suggest that GDS is able to 
turn over this product to a germacrene-D analogue in addition to 181 
depending on the deprotonation step, Scheme 4.22. 
 






Figure 4.17 Normalised gas chromatogram of the pentane extractable products arising from  
incubation of 7-methylene-FDP with GDS (top) and mass spectrum of the major product (bottom 
left) and of germacrene D (bottom right) 
GdolS is able to turn over 180 to generate a number of products. In addition to 
181 already discussed (B, retention time 26.88 minutes, 24 %), the major 
product has a retention time of 30.09 minutes (43 %) and the mass spectrum 
shows a molecular ion with m/z = 222. The two minor products with retention 
times of 31-32 minutes (9 %) also show molecular ions with m/z = 222 and the 
mass spectra of these three peaks (30.09, 31.01 and 31.61 minutes) are all 
very similar, and similar to that obtained for germacradien-4-ol (79). This 
suggests that GdolS is able to generate the germacradien-4-ol analogue from 
180. Incubation with this enzyme also generates 4 other minor products (24 
%) each possessing molecular ions with m/z = 204.  























Figure 4.18 Normalised gas chromatogram of pentane extractable products arising from 
incubation of 180 with GdolS (Top) and mass spectra of the product at 30.1 minutes (bottom 
left) and of germacradien-4-ol, 79 (bottom right). 
Incubation with DCS produces 181 (retention time 26.88 minutes, 70 %) and 
the same terpene alcohol as with GdolS (retention time 30.1 minutes, 21 %) in 
addition to minor traces of other products (4 %), Figure 4.19. 






















Figure 4.19 Normalised overlaid gas chromatogram of pentane extractable products arising 
from incubation of 180 with DCS, GAS and GdolS 
While incubation with ADS does produce 181, this is a minor product in this 
incubation (~5 %) with the major product having a retention time of 26.07 
minutes (51 %) and 3 other minor products (39 %). It is not possible for ADS to 
generate amorpha-4,11-diene from 181 due to the necessity of the 6,7-double 
bond in the initial 1,6-ring closure. However, if the isomerisation to 7-
methylene-NDP, 196, were to occur followed by 1,10-ring closure, the newly 
formed double bond in the 10-membered macrocycle would have (Z)-
stereochemistry, yielding the 7-methylene derivative of helminthogermacrene 
A, 197, Scheme 4.23. 
 
 
Figure 4.20 Normalised gas chromatogram of the pentane extractable products arising from 
incubation of 180 with ADS (left) and mass spectrum of the major product (right)  











































Scheme 4.23 Cyclisation of 180 via 7-methylene-NDP,(196) 
4.3 Summary 
A number of functionalised-FDP analogues have been synthesised and 
incubated with a range of sesquiterpene synthases to investigate the scope of 
these enzymes; how they are able to turnover unnatural substrates and if they 
are able to generate novel sesquiterpenoids. 
The 10,11-epoxy-FDP 147, was found to be turned over by a number of the 
enzymes and the products identified as a 11-membered macrocyclic ether 158, 
proposed to result from the direct quenching of the farnesyl cation followed by 
a deprotonation. A second analogue was designed and synthesised to test this 
theory, the 10-hydroxy-11-ene-FDP 162, which could also directly trap the 
farnesyl cation, but without the need for further deprotonation, pleasingly this 
analogue generated the same macrocyclic ether 158. Due to the enforced 
folding of the substrate in the active site both enantiomers of the hydroxyl 
group are in close proximity to the generated farnesyl cation leading to no 
stereochemical preference in the generation of the ether. The generation of 158 
from both 147 and 162 demonstrate the first method in the literature of 
trapping the proposed farnesyl cation to date. Extending this principle, an 
analogue without the isopropyl tail 172, was generated and demonstrated that 
this analogue was still turned over by all enzymes, producing what was 
proposed to be the cyclic ether 176, due to the high reactivity of the allylic 




Scheme 4.24 Key products from incubations of sesquiterpene synthases with FDP-analogues 
While modifications to the nature of the farnesyl chain were reasonably well 
tolerated around the distal double bond, with cyclisation’s efficiently producing 
specific products, epoxidation to the C6,C7 double bond was less successful 
with only two of the tested cyclases able to use 146 as a substrate (PR-AS and 
GdolS), neither of which produced a single overriding product. Epoxidation of 
the 2,3-double bond produced an FDP analogue, 145, that was not a substrate 
for any of the enzymes tested, and the analogue with epoxides in place of both 
the C6,C7- and C10,C11-double bonds, 148, was only turned over by EBFS to 
generate farnesene analogues. 
The 7-methylene-FDP, 180, transposed the trans 6,7-double bond out of the 
main chain, to investigate the versatility of PR-AS and the ability of 
sequiterpene synthases to accept more minor changes to the centre of the 
farnesyl chain. This analogue was accepted by all the tested enzymes to 
varying extents and in the case of PR-AS, was turned over to the natural 
product 66, albeit with lower specificity than the natural substrate. All the 
other enzymes tested are proposed to be able to turnover this substrate into 
monocyclic products. 
These results indicate a level of flexibility in the purely hydrocarbon half of 
FDP (C7 – C10), which enables many sesquiterpene synthases to accept 
analogues of FDP with modifications in this region. While the 6,7-epoxy-FDP 
146, was turned over by PR-AS and GdolS, the effect of changing configuration 
and imposing stereochemistry at two centres proved too much for the other 
enzymes, and even in the cases of PR-AS and GdolS turnover was lower, and 
these normally high-fidelity enzymes produced numerous products. The more 
minor change in the 7-methylene-FDP 180, affecting only the single centre on 
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the farnesyl chain, was well accepted by all enzymes and turned over to 
primarily cyclic products. 
 
Scheme 4.25 Summary of products generated by incubation of 180 with sesquiterpene 
synthases 
The generation of 147 and 162 were turned over in varying degrees, but 
produced the same macrocyclic ether in all cases, demonstrating the first 
reported trapping of the farnesyl cation. With the lack of stereochemical bias in 
the cyclisation of the 10-hydroxy-11-ene-FDP demonstrating a degree of 
freedom in the isopropyl tail and pointing to this region of FDP as an ideal 




















This thesis investigated means of generating simple terpenoids using terpene 
synthases. Two distinct and complementary approaches were employed. These 
involved a mechanistic investigation of germacradien-4-ol synthase, a 
sesquiterpene synthase which incorporates water in the cyclisation cascade to 
generate a single terpene alcohol, and the synthesis of a range of FDP-
analogues designed to offer means of trapping carbocation intermediates in the 
catalysis by a range of sesquiterpene synthases. 
5.1 Mechanistic investigation of germacradien-4-ol synthase 
Fluorinated FDP analogues 2-F-FDP and 15-CF3-FDP proved to be potent 
inhibitors of GdolS, suggesting a stepwise mechanism for the cyclisation to the 
germacryl cation through the farnesyl cation. The intermediacy of the farnesyl 
cation was further evidenced by the turnover of the 12,13-difluoro-FDP to the 
12,13-difluorofarnesene. While GdolS also turned-over the 10-F-FDP to the 10-
F-farnesene, due to destabilisation of the germacryl cation, it was also able to 
direct a 1,11-cyclisation to form the fluorinated--humulene derivative. 
Incubation of GdolS with 1-2H2-FDP demonstrated that the enzyme catalyses a 
1,3-hydride shift subsequent to the ring closure, and the stereochemistry of 
this shift was investigated using 1-(R-2H1)-FDP. Suprisingly, we saw no 
stereochemical preference in this shift counterintuitive to the highly 
stereodefined methyl- and hydride-shift reported in other sesquiterpene 
synthases. This has lead us to propose a longlived, stabilised allylic-cation in 
rapid equilibrium with the germacryl cation, causing a loss of sterochemical 
information. This allylic cation is then proposed to be quenched from the bulk 
solvent due to the opening of the active site in the product-release step. 
Incubations of GdolS with FDP in buffers prepared with 2H2O and H218O are 
congruent with this proposal; indicating that both the proton and oxygen in 
the 4-hydroxyl group originate from the bulk solvent. This simple mechanism 
of carbocation quenching, incorporating the hydroxyl group is unusual in 
catalysis by terpene synthases due to the highly reactive nature of the 
carbocation intermediates. Terpene synthases typically function by desolvating 
the active site upon formation of the Michaelis complex to prevent water 
ingress and carbocation quenching. 
Incubations with NDP, both racemic and the 3-(R)-stereoisomer, suggested 
that the cyclisation may go via the formation of the tertiary diphosphate NDP, 
a mechanism further supported by the ability of GdolS to turn over the shorter 
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10-carbon isoprenoid precursor, GDP, to cyclic products. This may suggest an 
insight into the evolutionary past of this enzyme; with the isomerisation to 
NDP a palimpsest for a previous mechanism that generated a product bearing 
a (Z)-double bond. Serendipitous mutations have lead to an enzyme which 
allows water to enter the active site and quench the intermediate prior to a 
second cyclisation. 
Incubation with (2Z, 6E)-FDP however, which would be set up for direct 
cyclisation without the need for conversion to NDP if this was indeed the 
necessary active site conformation, produced only minor amounts of 
germacradien-4-ol amongst numerous other, unidentified, products. The 
proposed active-site conformation of 3-(R)-NDP potentially shows a favourable 
alignment of *-anti-bonding orbitals. This could allow concerted ring-closure 
and allylic elimination of the diphosphate in a single step.  The initial 
ionisation of FDP is widely accepted as being the chemical rate determining 
step, and so direct generation of the germacryl cation in a concerted manner 
could be postulated to accelerate the mechanism. 
5.2 Structure–function investigation into germacradien-4-ol 
synthase (GdolS) by site-directed mutagenesis 
Point mutations to the metal-binding domains proved detrimental to the 
catalytic efficiency of GdolS, highlighting the importance of these regions to 
catalysis with particular emphasis on the first aspartate in the DDxxD motif 
and to the whole of the NSE-motif. Interestingly, the arginine of the NSE-motif 
(arginine-218) was also implicated in the quenching of the intermediate 
carbocation by water to yield the product. Mutation of the arginine to 
glutamine caused the production of 45 % germacrene A, however, replacement 
of this residue with a lipophilic leucine reverted to the product distribution of 
wildtype. The NSE-arginine has been identified in X-ray crystal structures of 
AT-AS as part of a coordination sphere of a water molecule bound in the active 
site. A further arginine residue (ATAS arginine-299) and a serine (ATAS serine-
303) were also identified in coordination to this water molecule and the 
corresponding residues in GdolS (tyrosine-303 and glutamate-307) were also 
targeted by site-directed mutagenesis. Mutations to these residues had only a 
minor effect on product distribution but were vital to the catalytic efficiency of 
the enzyme. The aromaticity of the tyrosine residue was vital, possibly in the 
stabilisation of carbocation intermediates, while the carbonyl functionality of 
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the glutamate side-chain is necessary. Mutation of the glutamate to a 
glutamine shows a minor reduction in catalytic activity while the generation of 
the methionine mutant was severely hampered in terms of activity. 
To further investigate interactions between arginine-218 and proximal residues 
a helix-switch approach was adopted; changing the terminal loop-helix region 
of GdolS with the same, slightly longer region, from DCS; a -cadinene 
synthase available in our lab. Unfortunately this generated hybrid showed only 
sparing solubility due to incomplete folding and was completely inactive. 
Following a report on the effect of the H-1 loop on product distribution in 
fungal sesquiterpene synthases, this region was analysed and mutated in 
GdolS. Two mutants were generated to disrupt ionic interactions between the 
H-1loop and the active site, resulting in one wildtype-like enzyme (R229E) 
and an inactive mutant (D231L); indicating the importance of the aspartate 
residue in closing the active site to form the Michaelis complex. 
5.3 Synthesis and evaluation of farnesyl diphosphate 
analogues 
A range of epoxy-FDP analogues were synthesised and incubated with a 
number of sesquiterpene synthases. Epoxidation of the 2,3-double bond lead 
to an FDP analogue which was not a substrate for any of the sesquiterpene 
synthases tested. The 6,7-10,11-epoxy-FDP was also not a substrate for any of 
the enzymes, while the 6,7-epoxy-FDP was poorly turned over by AS and 
GdolS. The 10,11-epoxy-FDP was found to be turned over by a number of the 
enzymes and the product identified as a macrocyclic ether, resulting from the 
direct quenching of the farnesyl cation followed by a deprotonation. A second 
analogue was designed and synthesised to test this theory, the 10-hydroxy-11-
ene-FDP, which also directly trapped the farnesyl cation, directly generating 
the same macrocyclic ether without an intermediate carbocation. The 10-
hydroxy-11-ene-FDP was prepared racemically and the generation of the 
macrocyclic ether showed no stereochemical bias, attributed to the close 
proximity of the hydroxyl enforced in the substrate folding in the active site.  
The ability of the 10,11-epoxy- and 10-hydroxy-11-ene-FDP’s to quench a 
carbocation and generate the macrocyclic ether demonstrate the first reported 
trapping of the proposed farnesyl cation to date. 
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To further investigate the trapping of the farnesyl cation an analogue lacking 
the isopropyl tail was generated, and demonstrated that this analogue was still 
turned over by all cyclases, producing what was proposed to be the cyclic ether 
176. This would suggest that the isopropyllidine tail of the farnesyl chain is 
not necessary for enforcing the correct folding of the substrate in the active 
site; with the reactivity of the allylic cation and the confinement of the active 
site overriding the lack of this directing influence.  
The 7-methylene-FDP was prepared from elongation of -geraniol with the 
transposition of the 6,7-double bond. This analogue was primarily synthesised 
to test the versatility of AS, but was also used to investigate if the other 
sesquiterpene synthases were able to more minor changes in configuration at 
the centre of the farnesyl chain. Pleasingly, AS was able to turnover this 
analogue to aristolochene through protonation of the 7-methylene double bond 
to drive the second cyclisation to the eudesmane cation. The other enzymes 
tested were also able to turn over this analogue to monocyclic products. 
These results indicate a level of flexibility in the purely hydrocarbon half of 
FDP (C7 – C10), which enables many sesquiterpene synthases to accept 
analogues of FDP with modifications in this region. While the 6,7-epoxy-FDP 
was turned over by AS and GdolS, the effect of changing configuration and 
imposing stereochemistry at two centres proved too much for the other 
enzymes, and even in the cases of AS and GdolS turnover was lower, and these 
normally high-fidelity enzymes produced numerous products. The more minor 
change in the 7-methylene-FDP, affecting only the single centre on the farnesyl 
chain, was well accepted by all enzymes and turned over to primarily cyclic 
products. 
5.4 Future approaches 
This investigation has characterised germacradien-4-ol synthases and 
determined that cyclisation of FDP by this enzyme occurs by a stepwise loss of 
diphosphate followed by 1,10-ring closure to the germacryl cation. We have 
postulated that the subsequent 1,3-hydride shift generates a long-lived 
stabilised allylic cation, which is then quenched by water from the bulk solvent 
upon the opening of the active site. Despite a targeted approach using the apo-
crystal structure and homology models to identify residues for site-directed 
mutagenesis we were unable to conclusively identify any residues solely 
responsible for the incorporation of water into the product. It would be of great 
151 
 
interest to obtain a crystal structure of GdolS with an inhibitor bound in the 
active site, since we have established 15-CF3-FDP as a potent competitive 
inhibitor, this is an ideal choice. This would allow detailed analysis of the 
Michaelis complex and could reveal details of the folded conformation of FDP 
in the active site giving further detail to the mechanism both of cyclisation and 
of water incorporation. 
The synthesis of a range of FDP-analogues has demonstrated the first trapping 
of the farnesyl cation, as well as highlighting the importance of the C10-
isopropyl tail of FDP in enforcing cyclisation. Further analogues of interest are 
highlighted in Figure 5.1, including those designed to trap the cisoid allylic 
cation arising after isomerisation to NDP and further minor modifications to 
probe the scope of sesquiterpene synthases in generating novel terpenoids. 
 
Figure 5.1 Prospective future analogues 
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6.1 Biological Methods 
6.1.1 Materials 
Oligonucleotide primers for site-directed mutagenesis were purchased from 
Eurofins or Sigma-Aldrich, the pET16b-SC1 plasmid construct was a generous 
gift from Prof. Yasuo Ohnishi, University of Tokyo; Restriction enzymes were 
purchased from NEB UK or Thermofisher Scientific, Pfu DNA polymerase and 
Unstained protein marker were purchased from Thermofisher scientific, dNTP’s 
were purchased from Promega, [1-3H]-FDP was purchased from American 
Radiolabelled Chemicals, ‘Ecoscint™ O’ scintillation fluid was purchased from 
National Diagnostics.  All other chemicals were purchased from Sigma-Aldrich, 
Fisher Scientific or Melford. All the mutated and ligated constructs were 
confirmed by DNA sequence analysis using the internal Walesbiogrid facilities 
(School of Bioscience, Cardiff University, UK). 
6.1.2 Bacterial strains and Preparation 
A number of strains of E. coli were used in the course of this investigation; 
XL1-Blue cloning strain was used for the production of plasmid DNA and for 
the transformation of SDM reactions; Bl21(DE3) and BL21-Star™-(DE3) 
expression strains were used for test expressions of GdolS-WT and ultimately 
BL21-(DE3) was used for the expression of all GdolS proteins and mutants. 
Stratagene competent cells (purchased from Agilent as part of the Strataclone 
Blunt PCR cloning kit) were used for the production of the DCS-fragment 
cloning vector in the preparation of the GdolS-DCS hybrid. 
6.1.3 Competent cells 
Calcium chloride Buffer I 
Calcium chloride (100mM) was dissolved in deionised water. The final volume 
was then made up and sterilised in an autoclave (121 °C, 20 minutes). 
Calcium chloride Buffer II 
Calcium chloride (100 mM) was dissolved in deionised water and glycerol (15% 
v/v) was added. The final volume made up with deionised water and in an 
autoclave (121 °C, 20 minutes). 
Competent Cell Preparation 
A 50 µL aliquot of the desired cell strain was incubated in LB-media overnight 
at 37 ºC, in the case of XL1-Blue cells, tetracycline was added to the media (15 
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mg L-1). 1 mL of the overnight culture was used to inoculate 100 mL of LB-
media (15 mg L-1 of tetracycline in the case of XL1-Blue) and grown at 37 ºC, to 
an optical density of 0.6 at 600 nm (OD600). The cells were put on ice for 15 
minutes, then harvested by centrifugation (3400 g, 5 minutes), and the 
supernatant discarded. The pellet was gently re-suspended in calcium chloride 
buffer I (40 mL) and incubated on ice for 15 minutes. Centrifugation was 
repeated and the pellet gently re-suspended in calcium chloride buffer II and 
incubated on ice for 15 minutes. The cells were divided into 50 µL aliquots, 
frozen immediately in liquid N2 and stored at -80 ºC. 
6.1.4 Supercompetent cells 
Rubidium chloride buffer I 
Potassium acetate (30 mM), rubidium chloride (100 mM) and calcium chloride 
(10 mM) were dissolved in deionised water, glycerol (15%) was added and the 
pH of the solution adjusted to 5.8 before addition of manganese chloride (50 
mM). The final volume was made up with deionised water and sterilised by 
filtering through a sterile 0.2 µM syringe filter under aseptic conditions, and 
stored at 4 °C. 
Rubidium chloride buffer II  
3-(N-morpholino)propanesulfonic acid (MOPS, 10 mM), calcium chloride (75 
mM) and rubidium chloride (10 mM) were dissolved in deionised water, glycerol 
(15) was added and the pH adjusted to 6.5. The final volume made up with 
deionised water and sterilised by filtering through a sterile 0.2 µM syringe filter 
under aseptic conditions, and stored at 4 °C. 
Super-competent cell preparation 
Supercompetent cells were prepared in the same manner as competent cells 
(6.1.3) but with rubidium chloride buffers I and II (0 and0) in place of calcium 
chloride buffers I and II (0 and 0) respectively. 
6.1.5 Growth media and antibiotic solutions 
Luria-Bertani (LB) medium 
Tryptone (10 g L-1), yeast extract (5 g L-1) and sodium chloride (10 g L-1) were 
dissolved in deionised water, the resulting solution was sterilised in an 
autoclave (121 °C, 20 minutes) and cooled to room temperature before use. 




LB Agar plates 
Tryptone (10 g L-1), yeast extract (5 g L-1), sodium chloride (10 g L-1) and agar 
(15 g L-1) were dissolved in deionised water, the resulting solution was 
sterilised in an autoclave (121 °C, 20 minutes). The agar was allowed to cool to 
approximately 40 °C before the required antibiotic was added and the LB agar 
poured into plates under aseptic conditions. Plates were allowed to cool and 
set before storage at 4 °C. 
Ampicillin 
Ampicillin was dissolved in deionised water to give a concentration of 100 mg 
mL-1. The solution was filtered through a sterile 0.2 µM syringe filter under 
aseptic conditions and stored at 4 °C. 
Kanamycin 
Kanamycin was dissolved in deionised water to give a concentration of 50 mg 
mL-1. The solution was filtered through a sterile 0.2 µM syringe filter under 
aseptic conditions and stored at 4 °C. 
Tetracycline 
Tetracycline was dissolved in deionised water to give a concentration of 15 mg 
mL-1. The solution was filtered through a sterile 0.2 µM syringe filter under 
aseptic conditions and stored at 4 °C. 
6.1.6 Cloning 
Site-directed mutagenesis 
Primers for SDM 
Oligonucleotide primers were designed using PrimerX 
(www.bioinformatics.org/primerx) with the consideration given to the following 
criteria: 
1. Both forward and reverse primer must contain the desired mutation and 
anneal to the same sequence on each strand of the template plasmid. 
2. The primers should be between 25 and 45 bases long with the mutation 
in the centre of the primer. 
3. The melting temperature, Tm, should be equal to or greater than 78 ºC 
4. The primers should begin and terminate with a G or a C and have 40 
and 60 % content of GC bases. Due to the GC rich nature of 
Streptomycetes this was not always possible and an upper limit of 75 - 
80 % was applied where necessary. 
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The primers are as follows in Table 6.1. 
Table 6.1 Oligonucleotide primers for site-directed mutagenesis (5’ to 3’) with the 
changed codon underlined and the mutated base(s) in italics 
Name 5′-Sequence-3’ 
GdolS-Y303F Fwd CTGGCTCGCGGGTTTTCTCCACTGGGAGTC 
GdolS-Y303F Rev GACTCCCAGTGGAGAAAACCCGCGAGCCAG 
GdolS-Y303I Fwd CTCTGGCTCGCGGGTATTCTCCACTGGGAGTC 
GdolS-Y303I Rev GACTCCCAGTGGAGAATACCCGCGAGCCAGAG 
GdolS-W306A Fwd GTTACCTCCACGCGGAGTCCCACAC 
GdolS-W306A Rev GTGTGGGACTCCGCGTGGAGGTAAC 
GdolS-E307Q Fwd GTTACCTCCACTGGCAGTCCCACACCCG 
GdolS-E307Q Rev CGGGTGTGGGACTGCCAGTGGAGGTAAC 
GdolS-E307M Fwd GTTACCTCCACTGGATGTCCCACACCCGC 
GdolS-E307M Rev GCGGGTGTGGGACATCCAGTGGAGGTAAC 
GdolS-Y303T Fwd CTCTGGCTCGCGGGTACCCTCCACTGGGAGTC 
GdolS-Y303T Rev GACTCCCAGTGGAGGGTACCCGCGAGCCAGAG 
GdolS-R172K Fwd CTATCTGACGCTCAAACGCGGTACCGCC 
GdolS-R172K Rev GGCGGTACCGCGTTTGAGCGTCAGATAG 
GdolS.SmaIns F GACCAACTCCCGGGCGCCTGCCGCTC 
GdolS.SmaIns R GAGCGGCAGGCGCCCGGGAGTTGGTC 
GdolS.R172Q Fwd CTATCTGACGCTCCAGCGCGGTACCGCCG 
GdolS.R172Q Rev CGGCGGTACCGCGCTGGAGCGTCAGATAG 
GdolS-D80E Fwd CTACTTCCTCTTCGAAGACCAGTTCGACAG 
GdolS-D80E Rev CTGTCGAACTGGTCTTCGAAGAGGAAGTAG 
GdolS-D81E Fwd CCTCTTCGACGAACAGTTCGACAGCC 
GdolS-D81E Rev GGCTGTCGAACTGTTCGTCGAAGAGG 
GdolS-D84E Fwd CGACCAGTTCGAAAGCCCGCTCGGG 
GdolS-D84E Rev CCCGAGCGGGCTTTCGAACTGGTCG 
GdolS-N218Q Fwd CATCCCGTCGTTCACCCAGGACGTGCGCTCCTTC 
GdolS-N218Q Rev GAAGGAGCGCACGTCCTGGGTGAACGACGGGATG 
GdolS-S222A Fwd CCAATGACGTGCGCGCGTTCGCACAGGAGTC 
GdolS-S222A Rev GACTCCTGTGCGAACGCGCGCACGTCATTGG 
GdolS-E226D Fwd CTTCGCACAGGATTCCGAGCGCGGC 
GdolS-E226D Rev GCCGCGCTCGGAATCCTGTGCGAAG 
GdolS-N218L Fwd CATCCCGTCGTTCACCCTGGACGTGCGCTCCTTC 
GdolS-N218L Rev GAAGGAGCGCACGTCCAGGGTGAACGACGGGATG 
GdolS-D80N Fwd GGTTCTACTTCCTCTTCAATGACCAGTTCGACAGCC 
GdolS-D80N Rev GGCTGTCGAACTGGTCATTGAAGAGGAAGTAGAACC 
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GdolS-D81N Fwd CTACTTCCTCTTCGACAATCAGTTCGACAGCCCGC 
GdolS-D81N Rev GCGGGCTGTCGAACTGATTGTCGAAGAGGAAGTAG 
GdolS-D84N Fwd GACGACCAGTTCAATAGCCCGCTCGG 
GdolS-D84N Rev CCGAGCGGGCTATTGAACTGGTCGTC 
GdolS-R134E Fwd CTTGGCATGACGGACGAATGGCGCGCACGGGC 
GdolS-R134E Rev GCCCGTGCGCGCCATTCGTCCGTCATGCCAAG 
GdolS-N218E Fwd CATCCCGTCGTTCACCGAAGACGTGCGCTCCTTC 
GdolS-N218E Rev GAAGGAGCGCACGTCTTCGGTGAACGACGGGATG 
GdolS-N218T Fwd CGTCGTTCACCACCGACGTGCGCTCC 
GdolS-N218T Rev GGAGCGCACGTCGGTGGTGAACGACG 
GdolS-R134A Fwd GCATGACGGACGCGTGGCGCGCACGG 
GdolS-R134A Rev CCGTGCGCGCCACGCGTCCGTCATGC 
GdolS-D231L Fwd GTCCGAGCGCGGCCTGGTGGCCAACCTG 
GdolS-D231L Rev CAGGTTGGCCACCAGGCCGCGCTCGGAC 
GdolS-R229E Fwd CACAGGAGTCCGAGGAAGGCGACGTGGCCAAC 
GdolS-R229E Rev GTTGGCCACGTCGCCTTCCTCGGACTCCTGTG 
 
Site-directed mutagenesis protocol 
Site-directed mutagenesis was carried out using the polymerase chain reaction 
(PCR), The reaction mixture was made up according to Table 6.2 and PCR 
carried out in a thermocycler programmed according to Table 6.3. 
After the SDM program was completed the reaction mixture was treated with 1 
L of DpnI endonuclease and incubated at 37 ºC for 1 hour to cleave the 
parental template plasmid. DpnI is specific to N6-methyladenine within the 
recognition sequence (G mA^TC), found in DNA isolated from almost all E.coli. 
Supercompetent E.coli XL1-blue were then transformed with 5 μL of the 
digested SDM mixture, Section 6.1.9. 
Table 6.2 SDM reaction mixture 
Component (Stock concentration) Volume (L) 
Forward primer (10 M) 2 
Reverse primer (10 M) 2 
dNTP’s (10 mM) 1 
Template plasmid 0.5 
Pfu DNA polymerase 0.5 
Pfu buffer + MgSO4 5 




Table 6.3 SDM program conditions 
Step Standard Program Long Program 
Temperature 
(ºC) 





















Final Elongation 72 10 75 10 
 *Denaturation, annealing, 
elongation steps cycled 15 
times 
*Denaturation, annealing, 
elongation steps cycled 15 
times 
 
Stocks of separate dNTP’s were purchased at 100 mM, these were diluted to a 
working concentration of 10 mM of each dNTP (40 mM total dNTP 
concentration), aliquoted and stored at -20ºC. 
Polymerase chain reaction (PCR) 
Polymerase chain reaction was used to amplify the desired section of the cDNA 
for DCS while also inserting an SmaI restriction site prior to this section.  
Primers for PCR 
The primers were designed manually. For the reverse primer, starting from the 
3′ end of the DCS cDNA, the sequence had no mismatched basepairs and it 
was ensured there was a suitable overlap after the BamHI site for efficient 
operation of the endonuclease. The forward primer contained a mismatched 
section containing the SmaI restriction site and a small section identical to 
GdolS prior to the loop-helix. The DCS complementary section was of equal 
length to the non-matched section and contained no mismatched basepairs, 
Table 6.4 
Table 6.4 PCR Primers 
 5′-Sequence-3′ 
DCS.PCR Fwd 5'- CTCCCGGGCGCCTGCCGCTCGTTTTTGAAACCAACAGAA -3' 
      -SmaI-            |-F--L--K--P--T--E- 
     GdolS helix end|DCS section start 
DCS.PCR Rev 5′-ATTCGGGATCCTCAAAGTGCAATTGGTTCAATGAGC-3′ 
 
PCR Protocol 
PCR was carried out using Pfu DNA polymerase and a protocol designed based 
on the recommended conditions. The reaction mixture was made up according 
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to Table 6.2 and PCR carried out using the designed protocol, Table 6.5. After 
PCR 5 µL of the product was analysed by electrophoresis on 2 % agarose and 
upon successful amplification of the segment, a sample was cloned into 
Strataclone holding vector and confirmed by DNA sequence analysis. 
Table 6.5 PCR protocol 
 Temperature (ºC) Time (min) 










Final Extension 74 5 
 *Denaturation, annealing, extension steps 
cycled 25 times 
 
Restriction digest of DNA 
Manufacturer’s guidelines regarding temperature, buffers and denaturation 
were followed in all restriction enzyme digests. Restriction digests were 
performed sequentially with SmaI (3.5 h, 25 °C) followed by BamHI (3 h, 37 
°C). SmaI was heat inactivated at 65 °C for 15 minutes before addition of the 
second enzyme. After digestion DNA fragments were isolated by agarose gel 
purification (0). 
Ligation of DNA into expression vectors 
Following restriction digest and agarose gel purification, the required gene and 
expression plasmid were ligated to form new expression vector constructs. 
Plasmid and insert were incubated in a 1:5 molar ratio, respectively, with T4 
ligase buffer (2 µL) and sterile dH2O in a volume of 20 μL. T4 ligase 1 (μL) was 
added and the ligation reaction incubated for 12 hours at 16 °C. The reaction 
was frozen for later use or immediately used to transform super-competent 
cells. 
Cloning into StrataClone PCR cloning vector 
StrataClone Blunt Cloning Buffer (3 μL), PCR product (2 μL) and StrataClone 
Blunt Vector Mix amp/kan (1 μL) were incubated at room temperature for 5 
minutes and 2 µL of the reaction used to transform Stratagene ultra-
competent cells. 
6.1.7 DNA visualisation 
TAE buffer 
Tris base (242 g), glacial acetic acid (57.1 mL) and 100 mL EDTA (0.5 M, pH 
8.0) were dissolved in deionised water and the total volume taken to 1 L with 
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deionised water. Immediately prior to use the solution was diluted in a 1:49 
ratio with deionised water. 
DNA loading buffer 
Glycerol (3 mL) and 0.5% bromophenol blue solution (2 μL) were added to 7 mL 
deionised water. 
Agarose gel electrophoresis 
Agarose gels were prepared using dilute TAE buffer (0) in a 1-2 % w/v ratio 
dependent on the size of fragment being analysed. 5 μL DNA loading buffer (0) 
was added to the DNA sample which was then loaded onto the gel and run at a 
constant voltage of 100 V for 1 hour before being placed in a dilute ethidium 
bromide solution for 10 minutes whilst shaking. The DNA bands were 
visualised using a Syngene GeneFlash UV light box (Syngene, Cambridge, UK) 
and compared to a molecular weight ladder run on the same gel. 
6.1.8 DNA purification 
Miniprep of DNA 
A single colony from an agar plate, or a spike from a glycerol stock, harbouring 
the required transformed cells was used to inoculate 10 mL of LB medium 
(containing the appropriate selective antibiotic) and incubated overnight at 37 
°C whilst shaking. Cells were harvested by centrifugation (3400 g, 5 minutes). 
The QIAprep spin miniprep kit (QIAGEN, Crawley, UK) was used with 
EconoSpin All-in-1 mini spin columns (Epoch Biolabs, Inc, TX, USA) to purify 
the plasmid following the manufacturer’s protocol.  
Agarose gel DNA purification 
The required samples underwent agarose gel electrophoresis (0) and the DNA 
visualised by staining in dilute ethidium bromide solution. DNA bands were 
visualised using a Syngene GeneFlash UV light box (Syngene, Cambridge, UK) 
and the appropriate DNA bands cut from the agarose gel using a razor blade. 
DNA was extracted from the agarose gel using a QIAquick gel extraction kit 
(QIAGEN, Crawley, UK) with EconoSpin All-in-1 mini spin columns (Epoch 
Biolabs, Inc, TX, USA) following the manufacturer’s protocol. 
6.1.9 Transformation of competent cells 
The appropriate competent cells and plasmid DNA were allowed to thaw slowly 
on ice. 0.5 – 1 µL plasmid DNA solution (5-10 μl in the case of ligation or SDM 
reactions) was transferred to the competent cells and mixed gently. The 
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cell/DNA mixture was incubated on ice for at least 20 minutes, heat shocked 
at 42 °C for 45 seconds and returned to ice for at least 2 minutes. Non-
selective LB medium (1 mL) was added to the cell/DNA mixture and incubated 
at 37 °C for 1 hour whilst shaking. Cells were harvested by centrifugation 
(3300 g, 1 minute, Eppendorf centrifuge 5415R) and the supernatant solution 
discarded. The cell pellet was re-suspended in 100 μL of LB medium, plated on 
agar plates containing the appropriate antibiotic and incubated at 37 °C 
overnight. 
6.1.10 Expression 
A single transformed colony was used to inoculate 100 mL of LB-media 
containing ampicillin (100 mg L-1); this was grown overnight at 37 °C with 
shaking. This starter culture was used to inoculate LB-media containing 
antibiotic (5 mL of culture per 500 mL of LB medium). The cultures were 
incubated at 37ºC until an optical density of 0.6 at 600 nm was reached, at 
which time gene expression was induced with isopropyl-β-D-1-
thiogalactopyranoside (IPTG) and incubated for the required time and 
temperature as judged by test expression, Table 6.6. Cells were harvested by 
centrifugation (3400 g, 10 minutes) and cell pellets stored at -20 °C. 
Test expression 
Test expressions were used to optimise the over-expression for production of 
proteins, investigating factors such as expression cells, temperature of 
expression, concentration of IPTG and length of expression. They were typically 
carried out on a 1 L scale, and a 1 mL sample was removed immediately prior 
to induction and at hourly intervals after induction. The cells in these samples 
were harvested by centrifugation, (3300 g, 1 minute, Eppendorf centrifuge 
5415R) the pellets resuspended in SDS-sample buffer and analysed by SDS-
PAGE. 







GdolS-WT 37  0.5 / 0.2 3 – 4 
D80E 37 0.2 4 
D80N 37 0.2 4 
D81E 37 0.2 4 
D81N 37 0.2 4 
D84E 37 0.2 4 
D84N 37 0.2 4 
E226D 37 0.2 4 
S222A 37 0.2 4 
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N218Q 37 0.2 4 
N218L 37 0.2 4 
N218T 16 0.2 21 
N218E 16 0.2 21 
R172K 37 0.2 4 
R172E 16 0.2 21 
Y303F 37 0.2 4 
Y303I 37 0.2 4 
Y303T 16 0.1 21 
W306A 37 0.2 4 
E307Q 37 0.2 4 
E307M 37 0.2 4 
GdolS-DCS hybrid 16 0.1 6 - 21 
D274G 37 0.2 4 
D231L 37 0.2 4 
R229E 37 0.2 4 
R134E 37 0.2 4 




Induced cells harvested after expression were re-suspended in buffer 
(dependent on purification technique) and lysed by sonication (5 second 
sonication period followed by 10 second rest period for a total of 15 minutes). 
The solution was clarified by centrifugation at 4 C, (38000 g, 30 minutes). 
Basic extraction 
Basic extraction was used to denature and refold protein found as insoluble 
inclusion bodies in order to solubilise the protein. The cell pellet after 
clarification (0) was re-suspended in buffer (20 mL, 20 mM Tris, pH 8.0) and 
stirred at 4 °C for 30 minutes before the pH was adjusted to 12 with sodium 
hydroxide at which point the solution becomes clearer. After stirring for a 
further 30 minutes at 4 °C, 2-mercaptoethanol is added to a concentration of 
10 mM and the pH gradually reduced to 8.0 by dropwise addition of 1 M 
hydrochloric acid. The solution at pH 8.0 is stirred at 4 °C for a further 30 
minutes at 4 °C before centrifugation (38000 g, 30 minutes), and the resulting 
supernatant and pellet analysed by SDS-PAGE. 
Ni-NTA affinity chromatography 
Ni-NTA Buffer I 
Tris-base (50 mM, 6.2 g), Sodium chloride (100 mM, 5.9 g) and Imidazole (10 
mM, 0.78 g) were dissolved in 800 mL deionised water and the pH adjusted to 
8.0. The solution was made up to a final volume of 1 L with deionised water 
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Ni-NTA Buffer II 
Tris-base (50 mM, 6.2 g), Sodium chloride (100 mM, 5.9 g) and Imidazole (250 
mM, 17.2g) were dissolved in 800 mL deionised water and the pH adjusted to 
8.0. The solution was made up to a final volume of 1 L with deionised water. 
Ni-NTA Buffer III 
Tris-base (50 mM, 3.1 g), Sodium chloride (100 mM, 2.9 g) and Imidazole (500 
mM, 17.2g) were dissolved in 400 mL deionised water and the pH adjusted to 
8.0. The solution was made up to a final volume of 500 mL with deionised 
water. 
Ni-NTA affinity chromatography protocol 
Harvested supernatant was applied to a column equilibrated with Ni-NTA 
buffer I and the flow-through collected. The column was then washed with 10 
column volumes (CV) Ni-NTA buffer I prior to elution with 5 CV Ni-NTA buffer 
II, and 5 CV Ni-NTA buffer III. All fractions were retained and analysed by 
SDS-PAGE, those containing the target protein were then dialysed. 
Dialysis 
Fractions from purification found to contain the desired protein were dialysed 
to remove the residual imidazole. Fractions of equal purity are combined in 
dialysis tubing (MWCO 12 – 14 kDa) and stirred overnight (16 h) in buffer (5 
L,10 mM Tris, pH 8.0). After dialysis the protein solution was concentrated by 
ultrafiltration (AMICON system, YM 30). 
6.1.12 SDS-PAGE 
Samples of protein were analysed by Sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Gels were prepared, cast and run using the Mini-
PROTEAN system from Bio-Rad. 
SDS resolving buffer 
Tris-Base (1.5 M, 27.23 g) was dissolved in deionised water and the pH 
adjusted to 8.8. The final volume was taken to 150 mL. 
SDS stacking buffer 
Tris-Base (0.5 M, 6.06 g) was dissolved in deionised water and the pH adjusted 
to 6.8. The final volume was then taken to 100 mL. 
Electrode running buffer 10X 
Tris-base (0.25 M, 30.3 g) and Glycine (2 M, 150.14 g) were dissolved in 600 
mL deionised water, once dissolved SDS (10% w/v, 10 g) was added and left to 
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stir slowly to dissolve. Once all the SDS had dissolved the final volume was 
brought up to 1 L with deionised water. Electrode running buffer 10X was 
diluted 10-fold prior to use. 
SDS sample buffer 
Deionised water (3.55 mL), SDS stacking buffer (1.25 mL), glycerol (2.5 mL), 
bromophenol blue (0.2 mL of 0.6% w/v solution), SDS (2 mL of 10% w/v 
solution) and -mercaptoethanol were mixed together and stored at room 
temperature. 
Resolving gel (12 %) 
30% acrylamide/bis-acrylamide (4.0 mL), resolving buffer (2.5 mL), 10% (w/v) 
SDS (0.1 mL) and deionised water (3.4 mL) were mixed together. Immediately 
prior to pouring, freshly made 10% ammonium persulfate (APS, 50 L) and 
N,N,N',N'-tetramethylenediamine (TEMED, 20 L) were added and the solution 
gently mixed to initiate polymerisation. 
Stacking gel (4%) 
30% acrylamide/bis-acrylamide (1.7 mL), stacking buffer (2.5 mL), 10% (w/v) 
SDS (0.1 mL) and deionised water (5.7 mL) were mixed together. Immediately 
prior to pouring, freshly made 10% ammonium persulfate (APS, 50 L) and 
N,N,N',N'-tetramethylenediamine (TEMED, 20 L) were added and the solution 
gently mixed to initiate polymerisation.  
SDS gel stain 
Coomasie brilliant blue R-250 (0.25 g) was dissolved in 1:1 Ethanol:Water (90 
mL), once dissolved glacial acetic acid (10 mL) was added. 
SDS gel destain 
Deionised water (500 mL) and ethanol (400 mL) were mixed together, and then 
glacial acetic acid (100 mL) was added. 
SDS-PAGE protocol 
Monomer solutions were prepared as above and the resolving gel poured, 
covered with a layer of isopropanol and allowed to polymerise. Isopropanol was 
then removed and the stacking gel poured, a comb inserted to create loading 
wells and allowed to polymerise. Fraction samples (10 L) were incubated with 
SDS sample buffer (10 L, 0) for 10 minutes at 85 °C and loaded into the gel. 





Once the gel had run, it was removed from the plates and stained for 30 
minutes with SDS gel stain, and then destained with gel destain in 30 minutes 
periods until bands were visible. 
6.1.13 BN-PAGE 
The non-denaturing polyacrylamide gel system was used for analysis of the 
GdolS-R134 mutants. 
Gel buffer 
BisTris (1.25 M, 26.13 g) was dissolved in deionised water and the pH adjusted 
to 7.5. The final volume was taken to 100 mL. 
Anode running buffer 10X 
BisTris (0.5 M) and Tricine (0.5 M) were dissolved in deionised water and the 
pH adjusted to 6.8. The final volume was brought up to 1 L with deionised 
water. Anode running buffer 10X was diluted 10-fold prior to use. 
Cathode buffer 1X 
To Anode running buffer was added Coomasie G250 brilliant blue dye (0.02% 
w/v) and stirred until dissolved. 
Sample buffer 
BisTris (50 mM, 105 mg) and sodium chloride (50 mM, 30 mg) were dissolved 
in 5 mL deionised water. Followed by the addition of glycerol (10% w/v, 1 mL) 
and Ponceau S dye (0.001% w/v, 0.1 mg). The pH was adjusted to 7.2 with HCl 
and the final volume made up to 10 mL. 
Resolving gel (10 %) 
30% acrylamide/bis-acrylamide (3.3 mL), gel buffer (2.9 mL) and deionised 
water (3.7 mL) were mixed together. Immediately prior to pouring, freshly made 
10% ammonium persulfate (APS, 50 L) and N,N,N',N'-tetramethylenediamine 
(TEMED, 20 L) were added and the solution gently mixed to initiate 
polymerisation. 
Stacking gel (4%) 
30% acrylamide/bis-acrylamide (1.3 mL), stacking buffer (2.9 mL) and 
deionised water (5.7 mL) were mixed together. Immediately prior to pouring, 
freshly made 10% ammonium persulfate (APS, 50 L) and N,N,N',N'-
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tetramethylenediamine (TEMED, 20 L) were added and the solution gently 
mixed to initiate polymerisation.  
BN-PAGE protocol 
BN-polyacrylamide gels were prepared as for SDS-PAGE following the above 
recipes. Anode running buffer was added to the tank and the cathode well 
filled with cathode running buffer. The gel was allowed to run at 150 V for 
1h30. 
Visualising 
Once the gel had run, it was removed from the plates and stained and 
destained as for SDS-PAGE. 
6.1.14 Bradford assay 
The Bradford assay was used to determine the concentration of protein in 
solution 
Bradford reagent 
Brilliant blue G250 (20 mg) was dissolved in 2 mL of ethanol and H3PO4 added 
(80%, 20 mL). The final volume was brought up to 200 mL with dH2O and 
stored in the dark at 4 °C. 
Bradford assay 
A 1 mg mL-1 sample of bovine serum albumin (BSA) in dH2O was used to 
prepare a range of concentrations from 0 to 100 µg mL-1 in 200 µL deionised 
water. Bradford reagent (1 mL, 0) was added and the absorbance measured 
from 400 to 600 nm using a Jasco V-660 spectrophotometer. The ratio of 
absorbances at 590 nm and 450 nm was calculated and used to plot a 
standard curve. The procedure was repeated for the purified proteins and the 
ratio of absorbances compared to the BSA standard to calculate the 
concentration of each sample. 
6.1.15 Circular dichroism spectroscopy 
CD measurements 
CD spectrum 
Circular dichroism experiments were performed on an Applied PhotoPhysics 
Chirascan spectrometer. Spectra of 10 µM protein in dH2O (or 20 mM Tris) 
were measured between 190 nm and 300 nm in a 10 mm quartz cuvettes 
under N2 with a 50 nm/min scan speed, 0.5 nm data pitch, 1 nm bandwidth 




Circular dichorism melts were performed measuring at 222 nm between 4 °C 
and 96 °C with a temperature ramp of 2 °C min-1, step of 0.5 °C and tolerance 
of 0.2 °C, with measurements taken for 12 s per point. 
CD spectra melt 
Circular dichroism spectra melts were performed with the measurement of full 
spectra between 190 nm and 300 nm between 5 °C and 90 °C with stepped 
temperature ramping enabled. Measurements were taken at 5 °C intervals with 
a 300 s settling time between measurements and a tolerance of 0.2 °C. 
pH spectra 
For the spectra measured at different pH values 10 µM protein in buffer was 
used (20 mM; pH 6, 4-morpholineethanesulfonic acid, MES; pH 7 - 9, Tris; pH 
10, N-cyclohexyl-2-aminoethanesulfonic acid, CHES). 
Mean residue ellipticity (MRE) 





[𝜽]MRE =  
[𝜽]
𝟏𝟎. 𝒏. 𝒄. 𝒍
 
 
Where [θ] = CD signal in millidegrees, n = number of peptide bonds, c = molar 
concentration of sample and l = pathlength of the cuvette in cm. 
6.1.16 Size-exclusion chromatography 
Size exclusion was carried out using a Superdex 200 10/300 GL prepacked gel 
filtration column (24 mL CV) with an AKTA FPLC system. Samples of 500 µL 
were loaded into the loop and washed through the column with 1.5 CV of 
buffer at a rate of 0.5 mL min-1 while monitoring UV absorbance at 280 nm. 
Size-exclusion buffer I 
Tris base (2.4 g, 20 mM), ethylenediaminetetraacetic acid (EDTA, 1.5 g, 5 mM) 
and 2-mercaptoethanol (350 µL, 5 mM) were dissolved in deionised water. The 
pH was adjusted to pH 8.0 and the final volume taken to 1 L. The solution was 
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filtered and degassed via vacuum pump (Vacuubrand GmbH +CO KG, MD4C, 
Werthein, Germany) and stored at 4 °C. 
Size-exclusion buffer II 
Tris base (2.4 g, 20 mM), ethylenediaminetetraacetic acid (EDTA, 1.5 g, 5 mM), 
sodium chloride (8.8 g, 150 mM) and 2-mercaptoethanol (350 µL, 5 mM) were 
dissolved in deionised water. The pH was adjusted to pH 8.0 and the final 
volume taken to 1 L. The solution was filtered and degassed via vacuum pump 
(Vacuubrand GmbH +CO KG, MD4C, Werthein, Germany) and stored at 4 °C. 
6.1.17 GC-MS analysis of products 
The pentane extracted products of small (250 µL) analytical incubations of 
enzymes with FDP were analysed by GC-MS. 
Incubation buffer 
Tris-base (1.2 g, 50 mM) and Magnesium chloride (200 mg, 5 mM) were 
dissolved in deionised water, 2-mercaptoethanol (70 µL, 5 mM) was added and 
the pH adjusted to 8 before the final volume was made up to 200 mL and 
stored at 4 °C. 
Incubation protocol 
The standard reaction mixture of 1 µM enzyme and 200 µM FPP in 250 µL 
incubation buffer was overlaid with 1 mL pentane. This mixture was incubated 
whilst shaking at room temperature for 4-6 hours before extraction of products 
into the pentane layer by vortexing for 10 seconds and analysis by GC-MS. 
GC-MS method 
GC-MS analyses were run on a Hewlett Packard 6890 GC fitted with a J&W 
scientific DB-5MS column (30 m x 0.25 mm internal diameter) and a 
Micromass GCT Premiere detecting in the range m/z 50-800 in EI+ mode with 
scanning once a second with a scan time of 0.9. A temperature gradient of 
50ºC (1 minute hold) to 150ºC (4ºC min-1, 13 minute hold) was used. 
6.1.18 GC-FID analysis 
GC-FID analysis was performed on an Agilent 7890A GC system fitted with a 
SUPELCO Aztec CHIRALDEX™ B-DM silica capillary column. 
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GC-FID method I 
A 5 - 10 µL sample was injected with a 50:1 split, the oven temperature was 
held at 70 ºC for 3 minutes and then raised 5 ºC min-1 to 160 ºC and held for 
30 minutes. 
GC-FID method II 
A 5 - 10 µL sample was injected with a 50:1 split, the oven temperature was 
held at 90 ºC for 2 minutes and then raised 5 ºC min-1 to 170 ºC and held for 
40 minutes. 
GC-FID method III 
A 5 - 10 µL sample was injected with a 50:1 split, the oven temperature was 
held at 155 ºC for 60. 
GC-FID method IV 
A 5 - 10 µL sample was injected with a 50:1 split, the oven temperature was 
held at 100 ºC for 2 minutes and then raised 2 ºC min-1 to 150 ºC and held for 
30 minutes. 
6.1.19 Measurement of steady-state kinetic parameters 
Kinetics buffer 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 2.4 g, 50 mM) and 
magnesium chloride (100 mg, 2.5 mM) were dissolved in deionised water, 2-
mercaptoethanol (70 µL, 5 mM) was added and the pH adjusted to 8 before the 
final volume was made up to 200 mL and stored at 4 °C. 
For the determination of optimum Mg2+ concentration a second identical 
kinetics buffer was prepared without the magnesium chloride. 
Kinetics protocol 
Steady-state kinetics assays based on previous methods were carried out using 
[1-3H]-(E,E)-FDP (240000 dpm nmol-1) in buffer. Reactions (250 L) were 
initiated by addition of enzyme (10 – 30 nm) to assay buffer solutions 
containing [1-3H]-(E,E)-FDP (0-7 µM) at 0 C overlaid with 1 mL of hexane. The 
resulting enzymatic preparations were incubated at 30 C for 10 minutes, 
cooled on ice and immediately quenched by addition of EDTA (50 µL, 0.5 M) 
and vortexing for 30 s. The organic overlay was then passed through a small 
silica column (~500 mg) into 15 mL EcoScintTM fluid (National Diagnostics), the 
aqueous portion was further extracted with a further two 750 µL portions of 
11:1 hexane/diethyl ether by vortexing for 10 s and the organic extracts 
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passed through the silica column into the EcoScintTM fluid. The silica column 
was washed with a 750 µL portion of 11:1 hexane/diethyl ether before analysis 
of the combined organic extracts in EcoScintTM fluid on a scintillation counter 
(Packard 2500 TRTM) in 3H mode for 4 min per sample. Background samples 
were run identically, across the range of FDP concentrations without the 
addition of enzyme. Background counts were plotted and subtracted from the 
enzyme reaction data. The KM and kcat were calculated by fitting the data to the 
Michaelis-Menten equation, Equation 2, using Systat Sigmaplot or 
KaleidaGraph: 
Equation 2 




The turnover number, kcat, was derived from the calculated Vmax using 
Equation 3. 
Equation 3 




Where Vmaz is in counts per minute (cpm), t is the incubation time in seconds, 
c is the enzyme concentration in µM and A is the activity of the FDP in cpm 
µM-1. 
Kinetics on alternate substrates 
For measurement of steady-state kinetic parameters with alternate substrates 
(rac-(3H)-NDP, (3H)-(3R)-NDP, (3H)-10F-FDP) the same procedure as previously 
described was followed but the initial run was prepared with a wider range of 
substrate concentrations (1 – 15 µM) to identify a suitable range. 
6.1.20 Inhibition studies 
Two methods of studying inhibition were used, both methods relying on 
double-reciprocal plots for identification of the type of inhibition. 
Lineweaver-Burk 
The Lineweaver-Burk plot arises from taking the reciprocal of the Michaelis-













A plot of 1/V against 1/[S] gives a straight line with the x-axis intercept at -
1/KM, the y-axis intercept 1/Vmax and the gradient KM/Vmax. 
Inhibition studies using this method of representation comprised of a series of 
incubations as above with increasing concentrations of inhibitor present, i.e. in 
each series the concentration of inhibitor is constant while concentration of 
substrate increases. The data was treated as described above to generate a 
Lineweaver-Burk plot for the calculation of Ki, where KM(apparent) = KM (1 + 
[I]/KI). 
Dixon 
In a Dixon plot the concentration of inhibitor is plotted against the reciprocal 
rate varying the substrate concentration each series, incubations were carried 
out with increasing [I] at constant [S], [S] was then increased to generate 
multiple series. The Ki can be read from the plot as the intersection of the 
lines. The data was then replotted in a Cornish-Bowden plot, S/v against [I], to 














6.1.21 Preparative-scale enzymatic incubation 
Preparative-incubations were used for the production of milligram quantities of 
enzymatic products for the purposes of analysis. Incubations were scaled to a 
suitable size dependent on the quantity of substrate being used to a final 
substrate concentration of 0.3 mM in buffer (50 mM tris, 5 mM MgCl2, 5 mM 
2-mercaptoethanol, pH 8.0) with a maximum enzyme concentration of 4 µM. 
Incubation 
Buffer was prepared and the enzyme added at room temperature while gently 
stirring, 50 % of the total FDP substrate was added and the incubation 
overlaid with pentane (5 – 10 % incubation volume) and stirred at room 
temperature for 24 h. The remaining FDP-substrate was then added at stirred 
for a further 12 – 24 h before it was cooled to 4 °C and stirred for a further 64 
h. 
Extraction 
The pentane overlay was removed and the aqueous layer was further washed 
with pentane (10 x 5% Vtot) by gentle swirling and slow separation. The 
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combined pentane extracts were washed with brine and solvent removed under 
reduced pressure (500 mbar) and 25 °C to yield the terpene product as an oil. 
6.1.22 Calculation of errors 
Standard Errors of the Mean 
The errors in this work are expressed as standard error of the mean (M) that is 
defined by the following equations: 




Where n is the number of samples and  is the standard deviation, defined as: 





Where X is each value in the sample and M is the mean of the sample. 
Propagation of the Errors 
Propagation of errors was performed where appropriate using the following 
equations: 
If 𝑍 = 𝑋 + 𝑌 or 𝑍 = 𝑋 − 𝑌 then ∆𝑍 =  √∆𝑋2 + ∆𝑌2 















If 𝑍 = 𝑒𝑋 then ∆𝑍 =  ∆𝑋𝑒𝑋 
Where X and Y are the experimentally measured values, X and Y are their 
respective errors, Z is the calculated value and Z the propagated error. 
6.1.23 Normalisation 
Where data has been normalised it has been performed using unity-based 
normalisation using the following equation: 




Where Xis the normalised value, X is the original value and Xmin and Xmax are 




6.2.1 General experimental 
All chemicals were purchased from Sigma-Aldrich, Alfa-Aesar or Fisher 
Scientific and used without further purification unless otherwise stated. 
Anhydrous tetrahydrofuran (THF), diethyl ether, toluene and acetonitrile were 
obtained from a MBraun SPS800 solvent purification system. 
Dichloromethane, and triethylamine were distilled from calcium hydride and 
KOH under nitrogen respectively. 
1H and 13C NMR spectra were measured on a Bruker Avance 500 NMR 
spectrometer or a Bruker Fourier300 NMR spectrometer and are reported as 
chemical shifts in parts per million downfield from tetramethylsilane, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), 
coupling (to the nearest 0.5 Hz) and assignment, respectively.  1H, 13C and 31P 
NMR spectra were measured on a Bruker Avance 500 NMR spectrometer and 
are reported as chemical shift downfield from tetramethylsilane, coupling 
constant where appropriate and assignment.  Assignments are made to the 
limitations of COSY, DEPT 90/135, gradient HSQC and gradient HMBC 
spectra.  2H, 19F and 31P NMR spectra were recorded on a Jeol Eclipse +300 
NMR spectrometer. 
Thin layer chromatography was performed on pre-coated aluminium plates of 
silica G/UV254. TLC visualizations were performed with 4.2% ammonium 
molybdate and 0.2% ceric sulfate in 5% H2SO4, or 0.1% berberine 
hydrochloride in EtOH or UV light. Reverse phase HPLC was performed on a 
system comprising of a Dionex P680 pump and a Dionex UVD170U detector 
unit. 
6.2.2 Experimental 
 (2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-yl tris-ammonium diphosphate 19 
 
A stirring solution of farnesol (200 mg, 0.90 mmol) and 2,4,6-collidine (654 
mg, 713 L, 5.4 mmol) in anhydrous DMF (20 mL) was cooled to 0 ºC and 
methanesulfonyl chloride (206 mg, 140 L, 1.8 mmol) added. The resulting 
milky solution was stirred for 15 minutes before the addition of LiCl (152 mg, 
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3.6 mmol) and then left to stir at 0 ºC for a further 2 h. The reaction was 
quenched with d.H2O and washed with hexane (5 x 5 mL). The combined 
organic fractions were washed with CuSO4, NaHCO3 and brine, dried (MgSO4) 
and the solvent removed under reduced pressure, and dried under high-
vacuum for 1 h to yield the chloride, which was used without further 
purification. 
The chloride intermediate was taken up in anhydrous acetonitrile and 
tris(tetrabutylammonium)hydrogen diphosphate (2.4 g, 2.7 mmol) added and 
stirred under N2 for 16 h. The acetonitrile was removed under vacuum and the 
sticky brown residue dissolved in 2 mL of ion-exchange buffer (25 mM 
NH4HCO3, 2% iPrOH), and the resulting cloudy solution was passed slowly 
through a column of Dowex 50W-X8 cation-exchange resin pre-equilibriated in 
ion-exchange buffer. Fractions were eluted with the same buffer and analysed 
by TLC (3:1:1, iPrOH:NH4OH:buffer) and the fractions found to contain product 
were combined and lyophilised. The white powder was dissolved in 2 mL ion-
exchange buffer and purified by reverse-phase HPLC (C18 column, eluting with 
10% A for 20 min, then a linear gradient to 60% A over 25 min and finally a 
linear gradient to 100% A over 5 min.; solvent A: CH3CN, solvent B: 25 mM 
NH4HCO3, flow rate 5.0 cm3 min-1, detecting at 220 nm) to give the title 
compound as a white solid in 64% yield (250 mg, 0.576 mmol) 
H (400 MHz, D2O) 5.44 (1 H, t, J 7.0, CCHCH2O), 5.24 – 5.12 (2 H, m, 2 x 
C=CH), 4.46 (2 H, t, J 6.0, CCHCH2O), 2.22 – 1.95 (8 H, m, 4 x CH2), 1.70 (3 H, 
s, CH3), 1.66 (3 H, s, CH3), 1.60 (6 H, s, 2 x CH3); P (122 MHz, D2O) -6.13 (d, J 
22.0), -9.85 (d, J 22.0); HRMS (ES-, [M - H]-) found 381.1235, C15H27O7P2 
requires 381.1232 
 (2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-yl-1,1-d2 trisammonium diphosphate 64 
 
This compound was prepared from 1,1-2H2-farnesol (50 mg, 0.22 mmol), which 
was a gift from Dr Juan A. Faraldos. This compound was prepared in a 
manner identical to that for the diphosphate 19, but without HPLC 
purification. Instead the crude pale yellow powder isolated after ion exchange 
was partially purified by trituration with anhydrous methanol (3 x 2 mL), and 
dried under N2 flow to yield a white powder in 87% yield (83.5 mg, 1.9 mmol).  
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H (500 MHz, D2O) 5.47 (1 H, s, CCHCD2O), 5.29 – 5.23 (1 H, m, C=CH), 5.23 – 5.18 (1 
H, m, C=CH), 2.22 – 1.99 (8 H, m, 4 x CH2), 1.74 (3 H, s, CH3), 1.70 (3 H, s, CH3), 1.64 
(6 H, s, 2 x CH3); P (202 MHz, D2O) -6.62; HRMS (ES-, [M - H]-) found 383.1369, 
C151H252H2O7P2 requires 383.1358. 
Tris(tetra-n-butyl ammonium)hydrogen diphosphate 106 
 
A solution of disodium dihydrogen diphosphate (3.3 g, 15 mmol) in ammonium 
hydroxide (15 mL, 10% v/v) was passed through a column of Amberlyst® 131 
cation exchange resin (Hydrogen-form) and the free acid eluted with deionised 
water (110 mL). The flowthrough (pH 1) was collected until the pH increased (~ 
pH 3-4) and immediately titrated with aqueous tetra-n-butyl ammonium 
hydroxide (40% w/v) to pH 7.3. The resulting clear solution (~150 mL) was 
lyophilised and the residue dried by azeotropic removal of water with 
acetonitrile (100 mL) and recrystallised from ethyl acetate to yield the title 
compound as hygroscopic white crystals in 48% yield (6.5 g, 7.2 mmol). 
H (300 MHz, CDCl3) 3.44 – 3.27 (2 H, m), 1.66 (2 H, m), 1.57 – 1.37 (2 H, m), 
0.98 (3 H, t, J 7.5); C (75 MHz, CDCl3) 58.88, 24.30, 19.84, 13.92; P (202 
MHz, CDCl3) -5.95.  
2-(((2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-pyran 126 
 
To a stirring solution of farnesol (3.93 g, 17.7 mmol) and 3,4-dihydropyran (3.7 
g, 4.0 mL, 44 mmol) in DCM (100 mL) at room temperature was added 
pyridinium p-toluenesulfonate (PPTS, 150 mg, 0.6 mmol) and left stirring at 
room temperature for 3 hours. Water was added to the mixture and the DCM 
layer separated. The aqueous layer was further washed with DCM (3 x 30 mL) 
and the combined DCM portions washed with brine, dried (MgSO4) and solvent 
removed in vaccuo. Purification by flash column chromatography on silica (7% 
EtOAc in hexane, Rf 0.34) gave the title compound as a clear free-flowing oil in 
98% yield (12.4 mmol). 
H (300 MHz, CDCl3) 5.36 (1 H, t, J 6.4, CHCH2O), 5.18 – 5.02 (2 H, m, 2 x  
CCHCH2CH2), 4.65 – 4.60 (1 H, m, OCHO), 4.13 (2 H, ddd, J 19.3, 11.9, 6.9, 
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CHCH2O), 3.95 – 3.45 [2 H, m, (CH2)3CH2O], 2.15 – 1.92 (8 H, m, 2 x CH2), 
1.90 – 1.48 (6 H, m, (CH2)3CH2O), 1.68 (6 H, s, 2 x CCH3), 1.60 (6 H, s, 2 x 
CCH3); C (75 MHz, CDCl3) 135.38 & 131.46 (CH3CCH), 124.46 & 124.02 
(CH3CCH), 120.68 (CHCH2O), 97.92 (OCHO), 63.79 (CHCH2O), 62.43 
[(CH2)3CH2O), 39.84 & 39.78 (CH2), 30.85 (CH2), 26.86 & 26.42 (CHCH2CH2), 
25.85 (CH3), 25.64 & 19.77 (CH2), 17.83, 16.57 & 16.16 (CH3); HRMS (APCI+, 




A stirring solution of 126 (5.33 g, 17.4 mmol) in THF:dH2O (120 mL, 2:1) was 
cooled to 0 ºC and N-bromosuccinimide (3.5 g, 19.7 mmol) added in portions 
over 30 minutes. The reaction was stirred at 0 ºC for 2 h before it was allowed 
to warm to room temperature for a further 2 h. The reaction was diluted with 
hexane and separated with brine, the aqueous layer was further washed with 
hexane (3 x 30 mL), dried (Na2SO4) and solvent removed under reduced 
pressure. Purification by flash column chromatography on silica (20% EtOAc 
in hexane, Rf 0.35) yielded the title compound as a pale yellow oil in 70% yield 
(4.97 g, 12.3 mmol).  
H (300 MHz, CDCl3) 5.36 (1 H, t, J 6.9, CHCH2O), 5.20 (1 H, t, J 6.4, 
CHCH2CH2), 4.62 (1 H, t, J 3.5, OCHO), 4.30 – 4.01 (2 H, m, CHCH2O), 4.01 – 
3.93 [1 H, m, CH(OH)], 3.93 – 3.42 (2 H, m, [(CH2)3CH2O], 2.40 – 1.70 [8 H, m, 
2 x CH(CH2)2], 1.68 (3 H, s, CH3), 1.59 (3 H, s, CH3), 1.65 – 1.44 [6 H, m, 
(CH2)3CH2O], 1.34 (3 H, s, CH3), 1.33 (3 H, s, CH3); C (75 MHz, CDCl3) 140.14 
(CH3CCH), 133.43 (CH3CCH), 125.79 (CHCH2CH2), 120.80 (CHCH2O), 97.88 
(OCHO), 70.82 (CH(OH)), 63.75 (CHCH2O), 62.41 (OCH2(CH2)3), 39.58 
(CHCH2CH2), 38.22 (CHCH2CH2), 32.09 (CH2), 30.80 (CH2), 26.62 (CH2), 26.33 
(CH3CBr), 25.96 (CH3CBr), 25.58 (CH2), 19.72 (CH2), 16.57 (CH3), 15.96 (CH3); 






To a solution of 127 (4.97 g, 12.3 mmol) stirring in MeOH (100 mL) at room 
temperature was added K2CO3 (3.4 g, 25 mmol) and the resulting slurry stirred 
for 1 h. The mixture was concentrated under reduced pressure and then 
diluted with hexane (50 mL) and dH2O (50 mL). The aqueous layer separated 
and washed with hexane (3 x  15 mL). The combined organic fractions were 
washed with HCl (1 M, 15 mL) and brine, dried (Na2SO4) and solvent removed 
under reduced pressure. Purification by flash column chromatography on 
silica (20% EtOAc in hexane, Rf 0.5) yielded the title compound as a clear oil in 
97% yield (3.94 g, 12.0 mmol).  
H (300 MHz, CDCl3) 5.36 (1 H, t, J 6.3, CHCH2O), 5.15 (1 H, t, J 6.1, 
CHCH2CH2), 4.62 (1 H, t, J 3.5, OCHO), 4.13 (2 H, ddd, J 19.2, 11.8, 6.9, 
CHCH2O), 3.95 – 3.44 (2 H, m, (CH2)3CH2O), 2.70 (1 H, t, J 6.3. C(O)CHCH2), 
2.23 – 1.97 (6 H, m, 3 x allylic CH2), 1.67 (3 H, s, CH3CCH), 1.92 – 1.38 (8 H, 
m, (CH2)3CH2O and C(O)CHCH2), 1.61 (3 H, s, CH3CCH), 1.30 (3 H, s, 
CH3C(O)CH), 1.25 (3 H, s, CH3C(O)CH);  C (75 MHz, CDCl3) 140.18 (CH3CCH), 
134.37 (CH3CCH), 124.55 (CCHCH2), 120.62 (CHCH2O), 97.86 (OCHO), 64.23 
(C(O)CH), 63.67 (CHCH2O), 62.43 (OCH2(CH2)3), 39.57 (CH2), 36.32 (CH2), 
30.72 (CH2), 27.43 (CH2), 26.28 (CH2), 25.50 (CH2), 24.93 (CH3C(O)CH), 19.65 
(CH2), 18.78 (CH3C(O)CH), 16.47 (CH3), 16.14 (CH3); HRMS (ES+, [M + Na]+) 
found 345.2400, C20H34O3Na requires 345.2406. 
(4E,8E)-4,8-Dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dienal 129 
 
A stirring solution of 128 (3.94 g, 12.2 mmol) in THF:dH2O (100 mL, 3:1) was 
cooled to 0 ºC and a solution of periodic acid (3.05 g, 13.4 mmol) and sodium 
periodate (1.3 g, 6.1 mmol) in d.H2O added dropwise over 15 minutes. The 
reaction was stirred at 0 ºC for a further 30 minutes before it was allowed to 
warm to room temperature. After stirring at room temperature for a further 2 h 
the reaction was quenched with sat. NaHCO3 (20 mL) and separated with 
hexane. The aqueous layer was washed with hexane (3 x 10 mL) and the 
combined organic fractions washed with HCl (1 M, 10 mL), brine, dried 
(Na2SO4) and solvent removed under reduced pressure. Purification by flash 
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column chromatography on silica (10% EtOAc in hexane) yielded the title 
compound as a pale yellow oil in 79% yield (2.69 g, 9.6 mmol). 
H (300 MHz, CDCl3) 9.75 (1 H, t, J 1.9, CHO), 5.35 (1 H, t, J 6.4, CHCH2O), 
5.14 (1 H, t, J 6.1, CHCH2CH2), 4.62 (1 H, t, J 3.5, OCHO), 4.13 (2 H, ddd, J 
19.0, 11.8, 6.6, CHCH2O), 3.94 – 3.45 (2 H, m, (CH2)3CH2O), 2.41 (2 H, dt, J 
61.0, 7.7, CHOCH2), 2.19 – 1.97 (6 H, m, 3 x CH2), 1.91 – 1.46 (6 H, m, 
(CH2)3CH2O), 1.66 (3 H, s, CH3), 1.61 (3 H, s, CH3); C (75 MHz, CDCl3) 202.46 
(CHO), 139.72 (CH3CCH), 133.20 (CH3CCH), 124.93 (CCHCH2), 120.81 
(CHCH2O), 97.73 (OCHO), 63.54 (CHCH2O), 62.19 (OCH2(CH2)3), 42.08 
(CHOCH2), 39.33 (CH2), 31.75 (CH2), 30.66 (CH2), 26.08 (CH2), 25.46 (CH2), 
19.58 (CH2), 16.31 (CH3), 16.05 (CH3); HRMS (ES+, [M + Na]+) found 303.1938, 
C17H28O3Na requires 303.1936. 
(4E,8E)-4,8-Dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dien-1-ol 130 
 
A stirring solution of 129 (3.28 g, 11.7 mmol) in methanol (70 mL) was cooled 
to 0 ºC and NaBH4 (660 mg, 17.5 mmol) added and stirred for 2 h. The volume 
of methanol was reduced by 80% in vaccuo and then diluted with water and 
separated with hexane. The aqueous layer was further washed with hexane (3 
x 20 mL) and the combined organic fractions washed with brine, dried 
(Na2SO4) and solvent removed under reduced pressure. Purification by flash 
column chromatography on silica (3% EtOAc in hexane, Rf 0.3) yielded the title 
compound as a clear oil in 69% yield (2.28 g, 8.07 mmol).  
H (300 MHz, CDCl3) 5.35 (1 H, t, J 6.2, CHCH2O), 5.13 (1 H, t, J 6.8, 
CHCH2CH2), 4.62 (1 H, t, J 3.5, OCHO), 4.13 (2 H, ddd, J 19.2, 11.5, 6.5, 
CHCH2O), 3.94 – 3.45 (2 H, m, (CH2)3CH2O), 3.60 (2 H, t, J 6.5, CH2OH), 2.21 – 
2.00 (6 H, m, 3 x CH2), 1.90 – 1.46 (8 H, m, (CH2)3CH2O and CH2CH2OH), 1.66 
(3 H, s, CH3), 1.60 (3 H, s, CH3); C (75 MHz, CDCl3) 140.05 (CH3CCH), 134.91 
(CH3CCH), 124.64 (CCHCH2), 120.92 (CHCH2O), 98.09 (OCHO), 63.90 
(CHCH2O), 62.56 (CH2OH), 62.51 (OCH2(CH2)3), 39.62 (CH2), 35.98 (CH2), 30.81 
(CH2), 30.52 (CH2), 26.12 (CH2), 25.59 (CH2), 19.78  (CH2), 16.42 (CH3), 15.96 





A stirring solution of 130 (508 mg, 1.8 mmol) and triethylamine (1.09 g, 1.5 
mL, 10.8 mmol) in anhydrous THF (35 mL) was cooled to -45 ºC and 
methanesulfonyl chloride (412 mg, 280 L, 3.6 mmol) added and stirred at -45 
ºC for 30 minutes. The reaction was then allowed to warm to room 
temperature, LiBr (1.56 g, 18 mmol) was added and the reaction stirred 
overnight. The reaction was quenched with water and separated with hexane. 
The aqueous layer was further washed with hexane (3 x 10 mL) and the 
combined organic extracts washed with brine, dried (MgSO4) and the solvent 
removed under reduced pressure. Purification by column chromatography on 
silica (7.5% EtOAc in hexane, Rf 0.28) yielded the title compound in 79% yield 
(483 mg, 1.4 mmol).  
H (300 MHz, CDCl3) 5.35 (1 H, t, J 6.9, CHCH2O), 5.15 (1 H, t, J 6.3, 
CHCH2CH2), 4.62 (1 H, t, J 3.5, OCHO), 4.13 (2 H, ddd, J 19.3, 11.9, 6.9, 
OCHO), 3.95 – 3.46 (2 H, m, (CH2)3CH2O), 3.36 (2 H, t, J 6.7, CH2Br), 2.21 – 
2.00 (6 H, m, 3 x CH2), 1.90 – 1.44 (8 H, m, (CH2)3CH2O and CH2CH2Br), 1.67 
(3 H, s, CH3), 1.59 (3 H, s, CH3); C (75 MHz, CDCl3) 140.16 (CH3CCH), 133.42  
(CH3CCH), 125.49  (CCHCH2), 120.86  (CHCH2O), 97.97  (OCHO), 63.78 
(CHCH2O), 62.44  (OCH2(CH2)3), 39.62 (CH2), 37.93 (CH2), 33.61 (CH2Br), 30.96 
(CH2), 30.84 (CH2), 26.31 (CH2), 25.62 (CH2), 19.76 (CH3), 16.52 (CH3), 
15.98(CH2); HRMS (APCI+, [M + Na]+) found 367.1231, C17H29O2BrNa requires 
367.1249. 
((4E,8E)-4,8-Dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dien-1-
yl)triphenylphosphonium bromide 125 
 
A solution of 131 (409 mg, 1.19 mmol) and triphenylphosphine (340 mg, 1.3 
mmol) in anhydrous acetonitrile (30 mL) was heated under reflux under an 
atmosphere of argon for 36 h. The mixture was allowed to cool and the 
acetonitrile removed under vacuum to yield a sticky brown residue. Partial 
purification by trituration with anhydrous diethyl ether yielded the title 
compound as an off-white hygroscopic solid. 
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H (250 MHz, CDCl3) 7.97 – 7.59 (15 H, m, ArH), 5.45 – 5.24 (1 H, m, C=CH), 
5.11 (1 H, t, J 7.0, C=CH), 4.58 (1 H, t, J 3.5, OCHO), 4.32 – 3.81 (2 H, m, 
CCHCH2O), 3.81 – 3.42 (2 H, m, (CH2)3CH2O), 2.29 (2 H, t, J 7.0, Ph3P+CH2), 
2.18 – 1.92 (6 H, m, 3 x CH2), 1.89 – 1.38 (8 H, m, 4 x CH2), 1.64 (3 H, s, CH3), 
1.43 (3 H, s, CH3); P (122 MHz, CDCl3) 29.85; HRMS (ES+, [M]+) found 
527.3071, C35H44O2P requires 527.3079. 
2-(((2E,6E)-12-Fluoro-11-(fluoromethyl)-3,7-dimethyldodeca-2,6,10-trien-1-
yl)oxy)tetrahydro-2H-pyran 132  
 
A stirring solution of 125 (140 mg, 0.23 mmol) in anhydrous THF (20 mL) was 
cooled to -78 ºC and n-BuLi (100 L 2.5 M, 0.25 mmol) added, developing a 
deep yellow colour as the ylide is formed. Difluoroacetone (23 mg, 19 L, 0.25 
mmol) was added dropwise and stirred at -78 ºC for 2 h before being allowed to 
warm to -20 ºC and quenched with water and Et2O (10 mL, 1:1). The aqueous 
layer was separated and further washed with Et2O (3 x 5 mL) and the 
combined ethereal extracts washed with brine, dried (MgSO4) and solvent 
removed under reduced pressure. Purification by column chromatography on 
silica (20% EtOAc in hexane, Rf 0.5) yielded the title compound in 47% yield 
(38 mg, 0.11 mmol). 
H (300 MHz, CDCl3) 5.89 – 5.79 (1 H, m, CH2FCCH), 5.40 – 5.31 (1 H, m, 
CCHCH2OH), 5.16 – 5.09 (1 H, m, CCHCH2), 4.99 (2 H, d, J 47.6, CHCCH2F), 
4.87 (2 H, d, J 47.6, CHCCH2F), 4.62 (1 H, t, J 3.5, OCHO), 4.13 (2 H, ddd, J 
68.0, 11.9, 7.2, CHCH2O), 3.95 – 3.46 (2 H, m, (CH2)3CH2O), 2.42 – 1.96 (6 H, 
m, 2 x CH2CH2), 1.96 – 1.46 (6 H, m, (CH2)3CH2O), 1.69 (3 H, s, CH3), 1.60 (3 
H, s, CH3); C (75 MHz, CDCl3) 140.19 (CH3CCH), 133.89 (CH3CCH), 125.23 
(CCHCH2), 120.80 (CHCH2O), 98.00 (OCHO), 84.91 (d, J 168.0, CH2F), 77.63 
(d, J 156.8, CH2F), 63.80 (CHCH2O), 62.46 (OCH2(CH2)3), 39.62 (CH2), 30.84 
(CH2), 26.34 (CH2), 25.62 (CH2), 19.77 (CH2), 16.56 (CH3), 16.07 (CH3); F (283 
MHz, CDCl3) -211.84 (t, J 47.6), -216.85 (t, J 47.6); HRMS (ES+, [M + Na]+) 





To a stirring solution of 132 (38 mg, 0.11 mmol) in methanol (10 mL) was 
added p-toluenesulfonic acid (cat.) and stirred at room temperature for 2 h. 
The volume of methanol was reduced by 80 % in vaccuo, diluted with sat. 
NaHCO3 and separated with hexane. The aqueous layer was further washed 
with hexane (3 x 5 mL) and the combined organic fractions washed with brine, 
dried (anhydrous MgSO4) and solvent removed under reduced pressure. 
Purification by column chromatography on silica (20% EtOAc in hexane, Rf 
0.29) yielded the title compound in 91% yield (28 mg, 0.10 mmol). 
H (300 MHz, CDCl3) 5.89 – 5.80 (1 H, m, CH2FCCH), 5.45 – 5.37 (1 H, m, 
CCHCH2OH), 5.19 – 5.09 (1 H, m, CCHCH2CH2), 4.99 (2 H, d, J 47.6, CH2F), 
4.87 (2 H, d, J 47.6, CH2F), 4.16 (2 H, d, J 6.9, CH2OH), 2.33 – 1.96 (8 H, m, 2 
x CH2CH2), 1.68 (3 H, s, CH3), 1.60 (3 H, s, CH3); C (75 MHz, CDCl3) 139.69 
(CH3CCH), 133.99 (CH3CCH), 125.11 (CCHCH2CH2), 123.55 (CCHCH2OH), 
84.84 (d J 164.3, CH2F), 77.63 (d, J 168.0, CH2F), 59.53 (CH2OH), 39.51 (CH2), 
38.96 (CH2), 26.31 (CH2), 16.41 (CH3), 16.06 (CH3); δF (283 MHz, CDCl3) -
214.24 (t, J 47.4), -219.22 (t, J 47.4); HRMS (APCI+, [M + Na]+) found 




This compound was prepared and purified from alcohol 112 in the same 
manner as diphosphate 19, to give the title compound as a white solid in 59% 
yield (27.7 mg, 0.059 mmol). 
H (500 MHz, D2O) 6.08 – 5.98 (1 H, m, CH2FCCH), 5.46 (1H, t,  J = 7.3 Hz,  
CCHCH2OH), 5.23 (1 H, t, J = 6.9, CCHCH2CH2), 5.10 (2 H, d, J 47.6, CH2F), 
4.95 (2 H, d, J 47.6, CH2F), 4.47 (2 H, t, J 6.6, CH2OH), 2.40 – 2.03 (8 H, m, 2 
x CH2CH2), 1.72 (3 H, s, CH3), 1.62 (3 H, s, CH3); F (283 MHz, D2O) -207.11 (t, 
J 47.4), -212.67 (t, J 47.5); P (202 MHz, D2O) -6.17 (d, J 19.0), -10.18 (d, J 
21). HRMS (ES-, [M - H]-) found 417.1037, C15H25O7F2P2 requires 417.1044. 
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(2E,6E)-3,7-Dimethyl-11-(methyl-d3)- 2,6,10-Dodecatrien-12,12,12-d3-1-ol  133 
  
A stirring solution of 125 (420 mg, 0.69 mmol) in anhydrous THF (10 mL) was 
cooled to -78 ºC and n-BuLi (280 L, 0.69 mmol) was added dropwise, a bright 
orange colour developed. The solution was allowed to warm to -10 ºC and d6-
acetone (51 L, 0.69 mmol) was added dropwise, the reaction was maintained 
at -10 ºC for 1 h and the colour of the ylid was slowly lost. The reaction was 
allowed to stir for a further hour at room temperature before quenching with 
d.H2O (5 mL) and diluting with methanol (10 mL). A catalytic amount of para-
toluenesulfonic acid was added and stirred vigorously for 30 minutes before 
quenching with NaHCO3 (5 mL). The mixture was separated with Et2O (10 mL) 
and the aqueous layer further washed with Et2O (3 x 5 mL), the combined 
ethereal extracts were washed with water, brine, dried (MgSO4) and solvent 
removed under reduced pressure. Purification by column chromatography on 
silica (20% EtOAc in hexane) yielded the title compound in 41% yield (88 mg, 
0.28 mmol).  
H (300 MHz, CDCl3) 5.42 (1 H, t, J 5.5 Hz, CHCH2O), 5.18 – 5.03 (2 H, m 2 x  
CHCH2CH2), 4.15 (2 H, d, J 7.0 Hz, CHCH2O), 2.26 – 1.91 (8 H, m, 2 x 
CH(CH2)2), 1.68 (3 H, s, CH3), 1.60 (3H, s, CH3); C (151 MHz, CDCl3) 140.02, 
135.54 & 128.38 (CH3CCH), 124.50 & 123.92 (CH3CCH), 123.50 (CHCH2O), 
59.59 (CHCH2O), 39.86, 39.70, 26.86 & 26.46(CHCH2CH2), 16.44 & 16.16 
(CH3); HRMS (EI+, [M]+) found 228.2354, C151H202H6O requires 228.2360. 
Acetoxyacetone 136 
 
A solution of hydroxyacetone (500 mg, 6.75 mmol) and acetic anhydride (1.5 
mL, 1.62 g, 15.9 mmol) in pyridine (3 mL) was stirred for 16 h, before it was 
diluted with dichloromethane and acetone (20 mL, 1:1), washed with water (20 
mL) and separated. The aqueous layer was further washed with DCM (3 x 10 
mL) and the combined organic extracts washed with sat. CuSO4 (20 mL), 
NaHCO3 (3 x 10 mL), brine, dried (Na2SO4) and solvent removed under reduced 
pressure. Purification by column chromatography on silica (30% EtOAc in 
hexane, Rf 0.34) yielded the title compound in 89% yield (700 mg, 6.03 mmol). 
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H (300 MHz, CDCl3) 4.65 (2 H, s, C(O)CH2O), 2.17 (3 H, s, CH3), 2.16 (3 H, s, 
CH3); C (75 MHz, CDCl3) 201.70 (CH3C(O)O), 170.39 (C(O)CH2), 68.44 
(C(O)CH2O), 26.22 (CH3), 20.64 (CH3); HRMS (EI+, [M]+) found 116.0472, 
C5H8O3 requires 116.0473. 
(E)-(3-(4,8-Dimethylnona-3,7-dien-1-yl)-3-methyloxiran-2-yl)methanol 137 
 
A stirring solution of farnesol (253 mg, 1.14 mmol) in anhydrous toluene (10 
mL) was cooled to 10 ºC and a catalytic amount of vanadyl acetoacetate added, 
and the solution turned a pale brown. Tert-butyl hydroperoxide (230 L, 1.25 
mmol, ~5.5 M in decanes) was added dropwise over 10 minutes, at which the 
solution turned a deep red. The reaction was stirred at 10 ºC for 1 h 45, over 
which time the colour faded to a pale yellow, and was quenched with 
NaOH/Brine (10 mL, 1:1) stirred for 10 minutes and separated. The aqueous 
layer was washed with EtOAc (3 x 10 mL) and the combined organic extracts 
washed with brine, dried (MgSO4) and solvent removed under vacuum. 
Purification on a silica plug (20% EtOAc in hexane, Rf 0.2) yielded the title 
compound in 95% yield (257 mg, 1.08 mmol).  
H (300 MHz, CDCl3) 5.09 (2 H, dt, J 6.7, 5.7), 3.89 – 3.63 (2 H, m), 2.98 (1 H, 
dd, J 6.6, 4.3), 2.21 – 1.89 (6 H, m), 1.67 (3 H, s), 1.60 (6 H, s), 1.80 – 1.39 (2 
H, m, J 16.5, 13.7, 8.0), 1.30 (3 H, s); C (75 MHz, CDCl3) 135.97, 131.63, 
124.33, 123.33, 62.99, 61.62, 61.33, 39.79, 38.65, 26.76, 25.84, 23.74, 17.84, 
16.93, 16.13. HRMS (ES-, [M – H2O - H]-) found 219.1752, C15H23O requires 
219.1749. 
(E)-3-Methyl-5-(3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)pent-2-en-1-yl acetate 143 
& (2E,6E)-9-(3,3-dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-yl acetate 142   
 
A stirring solution of farnesyl acetate (608 mg, 2.3 mmol) in DCM (40 mL) was 
cooled to 0 ºC and 3-chloroperbenzoic acid (430 mg, 2.5 mmol) added. The 
solution was allowed to warm to room temperature and stirred for 1 h, before 
quenching with NaOH (20 mL, 2.5 M) and diluting with d.H2O. The DCM was 
separated and the aqueous layer further washed with DCM (3 x 5 mL), and the 
combined organic extracts washed with brine, dried (MgSO4) and solvent 
removed under reduced pressure. Purification by flash column 
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chromatography on silica (5% EtOAc in hexane) yielded the mixed mono-
epoxides in 75% yield (477 mg, 1.7 mmol) along with recovered starting 
material (13%, 80 mg, 0.3 mmol) and diepoxide (<5%). 
H (300 MHz, CDCl3) 5.47 – 5.28 (1 H, m, CCHCH2), 5.14 (0.58 H, t, J 6.3, 
CCHCH2), 5.07 (0.42 H, t, J 7.2, (CH3)2CCH), 4.58 (2 H, d, J 7.1, CCHCH2O), 
2.70 (1 H, t, J 6.3, C(O)CH), 2.05 (3 H, s, J 0.6, OC(O)CH3). 
(E)-3-Methyl-5-(3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)pent-2-en-1-ol 138 & 
(2E,6E)-9-(3,3-dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-ol 139 
 
To a stirring slurry of K2CO3 (470 mg, 3.4 mmol) in methanol (10 mL) was 
added mixed epoxides (DG021, 1.7 mmol) and stirred for 1 h at room 
temperature. The reaction was concentrated by 80 % under reduced pressure, 
diluted with d.H2O (10 mL) and separated with hexane (10 mL). The aqueous 
layer was further washed with hexane (3 x 5 mL) and the combined organic 
extracts washed with brine, dried (MgSO4) and solvent removed under reduced 
pressure. Purification by automated chromatography (Biotage® Isolera Four) on 
silica (100 g Biotage® SNAP-Ultra cartridge) using Et2O in hexane (10 – 50% 
over 10 CV, 50 – 80% over 10 CV) yielded the purified title compounds in 21% 
(0.37 mmol) and 33% (0.55 mmol) yields respectively as well as recovering 20% 
mixed epoxides (80 mg, 0.34 mmol). 
(E)-3-Methyl-5-(3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl)pent-2-en-1-ol) 138 
 
H (300 MHz, CDCl3) 5.49 – 5.40 (1 H, m, CCHCH2OH), 5.11 – 5.00 (1 H, m, 
(CH3)2CCH), 4.15 (2 H, d, J 6.8, CCHCH2OH), 2.70 (1 H, t, J 6.2, C(O)CH), 2.30 
– 1.99 (4 H, m, 2 x CH2), 1.69 (3 H, s, CH3), 1.67 (3 H, s, CH3), 1.60 (3 H, s, 
CH3), 1.67 – 1.28 (4 H, m, 2 x CH2), 1.25 (3 H, s, CH3); C (75 MHz, CDCl3) 
138.87 (CH3CCH), 132.05 (CH3CCH), 123.96 (CCHCH2OH), 123.74 
((CH3)2CCH), 63.37 (C(O)CH), 60.95 (CH3C(O)CH), 59.41 (CCHCH2OH), 38.89 
(CH2), 36.32 (CH2), 27.14 (CH2), 25.84 (CH3), 23.99 (CH2), 17.80 (CH3), 16.62 






In addition to the method described above, this compound was also prepared 
by treatment of bromohydrin 170 (327 mg, 0.91 mmol) with K2CO3 (248 mg, 
1.8 mmol) in methanol in the same manner as for 128. Purification by flash 
column chromatography on a silica plug (30% EtOAc in hexane) yielded the 
pure product in 91% yield (198 mg, 0.83 mmol)  
H (300 MHz, CDCl3) 5.45 – 5.35 (1 H, m, CCHCH2OH), 5.23 – 5.09 (1 H, m, 
CCHCH2CH2), 4.14 (2 H, d, J 6.8, CCHCH2OH), 2.70 (1 H, t, J 6.2, C(O)CH), 
2.20 – 1.98 (6 H, m, 3 x CH2), 1.67 (3 H, s, CH3), 1.72 – 1.57 (2 H, m, CH2), 
1.61 (3 H, s, CH3), 1.30 (3 H, s, CH3), 1.25 (3 H, s, CH3); C (75 MHz, CDCl3) 
139.51(CH3CCH), 134.47 (CH3CCH), 124.64 (CCHCH2CH2), 123.70 
(CCHCH2OH), 64.31 (C(O)CH), 59.47 (CCHCH2OH), 58.57 (C(O)CH), 39.51 
(CH2), 36.45 (CH2), 27.36 (CH2), 26.23 (CH2), 25.00 (CH3), 18.91 (CH3), 16.36 





To stirring solution of farnesyl acetate (200 mg, 0.9 mmol) in dichloromethane 
(20 mL) at 0 ºC was added mCPBA (520 mg, 2.25 mmol) and stirred for 1 h. 
The reaction was quenched with NaOH (10 mL, 1 M) and stirred for 5 minutes 
before the aqueous layer was separated and washed with DCM (3 x 5 mL). The 
combined organic fractions were washed with brine, dried (MgSO4) and solvent 
removed under reduced pressure. The resulting residue was taken up in MeOH 
(20 mL), K2CO3 (250 mg, 0.8 mmol) added and the resulting slurry stirred for 1 
h. The volume of MeOH was reduced by 80 % and the remaining solution 
diluted with H2O/EtOAc (20 mL, 1:1) and separated. The aqueous layer was 
washed with EtOAc (3 x 10 mL) and the combined organic fractions washed 
with HCl (10 mL, 1 M), brine, dried (MgSO4) and solvent removed under 
reduced pressure. Purification on a silica plug (40% EtOAc in hexane, Rf 0.3, 




H (300 MHz, CDCl3) 5.53 – 5.39 (1 H, m, CCHCH2OH), 4.16 (2 H, d, J 7.0, 
CCHCH2OH), 2.78 – 2.67 (2 H, m, 2 x C(O)CH), 2.31 – 2.07 (2 H, m, CH2), 1.69 
(3 H, s, CH3), 1.83 – 1.54 (6 H, m, 3 x CH2), 1.31 (3 H, s, CH3), 1.28 (3 H, s, 
CH3), 1.26 (3 H, s, CH3); C (75 MHz, CDCl3) 138.78 (CCHCH2OH), 124.21 
(CCHCH2OH), 64.16 & 62.84 (C(O)CH), 59.44 (CCHCH2OH), 35.33, 27.02, 
24.98, 24.91 (CH2), 24.70, 18.79, 16.89 & 16.40 (CH3); HRMS (APCI+, [M + 




Bis-triethylammonium phosphate (TEAP) was prepared immediately prior to 
use by the dropwise addition of a solution of phosphoric acid in acetonitrile to 
a stirring solution of triethylamine in acetonitrile. TEAP was then added in 
three portions (3 x 1 mL) at 5 minute intervals to a solution of 137 (150 mg, 
0.63 mmol) in trichloroacetonitrile (1 mL) at 37 ºC. The reaction was incubated 
at 37 ºC for a further 5 minutes after the final addition and the entire reaction 
mixture applied to a silica column and washed onto the column with 
isopropanol. The mobile phase (isopropanol : conc. NH4OH : H2O, 6 : 2.5 : 0.5) 
was then begun and fractions collected and analysed by TLC (isopropanol : 
conc. NH4OH : H2O, 6 : 3 : 1, visualised with basic KMnO4), and those 
containing the diphosphate (Rf 0.26) were combined, ammonia and isopropanol 
removed under vacuum and the resulting aqueous solution diluted to 60 mL 
with 25 mM NH4HCO3 and lyophilised to yield the title compound as a light 
fluffy powder in 46 % yield (129 mg, 0.29 mmol). 
H (500 MHz, D2O) 5.15 – 5.07 (2 H, m, 2 x C=CH), 4.25 – 3.78 (2 H, m, 
C(O)CHCH2O), 3.21 (1 H, dd, J 7.5, 3.5, C(O)CHCH2O), 2.10 – 1.89 (6 H, m, 3 x 
CH2), 1.59 (3 H, s, CH3), 1.54 (3 H, s, CH3), 1.53 (3 H, s, CH3), 1.27 (3 H, s, 
CH3); C (126 MHz, D2O) 136.90 (C=C), 133.53 (C=C), 124.50 (C=CH), 123.71 
(C=CH), 64.47 (C(O)CHCH2O), 63.77 (C(O)CHCH2O), 38.84 (CH2), 37.67 (CH2), 
25.84 (CH2), 24.89 (CH3), 23.02 (CH2), 17.02 (CH3), 15.72 (CH3), 15.23 (CH3); P 
(202 MHz, D2O) -6.24, -10.32; HRMS (ES-, [M – H]-) found 397.1179, 




trisammonium diphosphate 146 
 
This compound was prepared and purified from alcohol 138 (42 mg, 0.18 
mmol) in the same manner as diphosphate 19, to give the title compound as a 
white solid in 58% yield (46 mg, 0.10 mmol). 
H (300 MHz, D2O) 5.49 – 5.40 (1 H, m, CCHCH2OH), 5.15 – 5.08 (1 H, m, 
CCHCH2CH2), 4.46 – 4.36 (2 H, m, CCHCH2OH), 3.00 – 2.93 (1 H, m, C(O)CH), 
2.21 – 2.00 (6 H, m, 3 x CH2), 1.67 (3 H, s, CH3), 1.63 (3 H, s, CH3), 1.57 (3 H, 
s, CH3), 1.25 (3 H, s, CH3); P (202 MHz, D2O) -6.48 (d, J 20.8), -10.27 (d, J 




This compound was prepared and purified from alcohol 139 (65 mg, 0.28 
mmol) in the same manner as diphosphate 19, to give the title compound as a 
white solid in 66% yield (81 mg, 0.18 mmol). 
H (300 MHz, D2O) 5.29 (1 H, t, J 7.0, CCHCH2OH), 5.10 (1 H, t, J 6.0, 
CCHCH2CH2), 4.29 (2 H, t, J 6.5, CCHCH2OH), 2.84 (1 H, t, J 6.5, C(O)CH), 
2.06 – 1.88 (6 H, m, 3 x CH2), 1.60 – 1.49 (2 H, m, CH2), 1.54 (3 H, s, CH3), 
1.48 (3 H, s, CH3), 1.14 (3 H, s, CH3), 1.12 (3 H, s, CH3). P (122 MHz, D2O) -
6.14, -9.83. HRMS (ES-, [M – H]-) found 397.1174, C15H27O8P2 requires 
397.1181. 
 (E)-5-(3-(2-(3,3-Dimethyloxiran-2-yl)ethyl)-3-methyloxiran-2-yl)-3-methylpent-2-en-1-yl 




This compound was prepared and purified from alcohol 140 (100 mg, 0.4 
mmol) in the same manner as diphosphate 137, to give the title compound as 
a white solid in 30% yield (55 mg, 0.12 mmol). 
H (500 MHz, D2O) 5.42 (1 H, t, J 6.5, CCHCH2O), 4.40 (2 H, t, J 6.0, 
CCHCH2O), 3.02 – 2.89 (2 H, m, 2 x C(O)CH), 2.14 (1 H, t, J 7.5, CH2), 1.65 (3 
H, s, CH3), 1.77 – 1.53 (6 H, m, 3 x CH2), 1.25 (3 H, s, CH3), 1.24 (6 H, s, 2 x 
CH3); P (202 MHz, D2O) -10.55. HRMS (ES-, [M – H]-) found 413.1126, 




A solution of 128 (390 mg, 1.2 mmol) and aluminium isopropoxide (450 mg, 
2.4 mmol) in anhydrous toluene (10 mL) was heated to 140 ºC in a sealed tube 
for 16 h. After being allowed to cool HCl:EtOAc (5 mL, 1:1, 1 M HCl) was added 
and stirred for 1 h. The mixture was separated and the aqueous layer washed 
with EtOAc (3 x 5 mL) and the combined organic extracts washed with brine, 
dried (MgSO4) and solvent removed under reduced pressure. Purification by 
column chromatography on silica (20% EtOAc in hexane, Rf 0.32) yielded the 
title compound in 65% yield (253 mg, 0.78 mmol). 
H (300 MHz, CDCl3) 5.42 – 5.28 (1 H, m, CCHCH2O), 5.15 (1 H, t, J 6.5, 
CCH(CH2)2), 4.94 (1 H, dd, J 1.5, 1.0, CHH=C(CH3)CHOH), 4.82 (1 H, dd, J 3.0, 
1.5, CHH=C(CH3)CHOH), 4.67 – 4.57 (1 H, m, OCHO), 4.31 – 3.95 (3 H, m, 
CCHCH2O & C=CCHOH), 3.95 – 3.44 (2 H, m, (CH2)3CH2O), 2.08 (6 H, m, 3 x 
CH2), 1.72 (3 H, s, CH3), 1.89 – 1.45 (9 H, m, ), 1.67 (3 H, s, CH3), 1.61 (3 H, s, 
CH3); C 147.62, 139.89 (C=C), 134.88 (C=C), 124.52 (CCHCH2), 120.86 
(CCHCH2), 97.84 (C=CCHOH), 63.71 (CCHCH2O), 62.30 (OCHO), 39.53, 35.66, 
33.09, 30.66, 26.12, 26.07, 25.50 & 19.58 (CH2), 17.61, 16.30 & 15.95 (CH3); 
HRMS (APCI+, [M + Na]+) found 345.2401, C20H34O3Na requires 345.2406. 
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(6E,10E)-12-Hydroxy-2,6,10-trimethyldodeca-1,6,10-trien-3-yl acetate 167 
 
To a stirring solution of 128 (253 mg, 0.78 mmol) in DCM (5 mL) was added 
acetic anhydride (0.408 g, 0.38 mL, 4 mmol) and pyridine (0.316 g, 0.32 mL, 4 
mmol) and stirred at room temperature for 3 days until judged complete by 
TLC. The reaction was diluted with hexane and separated with water. The 
aqueous layer was further washed with hexane and the combined organic 
fractions dried (anhydrous MgSO4) and solvent removed under reduced 
pressure. The resulting oil was taken up in methanol and a catalytic amount of 
p-toluenesulfonic acid added and stirred at room temperature for 1h. The 
reaction was quenched with NaHCO3 and separated with hexane, the aqueous 
layer was further washed with hexane and the combined organic extracts 
washed with brine, dried (anhydrous MgSO4) and solvent removed under 
reduced pressure. Purification by flash column chromatography on silica (30% 
EtOAc in hexane, Rf 0.3) yielded the title compound as a yellow oil in a 65% 
yield (142 mg, 0.51 mmol) over two steps. 
H (300 MHz, CDCl3) 5.46 – 5.35 (1 H, m, CCHCH2O), 5.18 – 5.04 (2 H, m, 
CCH(CH2)2 & C=CCHOAc), 4.99 – 4.91 (1 H, m, CHH=C(CH3)CHOH), 4.91 – 
4.86 (1 H, m, CHH=C(CH3)CHOH), 4.15 (2 H, d, J 7.0, CCHCH2O), 2.06 (3 H, s, 
CH3C(O)O), 2.18 – 1.87 (6 H, m, 3 x CH2), 1.82 – 1.62 (2 H, m, CH2), 1.71 (3 H, 
s, CH3), 1.67 (3 H, s, CH3), 1.60 (3 H, s, CH3); C (75 MHz, CDCl3) 170.64 
(CH3C(O)), 143.23 (C=C), 139.41 (C=C), 134.29 (C=C), 124.69 (CCH(CH2)), 
123.75 (CCHCH2OH), 112.98 (CHH=C(CH3)CHOH), 77.10 (C=CCHOAc), 59.55 
(CCHCH2OH), 39.45, 35.34, 30.88 & 26.18 (CH2), 21.40 (CH3C(O)), 18.19, 
16.38 & 16.13 (CH3); HRMS (APCI+, [M + Na]+) found 303.1925, C17H28O3Na 
requires 303.1936. 
(2E,6E)-10-Acetoxy-3,7,11-trimethyldodeca-2,6,11-trien-1-yl trisammonium diphosphate 
169 
 
This compound was prepared and purified from alcohol 167 (79 mg, 0.26 
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mmol) in the same manner as diphosphate 19, to give the title compound as a 
white solid in 74% yield (93 mg, 0.19 mmol). 
H (300 MHz, D2O) 5.31 (1 H, t, J 7.5, CCHCH2O), 5.05 (1 H, t, J 7.0, 
CCH(CH2)2), 4.89 (1 H, t, J 6.5, CHOAc), 4.79 (2 H, bs, (CH3)C=CHH), 4.31 (2 
H, t, J 6.5, CCHCH2O), 1.97 (3 H, s, CH3), 2.09 – 1.84 (8 H, m, 4 x CH2), 1.71 – 
1.59 (2 H, m, CH2), 1.56 (6 H, s, 2 x CH3), 1.47 (3 H, s, CH3); P (202 MHz, D2O) -
6.53 (d, J 22.0), -10.25 (d, J 22.0).; HRMS (ES-, [M – H]-) found 439.1298, 
C17H29O9P2 requires 439.1287. 
(2E,6E)-10-Hydroxy-3,7,11-trimethyldodeca-2,6,11-trien-1-yl trisammonium   
diphosphate 162 
 
To a stirring solution of 163 (108 mg, 0.45 mmol) and trimethylamine (367 mg, 
500 L, 0.9 mmol) in THF (10 mL) was added para-Toluenesulfonyl chloride 
(86 mg, 0.45 mmol) and the reaction left to stir in darkness for 16 h before it 
was quenched with d.H2O and separated with Et2O. The aqueous layer was 
further washed with Et2O and the combined ethereal extracts washed with 
CuSO4, NaHCO3, and brine, dried (MgSO4) and solvent removed under reduced 
pressure. The tosylate was dried under high-vaccuum for 2 h before being 
used without further purification 
 The tosylate intermediate was treated with tris(tetrabutylammonium)hydrogen 
diphosphate (1.53 mmol, 1.38 g) in anhydrous acetonitrile, and further treated 
and purified in the same manner as diphosphate 19 to yield the title 
compound as a white powder in 54% yield (95 mg, 0.24 mmol). 
This compound was also prepared by treatment of 169 (50 mg, 0.10 mmol) 
with NH4OH (1 mM) in D2O (3 mL), and followed by 1H-NMR of a 500 L 
sample at 12 hourly intervals. Upon complete disappearance of the acetate 
signal (2.1 ppm, 36 h) the reaction was diluted with d.H2O and lyophilised to 
yield the title compound as a white powder in 90% yield (41 mg, 0.09 mmol). 
H (300 MHz, D2O) 5.32 (1 H, t, J 6.5, CCHCH2O), 5.09 (1 H, t, J 6.0, 
CCH(CH2)2), 4.79 (1 H, s, CHH=C(CH3)CHOH), 4.76 (1 H, s, 
CHH=C(CH3)CHOH), 4.33 (2 H, t, J 6.5, CCHCH2O), 3.93 (1 H, t, J 7.0, 
C=CCHOH), 2.09 – 1.80 (6 H, m, 3 x CH2), 1.60 – 1.48 (2 H, m, CH2), 1.58 (3 H, 
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s, CH3), 1.55 (3 H, s, CH3), 1.49 (3 H, s, CH3); P (202 MHz, D2O) -8.93, -10.35. 
HRMS (ES-, [M – H]-) found 397.1193, C15H27O8P2 requires 397.1181. 
(2E,6E)-3,7,11-Trimethyldodeca-2,6,11-triene-1,10-diol 163 
 
This compound was prepared from alcohol 139 (113 mg, 0.48 mmol) in the 
same manner as 165. Purification by column chromatography on silica (40% 
EtOAc in hexane) yielded the title compound in 65% yield (74 mg, 0.31 mmol). 
H (300 MHz, CDCl3) 5.49 – 5.33 (1 H, m, CCHCH2O), 5.24 – 5.10 (1 H, m, 
CCH(CH2)2), 4.97 – 4.88 (1 H, m, CHH=C(CH3)CHOH), 4.89 – 4.79 (1 H, m, 
CHH=C(CH3)CHOH), 4.13 (2 H, d, J 7.0, CCHCH2O), 4.04 (1 H, dd, J 7.5, 5.0, 
C=CCHOH), 2.24 – 2.00 (6 H, m, 3 x CH2), 1.72 (3 H, s, CH3), 1.66 (3 H, s, 
CH3), 1.69 – 1.60 (2 H, m, CH2), 1.63 (3 H, s, CH3); C (151 MHz, CDCl3) 147.59 
(C=C), 139.24 (C=C), 135.53 (C=C), 124.92 (CCH(CH2)), 124.16 (CCHCH2OH), 
110.96 (CHH=C(CH3)CHOH), 75.71(C=CCHOH), 59.51 (CCHCH2OH), 39.50, 
36.08, 32.89 & 25.99 (CH2), 17.97, 16.14 & 16.04 (CH3; HRMS (ES-, [M – H2O 
- H]-) found 219.1747, C15H23O requires 219.1749. 
 (2E,6E)-11-Bromo-10-hydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl acetate 170 
 
This compound was prepared from farnesyl acetate (1.5 g, 5.7 mmol) in the 
same manner as 127. Purification by column chromatography on silica (15% 
EtOAc in hexane, Rf 0.3 in 20%) yielded the title compound as a clear oil in 
56% yield (1.15 g, 3.2 mmol). 
H (300 MHz, CDCl3) 5.40 – 5.29 (1 H, m, CCHCH2O), 5.19 (1 H, t, J 6.0, 
CCH(CH2)2), 4.59 (2 H, d, J 7.0, CCHCH2O), 3.97 (1 H, dd, J 11.0, 2.0, 
CBrCHOH), 2.41 – 1.90 (8 H, m, 4 x CH2), 2.06 (3 H, s, CH3C(O)), 1.71 (3 H, s, 
CH3), 1.59 (3 H, s, CH3), 1.35 (3 H, s, CBrCH3), 1.33 (3 H, s, CBrCH3); C (151 
MHz, CDCl3) 171.30 (C(O)CH3), 142.10 (C=CH), 133.72 (C=CH), 125.52 (C=CH), 
118.64 (C=CHCH2O), 70.90 (CHOH), 61.56 (C=CHCH2O), 39.52, 38.28, 32.20 & 
26.74 (CH2), 26.29 & 26.03 (CBr(CH3)2), 21.21 (C(O)CH3), 16.61 & 16.00 




((2E,6E)-10-Hydroxy-3,7-dimethyldeca-2,6-dien-1-yl tris(tetrabutylammonium)  
diphosphate 172 
 
This compound was prepared from diphosphate 174 (52 mg, 0.046 mmol) by 
treatment with NH4OH (1 mM) in D2O (2 mL), and followed by 1H-NMR of a 500 
L sample at 12 hourly intervals. Upon complete disappearance of the acetate 
signal (~2.1 ppm, 24 h) the reaction was diluted with d.H2O and lyophilised to 
yield the title compound as an off-white powder in 96% yield (48 mg, 0.044 
mmol). 
H (500 MHz, D2O) 5.40 (1 H, t, J 6.5, CCHCH2O), 5.17 (1 H, t, J 7.0, 
CCH(CH2)2), 4.44 (2 H, s, CCHCH2O), 3.51 (2 H, t, J 6.5, (CH2)2CH2OH), 3.23 – 
3.04 (24 H, m, 12 x N+CH2(CH2)2CH3), 2.20 – 2.02 (4 H, m, 2 x CH2), 1.99 (2 H, 
t, J 7.5, CH2(CH2)2OH), 1.86 (3 H, s, CH3), 1.66 (3 H, s, CH3), 1.64 – 1.51 (26 H, 
m, 12 x N+CH2CH2CH2CH3 & CH2), 1.37 – 1.23 (24 H, m, 12 x N+(CH2)2CH2CH3), 
0.89 (36 H, t, J 7.5, 12 x N+(CH2)3CH3); P (202 MHz, D2O) -8.33, -8.64; HRMS 
(ES-, [M – H]-) found 357.0867, C12H23O8P2 requires 357.0868. 
4E,8E)-10-Hydroxy-4,8-dimethyldeca-4,8-dien-1-yl acetate 173 
 
A solution of alcohol 130 (170 mg, 0.6 mmol) in pyridine (2 mL) and acetic 
anhydride (1 mL) was allowed to stir at room temperature for 16 h before being 
diluted with hexane/H2O (10 mL, 1:1) and separated. The aqueous layer was 
further washed with hexane (5 x 5 mL) and the combined organic fractions 
washed with CuSO4 (10 mL), NaHCO3 (3x 10 mL), brine, dried (MgSO4) and 
solvent removed under reduced pressure. 
The resulting residue was then taken up in MeOH (10 mL) and a catalytic 
amount of para-toluenesulfonic acid was added, the reaction stirred for 1 h 
and then quenched with NaHCO3 (1 mL). The MeOH was removed under 
reduced pressure, the aqueous layer diluted with H2O/Et2O (10 mL, 1:1) and 
separated. The aqueous layer was further washed with Et2O (3 x 5 mL) and the 
combined ethereal extracts washed with brine, dried (MgSO4) and the solvent 
removed. Purification by column chromatography on silica (20 % EtOAc in 
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hexane) yielded the title compound in 61 % yield over two steps (88 mg, 0.37 
mmol). 
H (300 MHz, CDCl3) 5.44 – 5.36 (1 H, m, CCHCH2OH), 5.15 – 5.07 (1 H, m, 
CCH(CH2)2), 4.15 (2 H, bd, J 6.5, CCHCH2OH), 4.02 (2 H, t, J 6.8, AcOCH2), 
2.18 – 1.99 (6 H, m, 3 x CH2), 2.05 (3 H, s, CH3C(O)), 1.78 – 1.67 (2 H, m, CH2), 
1.67 (3 H, s, CH3), 1.60 (3 H, s, CH3); C (75 MHz, CDCl3) 139.35 (C=C), 134.10 
(C=C), 124.87 (CCH(CH2)2, 123.85 (CCHCH2OH), 64.28 (AcOCH2), 59.55 
(CCHCH2OH), 39.49, 35.79, 26.64 & 26.17 (CH2), 21.17 (CH3C(O)), 16.33 & 
15.97 (CH3); HRMS (ES+, [M]+) found 198.1619, C12H22O2 requires 198.1620. 
(2E,6E)-10-Acetoxy-3,7-dimethyldeca-2,6-dien-1-yl tris(tetrabutylammonium)  
diphosphate 174 
 
A solution of tetrabutyl dihydogen phosphate (250 mg, 0.74 mmol) in 
acetonitrile (1 mL) was added in three portions (3 x 1 mL) at 5 minute intervals 
to a solution of 173 (78 mg, 0.32 mmol) in trichloroacetonitrile (0.5 mL) at 37 
ºC. The reaction was incubated at 37 ºC for a further 5 minutes after the final 
addition and the entire reaction mixture applied to a silica column and washed 
onto the column with isopropanol. The mobile phase (isopropanol : conc. 
NH4OH : H2O, 6 : 2.5 : 0.5) was then begun and fractions collected and 
analysed by TLC (isopropanol : conc. NH4OH : H2O, 6 : 3 : 1, visualised with 
basic KMnO4), and those containing the diphosphate (Rf 0.26) were combined, 
ammonia and isopropanol removed under vacuum and the resulting aqueous 
solution diluted to 60 mL with 25 mM NH4HCO3 and lyophilised to yield the 
title compound as an off-white powder in 31% yield (111 mg, 0.10 mmol). 
H (500 MHz, D2O) 5.47 (1 H, bs, CCHCH2O), 5.23 (1 H, t, J 6.5, CCH(CH2)2), 
4.50 (2 H, s, CCHCH2O), 4.07 (2 H, t, J 6.5, AcOCH2), 3.25 – 3.13 (24 H, m, 12 
x N+CH2(CH2)2CH3), 2.25 – 2.02 (6 H, m, 3 x CH2), 2.09 (3 H, s, CH3C(O)), 1.80 
– 1.73 (2 H, m, CH2), 1.73 (3 H, s, CH3), 1.71 – 1.60 (27 H, m, 12 x 
N+CH2CH2CH2CH3 & CH3), 1.41 – 1.31 (24 H, m, 12 x N+(CH2)2CH2CH3), 0.94 
(36 H, t, J 7.5, 12 x N+(CH2)3CH3); C (126 MHz, D2O) 124.92 (CCH(CH2)2), 124.91 
(CCHCH2OH), 65.13 (AcOCH2), 62.64 (CCHCH2OH), 58.19 (N+CH2(CH2)2CH3), 
35.15, 26.56 & 25.66 (CH2), 23.19 (N+CH2CH2CH2CH3), 20.47 (CH3C(O)), 19.18 
196 
 
(N+(CH2)2CH2CH3), 12.86 (N+(CH2)3CH3); P (202 MHz, D2O) -6.00, -10.95; HRMS 
(ES-, [M – H]-) found 399.0988, C14H25O9P2 requires 399.0974. 
7-Methyl-3-methyleneoct-6-en-1-ol 183 
 
A stirring solution of TMEDA (6.5 g, 8.4 mL, 56 mmol) in anhydrous Et2O (8 
mL) was cooled to -5 ºC and n-BuLi (16 mL, 2.5 M in hexane, 40 mmol) was 
added dropwise and stirred for 1 hour at room temperature. The mixture was 
then cooled to 0 ºC and 3-methylbut-3-en-1-ol (1.7 g, 2.0 mL, 20 mmol) added 
slowly over 30 minutes. After complete addition of the alcohol the mixture was 
allowed to warm to room temperature and stirred for a further 6 hours, before 
cooling to -78 ºC and a room temperature solution of 3,3-dimethylallyl bromide 
(2.2 g, 1.7 mL, 15 mmol) in THF (5 mL) added by syringe driver over 50 
minutes. The reaction was stirred at -78 ºC and allowed to warm slowly to 
room temperature overnight before quenching with saturated NH4Cl (20 mL). 
The organic layer was separated and the aqueous layer further washed with 
Et2O (3 x 15 mL) and the combined ethereal extracts washed with brine and 
dried (MgSO4) before the solvent was removed under reduced pressure. 
Purification by flash column chromatography on silica (10 % EtOAc in hexane) 
gave the title compound as a pale yellow oil in 63 % yield (1.46 g, 9.5 mmol). 
H (300 MHz, CDCl3) 5.16 – 5.03 (1 H, m, (CH3)2CCH), 4.88 (1 H, s, C=CHH), 
4.83 (1 H, s, C=CHH), 3.71 (2 H, t, J 6.3, CH2OH), 2.30 (2 H, t, J 6.3, 
CH2CH2OH), 2.21 – 1.99 (4 H, m, 2 x CH2), 1.68 (3 H, s, CH3), 1.61 (3 H, s, 
CH3); C (75 MHz, CDCl3) 145.98, 132.09, 123.90 ((CH3)2CCH), 111.89 
(C=CHH), 60.42 (CH2OH), 39.41 (CH2CH2OH), 35.84 (CH2), 26.45 (CH2), 25.84 




To a stirring solution of prenol (5 g, 58 mmol) and 3,4-dihydropyran (9.8 g, 11 
mL, 116 mmol) in DCM (150 mL) was added a catalytic amount of PPTS (1 mol 
%) and stirred at room temperature for 1 h, before d.H2O (50 mL) was added 
and the mixture separated. The aqueous layer was further washed with DCM 
(3 x 20 mL) and the combined organic extracts washed with brine, dried 
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(MgSO4) and sovent removed under reduced pressure. Purification by column 
chromatography on silica (10% EtOAc in hexane) yielded the title compound as 
a clear oil in 98% yield (56.7 mmol). 
H (300 MHz, CDCl3) 5.43 – 5.27 (1 H, m, CCHCH2), 4.71 – 4.55 (1 H, m, 
OCHO), 4.10 (2 H, ddd, J 73.1, 11.7, 7.2, CCHCH2O), 3.95 – 3.42 (2 H, m, 
(CH2)3CH2O), 1.90 – 1.44 (6 H, m, 3 x CH2), 1.75 (3 H, s, CH3), 1.69 (3 H, s, 
CH3); C (75 MHz, CDCl3) 137.37 (CH3CCH), 120.91 (CCHCH2), 98.04 (OCHO), 
63.81 (CCHCH2O), 62.43 ((CH2)3CH2O), 30.83 (CH2), 26.03 (CH3), 25.62 (CH2), 




A stirring solution of 183 (600 mg, 3.9 mmol) and Et3N (2.36 g, 3.25 mL, 23 
mmol) in anhydrous THF (50 mL) was cooled to -10 ºC and methanesulfonyl 
chloride (893 mg, 603 μL, 7.8 mmol) added dropwise over 5 minutes. The 
reaction was stirred for a further 30 minutes before lithium bromide (3.4 g, 39 
mmol) was added and the reaction allowed to warm to room temperature and 
stirred for a further 20 h. The reaction was quenched with d.H2O (15 mL) and 
separated with Et2O (10 mL). The aqueous layer was further washed with Et2O 
(3 x 10 mL) and the combined organic extracts washed with brine, dried 
(MgSO4) and the solvent removed under reduced pressure. Purification by 
column chromatography on silica (5% EtOAc in hexane) yielded the title 
compound in 72% yield (605 mg, 2.79 mmol). 
H (300 MHz, CDCl3) 5.23 – 5.04 (1 H, m, (CH3)2CCH), 4.91 – 4.85 (1 H, m, C=CHH), 
4.85 – 4.78 (1 H, m, C=CHH), 3.47 (2 H, t, J 7.5, CH2Br), 2.58 (2 H, t, J 7.5, 
CH2CH2Br), 2.19 – 1.99 (4 H, m, CCHCH2CH2), 1.69 (3 H, d, J 1.0, CH3), 1.61 (3 H, s, 
CH3); C (75 MHz, CDCl3) 146.48 (C=C), 132.18 (C=C), 123.77 ((CH3)2CCH), 111.73 
(C=CHH), 39.58, 35.80, 31.17 & 26.39 (CH2), 25.85 & 17.89 (CH3); HRMS (APCI+, [M 
+ H]+) found 217.0593, C10H18Br requires 217.0593. 
Ethyl 11-methyl-7-methylene-3-oxododec-10-enoate 192 
 
To an oven-dried RBF charged with a magnetic stirrer bar was added sodium 
hydride (8.4 mmol, 335 mg, 60% in mineral oil) and washed with anhydrous 
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hexane (3 x 20 mL) by stirring for 5 minutes and removal of the hexane by 
syringe. The washed sodium hydride was taken up in THF (40 mL) and cooled 
to 0 ºC before the dropwise addition of ethyl acetoacetate (4.2 mmol, 531 L) 
over 20 minutes and then stirred at 0 ºC for a further 20 minutes. A solution 
of nBuLi (4.9 mmol, 1.96 mL, 2.5 M in hexane) was then added dropwise over 
20 minutes at 0 ºC and the solution stirred for a further 30 minutes. A room 
temperature solution of 187 (1.4 mmol, 300 mg) in THF (2 mL) was added 
dropwise over 20 minutes and stirred for 3 h allowing it to slowly warm to 10 
ºC. The reaction was quenched by dropwise addition of HCl (5 mL, 10% v/v) 
and stirred for 30 minutes before it was diluted with d.H2O:EtOAc (1:1, 20 mL) 
separated and the aqueous layer washed further with EtOAc (3 x 20 mL). The 
combined organic extracts were washed with brine, dried (MgSO4) and solvent 
removed under vaccum. Purification by column chromatography on silica (10% 
EtOAc in hexane, Rf 0.56 in 20%) gave the title compound in 65% yield (241 
mg, 0.9 mmol). 
H (300 MHz, CDCl3) 5.15 – 5.05 (1 H, m, (CH3)2CCH), 4.75 (1 H, bs, C=CHH), 
4.72 (1 H, bs, C=CHH), 4.19 (2 H, q, J 7.0, CH3CH2OC(O)), 3.43 (2 H, s, 
C(O)CH2C(O)OEt), 2.54 (2 H, t, J 7.5, CH2C(O)CH2C(O)OEt), 2.17 – 1.94 (6 H, 
m, 3 x CH2), 1.81 – 1.69 (2 H, m, CH2CH2C(O)), 1.68 (3 H, d, J 1.0, CH3), 1.60 
(3 H, s, CH3), 1.28 (3 H, t, J 7.0, CH3CH2O); C (75 MHz, CDCl3) 202.89 
(C(O)CH2), 167.38 (C(O)OEt), 148.67 (C=C), 131.84 (C=C), 124.14 (C=C), 
109.84 (C=CHH), 49.55 (C(O)CH2C(O)OEt, 35.88, 35.31, 26.48, 25.84, 21.38 
(CH3), 17.86  (CH3), 14.25 (CH3); HRMS (APCI+, [M + Na]+) found 289.1768, 
C16H26O3Na requires 289.1780. 
Ethyl (Z)-3-((diethoxyphosphoryl)oxy)-11-methyl-7-methylenedodeca-2,10-dienoate194 
 
To an oven dried round-bottom flask charged with a magnetic stirrer bar and 
flushed with argon was added sodium hydride (256 mg, 6.4 mmol, 60 % 
dispersion in mineral oil) and washed twice with dry hexane. The washed NaH 
was taken up in dry Et2O (30 mL) and cooled to 0 ºC while stirring, a room 
temperature solution of 192 (340 mg, 1.28 mmol) in dry Et2O (10 mL) was 
then added dropwise over 15 minutes before being allowed to warm to room 
temperature and stirred for a further 30 minutes. The reaction was then cooled 
to 0 ºC and neat diethyl chlorophosphate (368 L, 440 mg, 2.55 mmol) added 
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dropwise over 15 minutes. The reaction was stirred for a further 30 minutes at 
0 ºC before it was quenched with dropwise addition of sat. NH4Cl (10 mL) and 
stirred for 10 minutes (0 ºC). The mixture was diluted with H2O (10 mL), 
separated, and the aqueous fraction further washed with Et2O (3 x 10 mL). 
Combined ethereal extracts were then washed with brine, dried (Na2SO4) and 
solvent removed under reduced pressure, the residue was then stored at -20 
ºC and used the following day without further purification. 
H (300 MHz, CDCl3) 5.36 (1 H, s, C(O)CHCOP(O)(OEt)2), 5.16 – 5.00 (1 H, m, 
(CH3)2CCH), 4.76 (1 H, bs, C=CHH), 4.73 (1 H, bs, C=CHH), 4.32 – 4.20 (4 H, m, 
P(O)(OCH2CH3)), 4.15 (2 H, q, J 7.0, CH3CH2OC(O)), 2.43 (2 H, t, J 7.5), 2.16 – 1.96 (6 
H, m, 3 x CH2), 1.78 – 1.69 (2 H, m, CH2), 1.68 (3 H, d, J 1.0, CH3), 1.60 (3 H, s, CH3), 
1.40 – 1.32 (6 H, m, P(O)(OCH2CH3)), 1.27 (7 H, t, J 7.0, CH3CH2OC(O)); P (122 MHz, 
CDCl3) -8.11 (s). 
Ethyl (E)-5,13-dimethyl-9-methylene-3-oxotetradeca-4,12-dienoate 195 
 
A stirring suspension of copper (I) iodide (495 mg, 2.6 mmol) and Et2O (30 mL) 
in an oven-dried round-bottom flask charged with a magnetic stirrer bar and 
flushed with argon was cooled to 0 ºC. Methyl lithium (3.25 mL, 5.2 mmol, 1.6 
M in Et2O) was added dropwise over 10 minutes and stirred at 0 ºC for 30 
minutes until all the CuI was dissolved to give a clear, almost colourless 
solution. The solutuion was then cooled to -78 ºC and a solution of 194 (1.3 
mmol assumed) in dry Et2O (7 mL) added dropwise over 30 minutes, a yellow 
colour developed which then deepened while stirring at -78 ºC for a further 2 
h. The mixture was then allowed to warm to -45 ºC and maintained at this 
temperature for a further 2 h, over which time the colour darkened and turned 
a deep purple. Neat methyl iodide (202 L, 461 mg, 3.25 mmol) was then 
added and stirred at -45 ºC for 20 minutes before the reaction mixture was 
poured into an ice-cold mixture of sat. NH4Cl and conc. NH4OH (100 mL, 4:1) 
and stirred for 30 minutes until all the copper salts were dissolved. The 
mixture was then separated, the aqueous layer further washed with Et2O (5 x 
15 mL) and the combined ethereal extracts washed with NH4OH (2 x 20 mL, 10 
% v/v), H2O (2 x 20 mL), brine, dried (MgSO4) and the solvent removed under 
reduced pressure. Purification by column chromatography on silica (10% 
EtOAc in hexane, Rf 0.7 in 20%) yielded the title compound in 31% yield over 2 
steps (106 mg, 0.40 mmol). 
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H (300 MHz, CDCl3) 5.67 (1 H, dd, J 2.5, 1.0, CCHC(O)OEt), 5.15 – 5.07 (1 H, 
m, (CH3)2CCH), 4.74 (1 H, bs, C=CHH), 4.73 (1 H, bs, C=CHH), 4.14 (2 H, q, J 
7.0, CH3CH2OC(O)), 2.16 (3 H, d, J 1.0, CH3CCHC(O)), 2.18 – 1.97 (8 H, m, 4 x 
CH2), 1.69 (3 H, d, J 1.0, CH3), 1.61 (2 H, m, CH2), 1.61 (3 H, s, CH3), 1.28 (3 
H, t, J 7.0, CH3CH2OC(O)); C (75 MHz, CDCl3) 149.10 (C(O)OEt), 131.84 (C=C), 
124.18 ((CH3)2CCH), 115.75 (CCHC(O)), 110.19 (C=CHH), 59.63 (CH3CH2OC(O)) 
40.64 (CH2), 35.70 (CH2), 26.52 (CH2), 25.85 (CH2), 25.53 (CH3), 18.88 (CH3), 




A stirring solution of 195 (106 mg, 0.40 mmol) in anhydrous toluene (15 mL) 
was cooled to -78 ºC for 15 minutes before the dropwise addition of DIBAL-H 
(1.2 mL, 1.2 mmol, 1 M in toluene) over 30 minutes. The reaction was stirred 
at -78 ºC for a further 1 h before the dropwise addition of methanol (1 mL) and 
the mixture allowed to warm to room temperature. A mixture of sat. NH4Cl and 
1 M HCl (1:1, 10 mL) was added and the mixture stirred vigorously for 30 
minutes before it was separated and the aqueous layer washed with Et2O (5 x 
5 mL). The combined organic extracts were washed with d.H2O and brine, 
dried (MgSO4) and solvent removed under reduced pressure. Purification by 
column chromatography on silica (10% EtOAc in hexane, Rf 0.26) yielded the 
title compound in 85% yield (76 mg, 0.34 mmol). 
H (300 MHz, CDCl3) 5.48 – 5.36 (1 H, m, CCHCH2OH), 5.16 – 5.06 (1 H, m, 
(CH3)2CCH), 4.73 (1 H, d, C=CHH), 4.72 (1 H, d, C=CHH), 4.16 (2 H, d, J 7.0, 
CCHCH2OH), 2.19 – 1.93 (8 H, m, 4x CH2), 1.69 (3 H, d, J 0.9), 1.67 (3 H, s, 
CH3), 1.61 (3 H, s, CH3), 1.59 – 1.48 (2 H, m, CH2); C (75 MHz, CDCl3) 149.64, 
140.05, 131.75, 124.29 ((CH3)2CCH), 123.49 (CCHCH2OH), 109.07 
(CH2)2CCH2(CH2)3), 59.56 (CCHCH2OH), 39.34 (CH2), 36.16 (CH2), 35.88 (CH2), 
26.56 (CH2), 25.90 (CH3), 25.85, 17.85 (CH3), 16.34 (CH3);  HRMS (EI+, [M – 
H2O]+) found 204.1879, C15H24 requires 204.1878. 




This compound was prepared and purified from alcohol 182 (76 mg, 0.34 
mmol) in the same manner as diphosphate 137, to give the title compound as 
a white solid in 45% yield (67 mg, 0.15 mmol). 
H (500 MHz, D2O) 5.41 (1 H, bs, CCHCH2OH), 5.15 (1 H, bs, (CH3)2CCH), 4.42 (2 
H, bs, CCHCH2O), 2.07 (8 H, bm, 4 x CH2), 1.66 (3 H, bs, CH3), 1.64 (3 H, bs, 
CH3), 1.60 – 1.48 (2 H, m, CH2), 1.58 (3 H, bs, CH3); P (202 MHz, D2O) -6.41 (d, J 
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8.1 NMR spectroscopic analysis of macrocyclic ether 158 
 
Compound 158 (12.2 mg, 0.055 mmol) was prepared by preparative-scale incubation of GdolS with compound 162 (60 mg, 0.134 
mmol) in 41% yield as described in Sections 4.2.3 and 6.1.21. 
H (500 MHz, CDCl3) 5.35 – 5.26 (1 H, m, CHCH2O), 4.97 (1 H, t, J 7.0, C=CHCH2CH2), 4.87 – 4.84 (1 H, m, C=CHH), 4.83 – 4.80 (1 H, 
m, C=CHH), 3.92 – 3.64 (2 H, m, CHCH2O), 3.54 – 3.42 (1 H, m, CH2OCHC=C), 2.30 – 2.03 (6 H, m, 3 x CH2), 1.70 (3 H, s, CH3), 1.63 (3 
H, s, CH3), 1.68 – 1.52 (2 H, m, CH2), 1.54 (3 H, s, CH3). C (126 MHz, CDCl3) 124.46 (CHCH2O), 110.82 (C=CH2), 77.80 
























Figure 8.6 1H-13C HMBC (300 MHz, CDCl3, 298 K) of macrocyclic ether 158. 
